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ABSTRACT OF THE DISSERTATION

Role of LEDGF/p75 in prostate cancer
by
Tracy Ruth Daniels
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, December 2004
Dr. Carlos A. Casiano, Chairperson

The serum autoantibody repertoire from cancer patients is currently being exploited for
the identification of tumor associated antigens (TAA) and the design of TAA arrays.
Such arrays would facilitate autoantibody profiling and potentially aid in the serological
diagnosis and prognosis of tumors. The goal of this study was to identify and characterize
prostate-specific TAA. We observed that while the general frequency and titers of
autoantibodies in PCa patients were relatively similar to those in matched controls,
significant differences could be detected between the two groups in the autoantibody
response to the lens epithelial-derived growth factor p75 (LEDGF/p75). LEDGF/p75 is a
survival protein that confers resistance to stress-induced cell death. Autoantibodies
targeting LEDGF/p75 were detected in 18.4% (38/206) of prostate cancer sera, as
opposed to only 4.5% (9/199) in sera from matched controls. This immune response
suggested that the protein might be aberrantly expressed in prostate tumors. To explore
this hypothesis the expression of LEDGF/p75 in prostate tissue was analyzed using the
Human prostate cancer Histo™-Array (Imgenex). The 3 normal prostate tissues on the
array showed negative staining. Of the 54 cancer specimens, 33 (61%) showed strong
staining, 17 of 54 (31%) showed weak staining, and 3 of 54 (6%) were negative.

xvi

LEDGF/p75 is known to be upregulated by oxidative stress. There is increasing evidence
that oxidative stress plays an important role in the development of prostate cancer. To
investigate the biological impact of LEDGF/p75 overexpression in prostate tumors,
RWPE-2 prostate cancer cells stably overexpressing LEDGF/p75 were developed.
Overexpression of LEDGF/p75 in RWPE-2 cells conferred resistance to caspaseindependent cell death induced by the pro-oxidants t-butyl hydroperoxide (TBHP) or
Taxotere® but not to cell death induced by classical apoptotic stimuli such as
staurosporine and TRAIL. RWPE-2 cells overexpressing LEDGF/p75 showed decreased
levels of reactive oxygen species and the upregulation of the endoplasmic reticulum
protein 57 (ERp57), a thiol-dependent reductase. Taken together, these results suggest
that overexpression of LEDGF/p75, which may be triggered by the oxidative stress
environment in the prostate, might provide a growth advantage to prostate cells through
the upregulation of ERp57 contributing to the development and progression of prostate
cancer.
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CHAPTER 1
INTRODUCTION
Autoantibodies and the Autoimmune Diseases
The immune response to self intracellular antigens has been studied extensively in
systemic autoimmune diseases such as lupus, scleroderma, and rheumatoid arthritis [1-2].
Each of these diseases is associated with a distinct set of specific, high-titer
autoantibodies reactive with intracellular proteins and nucleic acids that serve as antigens.
For example, patients with systemic lupus erythematosis produce anti-Smith antigen
antibodies that recognize the small nuclear ribonucleoproteins and anti-double stranded
DNA antibodies [1]. These profiles of autoantibodies have served as diagnostic markers
for the clinical differentiation of systemic autoimmune diseases. Since autoantibodies in
these diseases target cellular antigens that are predominantly nuclear proteins, they have
been called antinuclear autoantibodies (ANA). ANA have also been used to screen cDNA
expression libraries in order to identify novel genes encoding autoantigens associated
with key cellular functions. This has lead to an increase in our knowledge of cellular
processes such as DNA replication, transcription, RNA processing, cell cycle-regulation,
mitosis, apoptosis, and signal transduction [3].
One question that remains unanswered is how self intracellular proteins, to which
the immune system is normally tolerant, become immunogenic and elicit the production
of ANA. An emerging hypothesis for this loss of tolerance is that self proteins are
modified during cell death and under pro-inflammatory conditions trigger an immune
response [4-5]. Such modifications include proteolysis [4,6-7], oxidation [8-9],
transglutaminase crosslinking [10], citrunillation [11], and ubiquitin conjugation and
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deconjugation [5]. There is evidence that proteolysis of self proteins into distinct
fragments occurs during the different forms of cell death: apoptosis [12-17], primary
necrosis [6], secondary necrosis, and caspase-independent cell death [15]. The cleavage
of these self proteins could lead to the presentation of cryptic or novel epitopes that may
have increased immunogenicity, ultimately resulting in the triggering of an autoantibody
response under pro-inflammatory conditions [4,6-7]. Other studies have shown that
autoantibodies may also play a role in disease conditions other than systemic
autoimmunity, including paraneoplastic neurologic syndromes [18], atopic dermatitis.
asthma, interstitial cystitis [19], and cancer [20-26].

Autoantibodies and Cancer
The production of autoantibodies in patients with cancer is now an area of
increasing interest in the field of cancer research. Autoantibodies produced in cancer
patients may play a role in the anti-tumor immune response associated with malignant
transformation and thus provide unique opportunities to identify and investigate the
nature of autoantigens associated with tumorigenesis. Also, the immune system often
recognizes abnormalities of cellular proteins involved in carcinogenesis before clinical
symptoms appear [27]. Thus, autoantibodies have potential diagnostic and prognostic
capabilities during the early stages of tumorigenesis.
Numerous studies have been conducted to determine the frequency of
autoantibodies in patients with cancer. Studies have shown that the frequency of ANA in
breast cancer patients is significantly higher than normal controls [26]. Another study
showed that higher frequencies of ANA are produced by lymphocytes infected with the
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Epstein Barr Vims in patients with nasopharyngeal carcinoma [28]. Scanlan et al. [20]
found a diverse spectrum of autoantibodies to intracellular proteins in patients with
colorectal cancer. These autoantibodies targeted transcription factors, DNA binding
proteins, metabolic enzymes, molecular chaperones, signaling molecules, cytoskeletal
proteins, and membrane associated proteins. It appears that the autoantigens targeted by
autoantibodies in cancer are often proteins intimately linked to the regulation of cell
growth, proliferation, and differentiation. These cancer-associated autoantigens are often
mutated or aberrantly expressed in tumors [23,29-32].
Perhaps the most widely studied ANA response in malignancy is that associated
with hepatocellular carcinoma (HCC). Covini et al. [25] found ANA in 31% of HCC
patients, compared to 10% in chronic hepatitis C patients, 9.5% in chronic hepatitis B
patients, 10% patients with alcoholic liver cirrhosis, and 4.5% in healthy donors. This
was consistent with a previous study in which Imai et al. [22] showed that 31% of HCC
patients produce ANA, compared to 14% in liver cirrhosis and 13% in chronic hepatitis.
This study also showed that the transition from cirrhosis or chronic hepatitis to
malignancy is associated with an increase in the frequency, titers, and specificities of
ANA. Among the autoantigens targeted in HCC is HCC1, a protein that belongs to a
family of non-snRNP splicing factors [33]. Fifteen percent of HCC patients were found to
produce autoantibodies to cyclin Bl, a protein involved in cell cycle regulation [34].
More recently, antibodies to p62 and CENP-F have been found in HCC patients, but not
in patients with chronic hepatitis or liver cirrhosis [35-36]. p62 is a member of a family
of mRNA binding proteins that binds to insulin-like growth factor II (IGF-II) mRNA and
regulates the translation of IGF-II [35]. Detection of the anti-p62 antibody emerged
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around the time of the diagnosis with HCC [35], suggesting that p62 may be involved in
malignant transformation. CENP-F is a cell cycle-related nuclear centromere protein with
maximum expression in G2 and M phase that is targeted by autoantibodies in HCC as
well as various other cancers [37-38].
Autoantibodies to known oncoproteins have also been detected in cancer patients.
For instance, the tumor suppressor protein p53 has been the most widely studied
autoantigen in cancer patients and is the most frequently mutated protein in human
cancer. These mutations lead to an abnormal accumulation of cytoplasmic p53.
Autoantibody responses to p53 have been shown in patients with gastric [39,40],
pancreatic [41], liver [25,34,42-43], ovarian [23,44], breast [23,45,46-47], lung [24,4849], bladder [45], colorectal [20,50-53], head and neck [54], esophageal [55], and
nasopharyngeal cancers [28],

as well as lymphoma [56] and melanoma [57].

Autoantibodies to p53 normally recognize epitopes in the N or C-terminal ends of the
mutated or wild type protein. It has been shown that approximately 10% of breast cancer
patients produce antibodies to p53 when it is complexed to heat shock protein 70 (hsp70),
a molecular chaperone, suggesting that hsp70 may be involved in the antigenic
presentation of p53 [58]. The oncogene c-myc is also often the target of the autoantibody
response in patients with colorectal cancer, breast cancer, osteosarcoma, and ovarian
cancer [59]. Breast cancer patients have been shown to produce anti-c-myb antibodies
[60] and anti-Her2/neu antibodies [30]. Her2/neu is an oncogenes associated with breast
cancer (discussed below in “oncogenes”). Endometrial cancer patients have been shown
to produce antibodies to cathepsin D, a lysosomal protease implicated in caspaseindependent cell death (further discussed later in this chapter under “caspase-independent
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cell death”) [61]. Antibodies to the survival protein Survivin are produced in 21.6% of
patients with lung cancer [53]. Survivin is a mammalian protein that acts as an inhibitor
of apoptosis protein (IAP) (discussed later in this chapter under “intrinsic pathway of
programmed cell death”) and is strictly regulated during ontogeny. Unlike other lAPs,
survivin expression is not detected in normal adult tissues, but is abundantly expressed in
fetal development and in a variety of human tumors.

Autoantibodies and Prostate Cancer
While there is abundant evidence that autoantibodies to intracellular proteins,
particularly oncoproteins, play a role in the immune response to tumors, a comprehensive
analysis on the autoantibody response associated with prostate cancer (PCa) has not yet
been undertaken. Initial studies by Ablin et al. [62] in 1972 showed that 29% of PCa
patients produce ANA, but these authors also found autoantibodies in 12% patients with
benign prostatic hyperplasia (BPH) (discussed below in “Other diseases of the prostate”)
[62-63]. This, along with the fact that ANA had not yet been widely associated with
cancer at the time, led these authors to conclude that in PCa the production of
autoantibodies might be representative of a non-specific response pointing to other
immunological processes.
In recent years, several groups have exploited the serum autoantibody repertoire
from PCa patients to identify several candidate tumor associated antigens (TAA). The list
of these antigens includes 5a-reductase [64], p53 [65], prostasomes [66], glucoseregulated protein-78 kD (GRP78) [67], MUC1 [68], cancer/testis antigen NY-ES0-1 [69]
and PARIS-1 [70]. The frequency of autoantibodies in cancer patients to a specific
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protein is often between 15-20%. This is due to the heterogeneous nature of cancer in
general and also to the heterogeneous nature of the autoimmune responses in cancer
patients. Thus, the autoantibody response to a single antigen in cancer patients may not
be relevant for diagnostic purposes. For this reason the concept of testing cancer patient
sera for autoantibodies to panels or arrays of TAA has now emerged. Zhang et al.. [71]
recently demonstrated the presence of serum autoantibodies to a panel of known TAA in
various human cancers, including a PCa population from Toma Linda University Medical
Center. In that study, autoantibody reactivity to the individual TAA rarely exceeded 20%
in the cancer patient populations (as compared to less than 5% in normal human sera).
However, successive addition of TAA to a mini-array of seven antigens resulted in a
dramatic increase in the number of positive antibody reactions in cancer patients but not
in healthy controls. Interestingly, cancers of the prostate, breast, and lung showed distinct
profiles of autoantibody reactivity in which specific TAA were preferentially targeted.
The concept of testing cancer sera against TAA in a mini-array was also explored
by Sreekumar et al.. [72]. The array used in this study consisted of 12 antigens: heat
shock protein (hsp47), hsp27, hsp25, hsp40, hsp60, heat shock cognate protein 70
kilodalton (hsc70), Escherichia coli K12 oxidoreductase, maltose-binding protein (MBP),
prostate specific antigen (PSA), carcinoembryonic antigen, a-methylacyl-CoA racemase
fused to the MBP (AMACR-MBP), and yeast cytosine deaminase. A significant increase
in immunoreactivity to AMACR was observed, while no significant differences were
observed with the other 11 antigens. No correlations between the presence of the
AMACR antibody and clinical or pathological parameters (PSA, Gleason score, tumor
stage, or biochemical recurrence) were found. However, when the humoral response to
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AMACR was used to detect PCa among a given population, a specificity of 71.8% and
sensitivity of 61.6% was observed. More importantly, when a population was narrowed
to patients having PSA levels from 4-10 ng/mL (discussed below), the humoral immune
response to AMACR had its sensitivity increased to 78.9% and the specificity increased
to 80.6% in discriminating PCa from control patients. These results strongly suggested
that uniquely constituted antigen panels or mini-arrays might provide a useful approach
for discriminating between cancer patients and control individuals and distinguishing
between some types of cancer. The identification of additional TAA is therefore essential
for designing specific antigen arrays for autoantibody profiling in cancer populations.
The focus of this study will be on the identification and characterization of novel prostate
cancer associated autoantigens.

Prostate Cancer
Statistics, Diagnosis, and Staging
PCa is the leading cause of illness and death among men in the United States and
Western Europe. In 2003, the American Red Cross estimated that 221,000 new cases of
PCa were diagnosed and about 29,000 men died of the disease (www.cancer.org). Small
prostate carcinomas have also been found in men at autopsy, up to 29% in men 30-40
years old and up to 64% in men 60-70 years old [73]. PCa is most often diagnosed with
the use of a clinical test known as the PSA test. In 1979, Wang et al. [74] isolated a
tissue-specific antigen of the prostate, which they called PSA. Others had identified this
protein earlier in the 1970’s, but called it gamma seminoprotein [75]. PSA is a serine
protease that belongs to the kallikrein family of proteins and is also known as human
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glandular kallikrein-3 (reviewed in [76]). PSA is produced by prostate epithelial cells and
functions in the liquification of the seminal fluid mediated by its proteolytic activity. The
mechanism by which PSA enters the blood stream is not known. Small amounts of PSA
are normally found in the blood complexed to anti-chymotrypsin or a-macroglobulin
[77]. However, higher levels of PSA are thought to escape epithelial cells when the
basement membrane of the glands and the prostatic stroma are broken down during times
of infection, inflammation, and malignant transformation.
After the identification of PSA by Wang et al. [74], this group subsequently
developed a serological test to determine PSA levels in the blood. Before the advent of
the PSA test, nearly 70% of men diagnosed with PCa were diagnosed with metastatic
disease, and only 30% were diagnosed with organ-confined disease [78]. Since 1986,
when the PSA test was introduced in clinical laboratories, the number of organ-defined
cases diagnosed has increased to 70-80% [78]. Because of the PSA test, most cases are
now diagnosed at a much earlier stage. Nowadays, the PSA test is not only used to screen
for the presence of PCa, but is also used to assess the tumor response to therapy and to
determine tumor progression. Serum PSA levels of 0-4 ng/mL are considered to be
normal. Four ng/mL and higher are considered clinically significant for PCa screening. A
major limitation of the serum PSA test is its lack of specificity, especially in the
intermediate area of 4-10 ng/mL, where specificity is 20% [72]. This is due to the fact
that other benign conditions such as BPH and prostatitis can also increase serum PSA
levels. Thus, other diagnostic tools are needed to assist in the accurate diagnosis of PCa,
especially within this PSA range. Hence, the clinical relevance of the humoral immune
response to other antigens such as AMACR, described above in “Autoantibodies and
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PCa”, becomes apparent. The humoral immune response to AMACR in patients with a
PSA of 4-10 ng/mL had a sensitivity of 78.9% and a specificity of 80.6% in
discriminating PCa from control patients [72]. This study provided evidence that the
addition of another diagnostic test to aid in the diagnosis of PCa is of great importance.
Besides PSA levels, prostate tumors are staged according to the Gleason grading
system. The Gleason score is a powerful prognostic indicator and the most frequently
used grading system for prostate cancer. This system was developed in 1974 by Gleason,
Mellinger, and the Veterans’ Administration Cooperative Study team [79]. It was shown
that the prognosis was not based on the highest grade within the tumor, but rather it was
best determined by an intermediate score between that of the first and second most
predominant patterns within the cancer. Thus, the Gleason score is the sum of the two
most predominant grades within the tumor. Grade 1 describes the most differentiated and
least advanced tumor, while grade 5 describes the most poorly differentiated and most
advanced tumors. Gleason scores range from 2 to 10. Gleason scores of 2-4 are
considered to be well-differentiated, low grade tumors; 5-6 are moderately differentiated,
7 moderately to poorly differentiated; and 8-10 poorly differentiated, high grade tumors
(Figure 1).
Prostate tumors are also assessed by clinical and pathological stages. Two staging
systems are currently used and thus are briefly reviewed here. The first is the WhitmoreJewett staging system, introduced by Whitmore in 1956 and subsequently modified by
Jewett in 1975 [80]. This staging system describes four different stages of PCa denoted
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Figure 1. Schematic diagram of the Gleason Grading System.
(www.prostatecentre.com) (Illistration by Craig Zuckerman)
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by A, B, C, and D. Stage A cancers cannot be felt, cause no symptoms, and are usually
found when surgery is performed for other reasons, such as BPH. Stage B tumors show
elevation in PSA levels or can be felt in the digital rectal exam. Here the cancer cells are
found only within the prostate gland. Stage C tumors have spread outside the capsule of
the prostate and into the seminal vesicles. Further metastasis beyond the seminal vesicles
is characteristic of stage D tumors. Metastatic sites include lymph nodes, bone, lungs, or
the brain. The second staging system is called the tumor, node, and metastasis (TNM)
system and was also adopted in 1975 [80]. Each tumor is given a score to describe the
primary tumor, any lymph node metastasis, and any metastasis that may exist. A
summary of the TNM staging criteria is given in Table 1.

Incidence and Risk Factors
Worldwide incidence levels of PCa vary from one country to another and are
often difficult to ascertain in developing countries. Incidence rates vary in different
geographical regions and also among different ethnicities [77]. The highest incidence
rates are reported from the Scandinavian countries, the United States, and the United
Kingdom. Low incidence rates are reported from countries in the Far East, especially
mainland China and Japan. Within one country different incidence rates have been
reported among races as well. Throughout the world, the highest incidence rates are
found in blacks, while the lowest incidence rates are found in the Asian population. It is
also interesting to note that there is an increased incidence in Asians who migrate to the
United States, indicating that factors other than genetics play a role in the development of
PCa.
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Table 1. TNM Staging. (Petersen 1986)
Stage

Extent of Invasion

Primary Tumor (T)

TX
TO
Tla

Minimum requirements to assess the primary' tumor cannot be met
No tumor present
No palpable tumor; on histologic sections no more than three high-power fields ot
carcinoma found

Tib

No palpable tumor; histologic sections revealing more than three high-power fields
of prostatic carcinoma

T2a

Palpable nodule less than 1.5 cm in diameter with compressible, normal-feeling
tissue on at least three sides

T2b
T3
T3a
T3b

Palpable nodule more than 1.5 cm in diameter or nodule or induration in both lobes

T4

Palpable tumor extending into or beyond the prostatic capsule
Palpable tumor extending into the periprostatic tissues or involving one seminal vesicle
Palpable tumor extending into the periprostatic tissues, involving one or both
seminal vesicles; tumor size more than 6 cm in diameter
Tumor fixed or involving neighboring structures

Nodal Involvement (N)
NX

Minimum requirements to assess the regional nodes cannot be met

NO

No involvement of regional lymph nodes

N1

Involvement of a single homolateral regional lymph node

N2

Involvement of contralateral, bilateral, or multiple regional lymph nodes

N3

A fixed mass present on the pelvic wall with a free space between this and the tumor

Distant Metastasis (M)
MX

Minimum requirements to assess the presence of distant metastasis cannot be met

MO

No (known) distant metastasis

Ml

Distant metastasis present. Specify site.*

* Specify sites according to the following notations: distant; lymph nodes, LYM; pulmonary, PI L; osseous, OSS;
hepatic, HEP; brain, BRA, pleura, PLE; skin, SKI; eye, EYE; other, OTH
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Lifestyle factors and dietary factors have been shown to increase the risk of PCa
(reviewed in [81]). Lifestyle factors such as number of sexual partners, age at first sexual
experience, and history of sexually transmitted disease have been associated with an
increased risk of PCa [77]. Diets rich in animal fats and meat have also been associated
with an increased risk. Although the components of red meat responsible for the increase
in risk of PCa have not been identified, it is known that when red meat is cooked at high
temperatures or broiled on charcoal grills polycyclic aromatic hydrocarbon carcinogens
often form and may be involved in PCa development. In contrast, diets rich in fruits and
vegetables are associated with a decreased risk of PCa. Antioxidants, such as lycopene,
vitamin E, and selenium, have been shown to decrease the risk of PCa (relevance to be
discussed below in “Inflammation, BPH, and PCa”)[83]. Lycopene is a cartenoid that has
been shown to have numerous modes of action that block PCa progression (reviewed in
[84]). Lycopene is a potent antioxidant and free-radical scavenger. It has also been shown
to block PCa progression by inhibiting cell growth by: downregulation of cyclin D1
which leads to cell cycle arrest at the G0/G1 phase of the cell cycle, upregulation of
insulin like growth factor (IGF) binding proteins that block the effects of IGFs (further
discussed in “The IGF System” below”), and downregulation of IL-6 and 5a-reducatase.
Vitamin E is an intracellular antioxidant located in the cell membrane and is known to
block lipid peroxidation [83]. Selenium is a required cofactor for glutathione peroxidase
antioxidant activity. Isothiocyanate sulforaphane, found in cruciferous vegetables, has
also been found to reduce the risk of PCa. This compound induces the expression of
carcinogen-detoxifying enzymes that limit DNA damage and thus sulforphane acts as an
indirect antioxidant. It was recently shown that spontaneous PCa incidence in transgenic
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mice could be reduced four fold when the mice were fed a combination of antioxidants
(vitamin E, selenium, and lycopene) at physiologically relevant levels [85].

Inherited Susceptibility Genes
Although diet and environmental factors play a critical role in the development of
PCa, there is evidence that there is also a hereditary component of PCa. Many studies
have been conducted to explore the genes that may be involved in carcinogenesis. A few
inherited PCa susceptibility genes have been identified (reviewed in [81,86-87]).
Chromosome lq24-25 has been identified as a potential prostate cancer susceptibility
locus, and was thus termed the hereditary prostate cancer I (HPCI) locus. One candidate
HPCI gene within this region is Ribonuclease L (RNASEL). RNASEL is constitutively
expressed as a latent endoribonuclease that is involved in the interferon inducible
antiviral response of the innate immune system and is thus an important antiviral defense
mechanism. Another candidate gene is the macrophage scavenger receptor I gene (MSRI)
located on chromosome 8p22. MSRI is expressed on the surface of macrophages in the
prostate and binds numerous ligands, including lipoproteins, apoptotic cells, and bacterial
lipopolysaccharides. More recently, a nonsynonymous change in the macrophageinhibitory cytokine-1 (MIC-1) gene was associated with an increased risk of PCa [88].
MIC-1 is a member of the transforming growth factor beta superfamily and plays an
important role in inflammation by regulating macrophage activity. RNASEL and MSRI
genes are involved in the innate immune response to pathogens and MIC-1 is involved in
the inflammatory process. This suggests that variation in the response to pathogens may
have an important role in prostate cancer susceptibility.
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Recently, a genetic variant in the ADP-ribosyltransferse (ADPRT) gene was also
shown to contribute to PCa susceptibility [89]. This gene, also known as poly (ADPribose) polymerase I (PARP-I), functions as a key enzyme in the base excision repair
pathway by maintaining genomic stability in response to genotoxic stress. ADPRT also
plays critical roles in genetic recombination and transcriptional regulation of tumor
suppressor genes such as p53. The genetic variant described in this study is an amino acid
substitution at residue 762 that moves this residue further away from residue 888, which
is part of the active site of the enzyme. Thus, this substitution results in reduced
enzymatic activity and decreased cellular repair function. This study found that this
substitution lead to an increased risk of PCa.
The androgen receptor (AR) has also been implicated as an inherited
susceptibility gene (reviewed in [81,86-87]). The AR is a ligand mediated transcription
factor. In the prostate, testosterone is converted to dihydrotestosterone (DHT) by the
enzyme 5a-reductase. DHT is 3-5 times more potent as an androgen than testosterone
itself [77]. Coincidentally, the 5-a-reductase gene, located on chromosome 2, also has a
high rate of polymorphism. DHT binding to the AR releases hsp90 and unmasks the
DNA-binding domain of the receptor. The AR then translocates to the nucleus and
mediates the transcription of various genes involved in growth and proliferation of the
prostate by binding the androgen response elements (ARE) in the promoter region of
these genes (Figure 2) [77]. Polymorphic polyglutamine repeats have been described in
the promoter region of the AR gene. Shorter repeats, often observed in black men, are
associated with an increased risk of PCa. Longer repeats, often observed in Asian men,
have been associated with a decreased risk.
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PDGF

Figure 2. Androgen action within the prostate. The enzyme 5areductase (5 a R II) converts testosterone to dihydrotesterone
(DHT), which then displaces hsp90 from the androgen receptor
(AR). The DHT-AR complex then translocates to the nucleus and
activates the transcription of prosurvival genes, such as epidermal
growth factor (EGF) and platelet-derived growth factor (PDGF), by
interaction with androgen response elements in the promoter
regions of these genes. (Kirby et al. 1996)
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Somatic Alterations
Somatic alterations also play an important role in the development of prostate
cancer (reviewed in [79,81,86-87]). These alterations are summarized in Figures 3 and 4
and are further discussed below [81]. The most common alteration is the
hypermethylation of CpG islands in the promoter region of the glutathione S-transferase
pi gene (GSTP1) that blocks its transcription. GSTP1 is located on chromosome llq.13
and serves as a caretaker gene that protects cells from genomic damage by detoxifying a
range of xenobiotics (such as polycyclic aromatic hydrocarbons produced by the cooking
of red meat described in “Incidence and risk factors” above). GSTP1 catalyzes the
nucleophilic attack of reduced glutathione on electrophilic compounds. GSTP1 is
normally expressed in the basal cells of prostate epithelium but is silenced in 70% of
prostatic intraepithelial neoplasia (PIN) lesions (a known precursor lesion to PCa,
discussed below in “Other disease conditions of the prostate”) and 90% of prostate
tumors. Loss of GSTP1 expression increases the susceptibility of the prostate cells to
DNA damage and subsequent tumor formation (Figure 4) [81].
Another common alteration found in PCa is allelic losses of NKX3.1, which
results in the decreased expression of the protein (reviewed in [79,81,86-87]). NKX3.1 is
a prostate-specific homeobox gene that binds DNA and prevents the transcription of the
PSA gene. It is located on chromosome 8p21, which is commonly lost in PCa, and has
been suggested to be a prostate specific tumor suppressor. NKX3.1 is the earliest marker
of
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Figure 3. Molecular events of in the pathogenesis of prostate cancer.
NKX3.1, PTEN, and p27 regulate cell growth and survival within
normal prostate cells. Loss of NKX3.1 and PTEN lead to decreased
expression levels of p27, increased proliferation, and decreased
apoptosis. Dotted circles indicated decreased expression levels. Red X
indicates blocked pathways by the molecular events described above. GF
= growth factor, GFR = growth factor receptor, FKHR = forkhead
transcription factor, and CDKN1B = cyclin-dependent kinase IB.
(Nelson et al. 2003)
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Figure 4. Loss of GSTPI activity in prostate cells leaves them
susceptible to DNA damage. GSTPI in normal prostate and PIA
lesions is able to detoxify (indicated by a red X) carcinogens and
reactive oxygen species (ROS) from various sources. However, loss
of GSTPI in PIN lesions and PCa leads to increased genomic
damage caused by carcinogens and ROS. (Nelson et al. 2003)
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throughout prostate differentiation. Interestingly, loss of NKX3.1 in mice induced the
development of PIN [90].
Loss of heterozygosity or mutations of the phosphatase and tensin homologue
(PTEN) and cyclin-dependent kinase inhibitor p27 (p27) are other common somatic
defects found in PCa (reviewed in [79,81,86-87]). PTEN, located on chromosome
10q.23.31, encodes a phosphatase that is a known tumor suppressor gene. It negatively
regulates the phosphatidylinositol 3’-kinase (PI3K)/protein kinase B/AKT survival
pathway. PTEN is frequently mutated or deleted in PIN lesions, prostate cancer cell lines,
and prostate tumors. Loss of PTEN expression has been correlated with higher Gleason
scores and advanced stages of PCa (reviewed in [87]). p27 is located on chromosome
12pl2-13 and regulates progression from G1 to S phase by inhibiting the cyclin E/cyclin
dependent kinase 2 complex. Loss of p27 expression in prostate cancer has been
associated with poor prognosis (reviewed in [87]). PI3K inhibits the expression of p27,
while PTEN increases p27 levels. Thus, low p27 levels are probably a consequence of
PTEN loss.
Another somatic defect observed in patients with PCa involves the AR (reviewed
in [79,81,86]). The AR, as described above in “Inherited susceptibility genes”, is required
for normal growth of the prostate. PCa is also initially dependent on androgens for the
growth of the tumor. Thus a common treatment of PCA is androgen ablation therapy
[79,91]. This type of therapy involves inhibiting either the production or activity of
androgens [91]. Inhibition of androgen production can be accomplished by surgical
orchidectomy (castration) or by chemical therapy using lutenizing hormone-releasing
agonists. Inhibition of androgen activity can also be achieved by chemical therapy using
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antiandrogens to interfere with androgens already in circulation. The initial response to
androgen ablation therapy is usually beneficial; however, progression to androgenindependent cancer is inevitable and usually occurs within 18-24 months from the start of
ablation therapy [79]. Surprisingly, androgen independent PCa not only continues to
express the AR but also often maintains AR-dependent signaling (reviewed in [79]). ARdependent signaling can be maintained in the absence of androgens by: amplification or
mutations of the AR leading to increased expression or altered function of the receptor;
increased AR expression that enhances the sensitivity of the AR to low levels of
circulating androgens; or mutations that lead to a change in ligand specificity that leads to
its activation in response to nonandrogens or antiandrogens. The AR can also be activated
in a ligand-independent manner by other intracellular signal transduction pathways [86].
Somatic defects of a few other proteins have also been implicated in the
development of PCa, albeit at lower frequencies than the above-mentioned defects. The
retinoblastoma susceptibility (Rb) gene is a candidate tumor suppressor gene located on
chromosome 13q. Rb suppresses cell division by preventing cells from progressing to S
phase of the cell cycle. Mutations and loss of expression of Rb have been reported in 2050% of PCa [87]. Prostate tumors can show upregulation of certain genes as well. One
example is the AMACR, which is located on chromosome 5:13. This protein catalyzes
the conversion of R and S-stereoisomers of branched-chain fatty acids to permit
metabolism through p-oxidation, which is required to produce energy for the cell when
glucose levels are low. Telomerase has also been identified as having somatic alterations.
Telomerase is an enzyme that maintains the telomere length that is normally lost through
the aging process. Telomerase activity has been associated with immortalization and
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carcinogenesis. Increased expression of prostate stem cell antigen correlates with high
Gleason scores. Loss of heterozygosity (and thus loss of expression) of the Kmppel-like
factor 6 (KLF6) has been observed in 77% of primary tumors. The KLF6 gene is located
on chromosome 1 Op and encodes a zinc finger transcription factor whose function is not
known (reviewed in [87]).
Prostate metastasis suppressor genes have also been identified (reviewed in [92]).
Epithelial-cadherin (E-cadherin) is a transmembrane protein that regulates cell adhesion
by binding to E-cadherin molecules on neighboring cells. Decreased expression of Ecadherin is often observed in high grade PCa. Decreased expression is caused by frequent
deletions of chromosome 16q. Another metastasis-associated genes are KAI-1 gene
(chromosome 1 Ipl 1.2-13) that codes for a membrane glycoprotein. Yu et al. [93] found a
loss of KAI-1 expression in high grade and invasive bladder cancer and suggested that it
functions in cell-cell interactions and cell-extracellular matrix binding. CD44, located on
chromosome 1 Ipl3, near KAI-1, is also a transmembrane glycoprotein whose decreased
expression is associated with tumor progression [94-95]. NM23 is another metastasis
suppressor gene that encodes a nucleoside diphosphate kinase and maps to chromosome
17. NM23 is thought to be involved in the control of normal proliferation and
differentiation [96]. One study showed by immunohistochemical analysis that NM23
expression decreased dramatically from BPH, PIN, to through the PCa stages, suggesting
that decreased NM23 expression is associated with poor prognosis [97-98].
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Oncogenes
Oncogenes are known to contribute to neoplastic transformation (reviewed in
[92]. Proto-oncogenes are cellular proteins that are involved in the normal proliferation of
cells. They function as growth factors, growth factor receptors, replication regulators, or
transcription regulators. Alterations such as insertional mutations, amplification, point
mutations, or translocations of these proto-oncogenes lead to an increase in growth rate
and ultimately malignant transformation. The presence of one altered allele is sufficient
for initiating the carcinogenic process as oncogenes act in a dominant manner.
Oncogenes play a role in the initiation of many human tumors; however, none
have been identified conclusively with the initiation or progression of PCa (reviewed in
[92]). The most widely studied oncogene in PCa is the ras oncogene. Ras is a GTPase
signal transduction molecule that is anchored to the cytoplasmic side of the cell
membrane. Oncogeneic ras becomes constitutively activated in the GTP-bound state
resulting in prolonged survival signals [99]. However, mutations of ras in PCa are
relatively uncommon and thus are irrelevant. Regulator of a-fetoprotein (Raf) has also
been studied in PCa [100]. Raf is a serine/threonine kinase and is activated upon growth
factor binding to its cognate receptor [101]. Raf then activates the mitogen activated
protein kinases (MAPK) through direct phosphorylation. So far no links between Raf and
PCa have been found. A third oncogene studied in PCa is c-myc, which is a transcription
factor involved in differentiation. One study shows an increase in the mRNa levels of cmyc in higher grade PCa tumors [102], but this remains controversial since another study
did not find an increase in c-myc expression in PCa [103]. C-erb-B2 or her-2-neu, an
oncogene associated with breast cancer, is homologous to the epidermal growth factor.
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The most common mechanism of her-2-neu activation is amplification, which is observed
at high levels in patients with breast cancer [104]. Her-2-neu is not frequently amplified
in PCa, although overexpression of the protein has been observed in hormone refractory
PCa [105] and correlated with advanced stages [106]. Other studies show low levels of
her-2-neu expression [107] and that expression did not predict clinical recurrence [108].
Whether her-2-neu is associated with PCa remains controversial and thus warrants further
study. The most promising oncogene that has been studied in PCa is the Enhancer of
zeste homologue 2 (EZH2). This protein is a repressor of transcription and functions by
increasing histone deacetylation via histone deacetylase-2 [109]. Varambally et al. [110]
found that both protein and mRNA levels were shown to be increased in PCa and that
expression predicts poor prognosis. EZH2 is a promising marker, but also merits further
study. The largest problem with these studies on oncogenes in PCa is that small cohorts
of patients were studied and thus the findings are not conclusive. Larger cohorts need to
be studied to confirm or refute these initial results.

Other disease conditions of the prostate
Benign Prostatic Hyperplasia (BPH)
Other disease conditions besides PCa develop in the prostate gland. BPH is one of
these conditions and is a non-cancerous growth of the prostate (reviewed in [111]).
Causes of BPH are not well understood and few risk factors have been identified. BPH
lesions have been found to contain variable amounts of chronic and often acute
inflammation in virtually all cases [86]. It is unclear at the present time whether
inflammation occurs prior to BPH formation or whether it is a response to the altered
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tissue morphology. No definitive conclusions can be made, however it is believed that
inflammation may be a cause of BPH formation and not an effect of it.
The only factor that has been identified with the development of BPH is the aging
process (reviewed in NIH Publication No. 04-3012 at www.//kidney.niddk.nih.gov and
[111]). Enlargement of the prostate due to BPH rarely causes problems before the age of
40. However, more than half of men in their sixties and as many as 90% of men in their
eighties show symptoms of BPH. Symptoms arise from the obstruction of the urethra and
often vary from patient to patient, but most often involve changes or problems with
urination, such as urgency and more frequent urination. Severe BPH can cause serious
problems over time. Urine retention can lead to urinary tract infections, bladder or kidney
damage, bladder stones, and incontinence. These complications can be avoided by early
detection and treatment.
Since BPH is a common condition associated with the aging process (as is PCa),
many have questioned whether BPH is linked to the development of PCa. Most clinicians
agree that BPH is not associated with carcinomas located within the peripheral zone of
the prostate, which account for about 75% of PCa cases [86]. However, the other 25% of
prostate carcinomas occur in the transition zone of the prostate, and do appear to arise
from nodes of BPH. These carcinomas are associated with a lower Gleason score and
thus are generally less aggressive cancers.

Prostatic Intraepithelial Neoplasia (PIN)
In contrast to BPH, PIN is now accepted as a precursor lesion to PCa. The term
PIN was introduced in 1987 by Bostwick and Brawer [112]. PIN can be divided into two
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groups: low grade PIN (LGPIN) and high grade PIN (HGPIN). LGPIN does not appear to
have any significant relationship to PCa other than it many develop into HGPIN. Thus,
HGPIN is often referred to as PIN. Like BPH, the incidence of PIN increases with age.
HGPIN has been found in 9% of men in their 20’s, 22% of men in their 30’s, 40% of men
in their 40’s, and by the age of 80 the incidence is 70% (reviewed at www.emedicine.com
and [113]). PIN has been defined as consisting of architecturally benign prostatic acini
lined by cells that seem to be malignant [79]. Bostwick and Brawer [112] described four
architectural patterns of PIN: tufting, micropapillary, cribriform, and flat. Most
specimens contain a variety of these patterns and besides the diagnostic utility, no
prognostic differences have been found between the different patterns.
There is convincing evidence that PIN is a precursor lesion to PCa. It coexists
with PCa in 95% of prostate specimens studied [114]. PIN also exhibits many similarities
with PCa that would indicate it is an early lesion in tumorigenesis. These include
morphological similarities (nuclear and nucleolar enlargement) and genetic similarities
(for example the loss of GSTP1 discussed above in “Somatic alterations”). Molecular
similarities were recently shown to exist between PIN and PCa [115]. These included
upregulation of the same 21 genes as well as downregulation of the same 63 genes in the
two lesions when compared to normal prostate tissue. These precisely similar expression
profiles of PIN and PCa are convincing evidence that there is a relationship between PIN
and PCa. Topographical similarities between PIN and PCa also exist. The prostate is
divided into three anatomical zones: the central, transitional, and peripheral zone [77]
(Figure 5). Seventy five percent of all prostate carcinomas arise in the peripheral zone of
the prostate [86]. PIN also preferentially develops in the peripheral zones of the prostate.
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Figure 5. Zonal anatomy of the prostate. Both frontal (left) and side
view (right) are shown. (CZ = Central zone, PZ = Peripheral zone,
and TZ = Transition zone). Adapted from Kirby et al, 1996.
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One of the pathological characteristics of PIN not observed in PCa is the presence of a
basal membrane (although it may be fragmented). This membrane is absent in PCa
specimens [77]. Although PIN appears to be the precursor lesion to many intermediate
and high-grade adenocarcinomas, it is not necessarily a precursor to all carcinomas. PIN
has not been found around areas of early cancers or those carcinomas originating in the
transition zone of the prostate. PIN can mimic prostate cancer on transrectal ultrasound,
but does not result in a rise in PSA levels unless it is associated with PCa.

Proliferative Inflammatory Atrophy (PIA)
Most pathologists are in agreement that PIN is a precursor lesion to PCa. De
Marzo et al. [116] identified another lesion that they believe is also a precursor to PCa.
These authors wanted to characterize the phenotype of atrophic cells found within the
prostate that are often associated with inflammation. As a result, they identified a lesion
within the prostate that was hyperproliferative, often associated with inflammation, and
contained the morphological appearance of atrophy. They suggested the term
“proliferative inflammatory atrophy” to describe this type of lesion that has discrete foci
of proliferative glandular epithelium with the morphological appearance of simple
atrophy. PIA lesions are usually found in the peripheral zone of the prostate and often
share molecular alterations observed in PIN. PIA shows increased GSTP1 and GSTA1
(another class of glutathione S-transferase also involved in detoxification of xenobiotics)
expression indicative of a stress-induced response within the lesion [116-117]. It was also
shown that PIA lesions show a very low apoptotic rate, which the authors attributed to the
increased expression of the anti-apoptotic protein Bcl-2 (discussed below in “Intrinsic
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Pathway of Programmed cell death”) [116]. PIA may develop as a consequence of
repeated epithelial damage caused by either infection, cell trauma caused by reactive
oxygen species (ROS), autoimmunity, hypoxia-related changes, ischemia, or toxin
exposure [116,118]. This damage is then followed by epithelial regeneration associated
with secondary inflammation or direct oxidant damage.
Recently, De Marzo et al. [116] proposed that PIA is a potential precursor to PCa
either directly or indirectly as a precursor of PIN (Figures 6). The following findings
suggest that PIA may indeed be a PIN precursor [116,119]. PIA cells show an increase in
proliferation in epithelial secretory cells that are normally non-dividing. The phenotypes
of many PIA cells most consistent with immature secretory cells, which is also seen in
PIN and PCa. PIA, PIN, and PCa all occur with high prevalence in the peripheral zone of
the prostate. There is also evidence that PIA merges with PIN lesions histologically
within the same gland of radical prostatectomy samples [116]. Despite this evidence, the
existence of PIA remains controversial. One group found no evidence that PIA is
associated with PIN or PCa in a group of 100 autopsy samples [120].

Inflammation, BPH, and Prostate Cancer
If PIA is indeed a precursor to PCa, inflammation would be a key factor in the
development of PCa. Chronic inflammation is a risk factor for other cancers such as liver,
colon, stomach, bladder, cervical, ovarian, and lung cancer [121]. It is also been
speculated that chronic inflammation may also be a risk factor for PCa development.
Inflammatory infiltrate has been associated with PCa in almost 60% of cases studied
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[122]. Despite the fact that prostate inflammation and PCa are often found in the same
patient, a clear association between the two has not been established. This is often
attributed to the following difficulties: 1) prostatitis is often asymptomatic and thus the
incidence of prostatitis is difficult to determine and 2) the clinical diagnosis of prostatitis
is challenging and subjective [86]. The current National Institute of Health (NIH)
consensus classification system of prostatitis divides the cases into four groups: 1) acute
bacterial prostatitis, 2) chronic bacterial prostatitis which consists of repeated bouts of
lower urinary tract infections where the source of infection can be localized to the
prostate (very rare), 3) chronic prostatitis/chronic pelvic pain syndrome, and 4)
asymptomatic inflammatory prostatitis [86]. Studies have shown an increased risk
associated with sexually transmitted infections regardless of the pathogen involved [86].
Even though a direct causal role for chronic inflammation in the development of
PCa has not been established, there is indirect evidence that the two are linked. Evidence
that antioxidant enzyme levels, specifically glutathione peroxidase and catalase, are
increased in PCa tissue suggests that the prostate is indeed in a state of oxidative stress
[123]. This suggests that even though the antioxidant levels increase, the oxidative stress
within the prostate is too heavy a burden to overcome. The oxidative stress within the
prostate may be induced by the aging process itself [124], dietary factors, increased
metabolism, mitochondrial dysfunction, hypoxia or from inflammatory cells that are
responding to the presence of a pathogen [125]. It was shown that hydrogen peroxide
levels are increased in both mouse and human prostate tumors and that in the mouse this
increased level of hydrogen peroxide correlates with increased tumorigenecity [126]. The
fact that dietary antioxidants have been shown to reduce the risk of PCa (discussed above
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in “Incidence and risk factors”) is also evidence that oxidative stress plays a role in PCa
tumorigenesis.
The observation that nitric oxide-donating non-steroidal anti-inflammatory drugs
inhibit proliferation and induce apoptosis in human prostatic epithelial cells lines
suggests that inflammation is also involved in the development of PCa [127]. A recent
study demonstrated that sequence variants of the Toll-like receptor 4 (TLR4) gene are
associated with PCa risk [128]. TLR4 is involved in the innate immune response to gram
negative bacteria. The sequence variant was observed in the 3 ’ untranslated region of the
gene and conferred a 26% increased risk of PCa and a 39% risk of being diagnosed
before the age of 65. This finding supports a role for a bacterial-associated response
pathway in the development of PCa. Given that innate immunity defense proteins
(RNASEL and MSR1) have been associated with carcinogenesis (discussed above in
“Inherited Susceptibility Genes”) also supports the concept that inflammation, not the
presence of a specific pathogen, facilitates carcinogenesis.
Konig et al. [129] examined the inflammatory network in both BPH and PCa and
found that while inflammatory cascades are crucial in the development of both diseases,
the cascades involved are different. For example, BPH tissues showed high expression
levels of the toll-like receptors (TLR) 4,5 and 7 while PCa tissues had strong TLR 1,2,
and 3 expression. These authors found the enzyme cyclooxygenase-2 (COX-2) to be
preferentially upregulated in PCa compared to BPH. This enzyme plays a role in the
pathophysiology of inflammation by converting arachadonic acid to prostaglandins.
Wang et al. [130] showed that Cox-2 is upregulated in the luminal epithelial cells of
prostate glands closely adjacent to chronic inflammation and in glands with different
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types of post-inflammatory epithelial cell atrophy. While inflammation has been found to
be associated with both BPH and PCa, it appears to be more associated with BPH [122].
Evidence that inflammation plays a role in the development of prostate cancer
also comes from the fact that Interleukin-6 (IL-6) expression correlates with tumor
progression to hormone refractory PCa [131]. IL-6 is a pleiotropic cytokine involved in
many cellular processes such as inflammation, cell differentiation, and proliferation. In
this study IL-6 was shown to protect the androgen-sensitive LNCaP cell line from
androgen-deprivation induced apoptosis.
The mechanisms by which inflammation and oxidative stress contribute to the
initiation and progression of PCa are unknown. Inflammatory cells can produce
cytokines, such as tumor necrosis factor (TNF-a), IL-6, and transforming growth factor [3
(TGF-P), and angiogenic factors, such as vascular endothelial growth factor, which have
various effects on host cells including cell survival, growth, differentiation, and
metastasis [132]. The association of inflammation with prostate cancer has recently
invoked the “chronic epithelial injury” hypothesis of prostate carcinogenesis [86]. The
proposed mechanism of PCa development is through the generation of ROS and reactive
nitrogen species (RNS) produced by inflammatory phagocytes designed to eradicate
pathogens [86,133]. These ROS not only cause damage to pathogens but also are thought
to cause damage to the host as well. This damage may not be adequately repaired before
regeneration occurs leading to the onset of cancer.
ROS include the superoxide anion, hydrogen peroxide, the hydroxyl radical, and
the peroxy radical. In normal cells low levels of ROS are produced by cellular processes.
Sources of intracellular production of ROS include the electron transport chain in the
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mitochondria, oxidizing enzymes, and the arachadonic acid cascade that results in the
synthesis of prostaglandins and leukotrienes [134-135]. Low levels of ROS regulate
cellular signaling and thus play an important role in normal cellular proliferation
(reviewed in [136]). ROS have also been shown to modulate apoptosis under stress
conditions (reviewed in [136]). Thus, ROS are key players in cell growth and cell death.
ROS readily react with other molecules and at high levels can lead to cellular damage as
a result of reaction with DNA, proteins, and lipids. The cell has antioxidant defense
mechanisms to prevent this damage. Antioxidants are divided into two groups: enzymatic
and nonenzymatic antioxidants (reviewed in [137]). The enzymatic antioxidants include
the

superoxide

dismutase,

catalase,

glutathione

peroxidase,

and

thioredoxin.

Nonenxymatic antioxidants are low molecular weight compounds such as glutathione,
ascorbate, a-tocopherol, bilirubin, and lipoic acid. However, when ROS levels get too
high, the cell is considered to be in a state of oxidative stress, which is defined as a
disturbance in the prooxidant-antioxidant balance [134]. Prolonged oxidative stress can
lead to increased cellular damage and ultimately to cell death.
Cancer cells are more prone to oxidative damage due to the high proliferation rate
in these cells [138]. DNA damage caused by ROS includes DNA strand breaks,
apurinic/apyrimidinic sites, DNA-protein crosslink formation, and modified base
production. Oxidative DNA base lesions include 8-hydroxyguanine (8-oxoG), 8hydroxyadenine (8-oxoA), and 5-hydroxycytosine (50HC). The hydroxyl radical, singlet
oxygen, and peroxynitrite have been shown to form these lesions [139]. Trzeciak et al.
[138] showed that levels of these damaged bases were shown to increase in PC3 and
DU 145 PCa cells when they were exposed to radiation and recovered under normal
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culture conditions to allow for a period of repair [138]. In their analysis of the repair
mechanism in these cells, these authors revealed that there is a decrease in the base
excision repair enzyme, OGGI, which is the glycosylase that repairs 8-oxoG lesions.
This suggests that there may be defective repair mechanisms in PCa cells that results in
sustained DNA damage. Another study confirmed the increase in 8-oxoG levels in the
urine of PCa patients [139]. This study did not find an association between pretreatment
PSA values, clinical T stage, metastasis, or Gleason score and the increase in 8-oxoG
levels. Fleshner et al. [83] have shown that oxidative stress in benign epithelium of PCa
patients is higher than that of normal patients. Thus oxidative stress leads to an increase
in DNA damage that often accumulates in prostate cells due the lack of appropriate cell
death and results in tumorigenesis.

Cell Death in Prostate Cancer
Extrinsic Pathway ofProgrammed Cell Death (Apoptosis)
When deficiencies are not present, programmed cell death (PCD), or apoptosis.
occurs through two main pathways (Figure 7). The first pathway is known as the extrinsic
pathway and is mediated by signals originating from outside of the cell (reviewed in
[140-142]). This pathway is also known as the death receptor-mediated pathway and is
initiated by the binding of ligands to death receptors. It is presumed that these receptors
are in the form of pre-associated trimers on the cell surface [141]. These death receptors
are members of the TNF receptor superfamily, which includes the TNF receptor I, Fas
receptor, and TNF-related apoptosis-inducing ligand (TRAIL) receptor.
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death receptors all contain a protein-protein interaction domain termed the death domain
(DD). Adapter molecules such as the Fas-associated DD containing protein (FADD)
interact with the death receptors directly via interactions between the DDs or indirectly
via other adaptor proteins, such a TNF receptor associated DD (TRADD) in the case of
TNF receptor pathway. FADD also contains another protein-protein interaction domain
called the death effector domain (DED), which aids in the recruitment and interaction
with initiator procaspases that also contain this domain. This complex of proteins.
including the death receptor, adaptor molecules, and initiator procaspases has been
termed the death inducing signaling complex (DISC).
Caspases are the main executioners of apoptosis and are synthesized and
expressed as nonactive zymogens (reviewed in [140-142]). Caspases are activated by two
proteolytic cleavages. The first cleavage generates the large and small subunits of mature,
active caspases and a second cleavage removes the prodomain. Caspases are cysteine
proteases that upon activation cleave specific amino acid sequences in the substrate
proteins, which contain an aspartate residue in the PI position. The caspases can be
divided into two groups: the initiator and effector caspases. The initiator caspases
transduce the first signals and activate the effector caspases that are responsible for the
cleavage of substrates that induce the morphological changes associated with apoptosis.
Initiator caspases are caspase-8, 9, and 10, while effector caspases are 3, 6, and 7.
Procaspase-8 molecules are the most common caspases recruited to the DISC. Once
procaspase-8

has associated with FADD, these zymogens

are activated by

oligomerization and autoactivation mechanisms. The active caspase-8 enzyme is a
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tetramer that consists of two pi 8 and two plO subunits. Active caspase-8 then cleaves
effector caspases and apoptosis ensues.
Two pathways of death receptor signaling have recently been described (reviewed
in [140-142]). In type 1 cells there is a high recruitment and activation of caspase-8 in the
DISC as described above. Active caspase-8 is then released from the DISC into the
cytoplasm where it then cleaves and activates effector caspases. In type II cells the DISC
is poorly formed and only a small amount of active caspase-8 results. Apoptosis in these
cells is dependant on the activation of the intrinsic pathway described below. In these
types of cells the small amount of caspase-8 that is activated cleaves a Bcl-2 family
member (described below) called Bid. The cleavage fragment formed, truncated BID
(tBID) translocates to the mitochondria and initiates the intrinsic pathway to not only
connect the two apoptotic pathways but also to amplify the death signal. Zhang et ah.
showed yet another pathway by which apoptosis can be induced via death receptors
[143]. This study showed that Fas can activate a protein kinase pathway, independent of
caspase-8, that results in the activation and translocation of Bak (another Bcl-2 family
member discussed in the following section) to the mitochondria. The activation of Bak
was not sufficient for full induction of apoptosis, but cells were sensitized to further
apoptotic stimuli. Another study identified a DISC that contained a DD protein known as
RIP [144]. This protein initiated a caspase-8 independent pathway through the Fas
receptor that resulted in a cell death with necrotic features. In some cases the decision to
undergo apoptosis or a caspase-independent type of cell death depends on hsp90, which
may alter the components of the DISC to activate either type of cell death pathway [145].
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There is also a ligand-independent apoptotic pathway, initiated by the drug ganciclovir or
by ultraviolet light exposure, that results in DISC formation [145].

Intrinsic Pathway of Programmed Cell Death (Apoptosis)
The intrinsic pathway of PCD is mediated by mitochondria and the release of
apoptogenic proteins from this organelle (reviewed in [146]). It is activated in response to
diverse stimuli including DNA damage, growth factor deprivation, or ER stress. The Bcl2 family of proteins is very intimately connected to this pathway of cell death. The
function of all Bcl-2 family members is to directly modulate mitochondrial membrane
permeability and thus regulate the release of apoptogenic factors from the intermembrane
space into the cytoplasm. Anti-apoptotic Bcl-2 family members inhibit the release of
these factors, while pro-apoptotic members promote their release. This family of proteins
shares one or more Bcl-2 homology (BH) domains and is divided into two groups: the
anti-apoptotic members and the pro-apoptotic members (summarized in figure 8)
(reviewed in [146-147]). The anti-apoptotic group consists of Bcl-2, Bc1-Xl, Mcl-1, and
Bfl-1 and share sequence homology within the BH1-BH4 domains. The pro-apoptotic
group is further divided into the multi-domain and BH3-only members. The multidomain members include Bax, Bak, and Bok and share homology in the BH1-BH3
domains. The BH3 only members include Bik, Bad, Bid, Bim, Hrk, Noxa, Blk, Bnip,
Puma, and Bmf and are homologous only in the BH3 region as the name implies. Most of
these BH3 only proteins are normally found in the cytoplasm. Upon a death signal, these
proteins are modified by different mechanisms and thus translocated to the mitochondria
leading to increased permeability of the outer mitochondrial membrane. For example,
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Zha et al. [148] showed that Bad is normally phosphorylated and sequestered in the
cytoplasm by the 14-3-3 protein. Once apoptosis is induced, Bad is dephosphorylated
freeing it from 14-3-3 and enabling it to translocate to the mitochondria.
The mechanisms by which the pro-apoptotic Bcl-2 family members initiate the
increase in membrane permeability and release of apoptogenic factors remains
controversial (reviewed in [146,149]). In one proposed model the outer mitochondrial
membrane ruptures as a consequence of mitochondrial swelling after the opening of the
permeability transition pore. Another model suggests that pro-apoptotic Bcl-2 members
induce permeabilization through the formation of pores, either directly or via interactions
with the mitochondrial permeability transition of voltage-dependent activated channels,
allowing the selective release of proteins from the intermembrane space of the
mitochondria. Anti-apoptotic Bcl-2 members appear to function in blocking the activated
BH3 only protein-induced disruption of the outer mitochondrial membrane.
Many factors are known to be released from the mitochondria upon outer
membrane permeabilization that occurs during apoptosis (Figure 9) (reviewed in
[146,150]). The first is cytochrome c, which is encoded by a nuclear gene whose protein
is imported into the mitochondria where it remains until the activation of the intrinsic
pathway. Under normal conditions cytochrome c is found in the intermembrane space of
the mitochondria and functions as electron shuttle between complex III and IV of the
electron transport chain. Upon release from the mitochondria during apoptosis,
cytochrome c forms drives the assembly of a complex known as the apoptosome.
Cytochrome c binds apoptosis activating factor-1 (Apaf-1), which facilitates the binding
of ATP to Apaf-1. This induces oligomerization of Apaf-1 that results in the recruitment
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Figure 9. Regulatory factors released from the mitochondria upon
membrane permeabilization during the intrinsic pathway of
apoptosis. (Ravagnan et al. 2002)

43

of procaspase-9. The interaction between Apaf-1 and procaspase-9 in mediated by the
protein-protein interaction domain termed the caspase recruitment domain (CARD).
Procaspase-9 is then activated by autocatalytic proteolysis within the apoptosome.
Activated caspase-9 then activates effector caspases and apoptosis proceeds.
The intrinsic apoptosis pathway is regulated by a family of proteins called the
lAPs (reviewed in [142,150]). IAPs inhibit apoptosis by direct interaction with caspases.
In turn IAP activity is regulated by Smac/Diablo, which is another factor that is released
from the mitochondria during the intrinsic apoptotic pathway. Smac/Diablo releases the
inhibition of caspases by direct interaction with IAPs and thus apoptosis can proceed.
HtrA2/Omi is another lAP-binding protein that is released from the mitochondria.
Apoptosis inducing factor (AIF) is also released from the mitochondria during apoptosis.
Upon release, AIF translocates to the nucleus where it induces peripheral chromatin
condensation and DNA fragmentation into 50 kilobase (kb) fragments. Endonuclease G
(EndoG) is the final factor that is released from the mitochondria. EndoG is a
mitochondrial nuclease that translocates to the nucleus were it generates fragmented
DNA. EndoG may act similarly to caspase-activated DNAse (CAD), whose activity is
responsible for the typical DNA fragmentation pattern that is observed during caspasedependent apoptosis. Interestingly, both AIF and EndoG-induced fragmentation is
caspase-independent, thus it cannot be blocked by caspase inhibitors.

Caspase-Independent Cell Death
A central dogma of cell death has been that death occurs either by PCD
(apoptosis) or by necrosis. PCD and apoptosis are two terms that have long been used
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interchangeably. However, these viewpoints are now being challenged as it becomes
more evident that many cell death pathways exist and apoptosis is not the only form of
PCD [151-152], Many of these pathways do not rely on caspases and fall under the
general category of caspase-independent cell death. Many terms have been put forth in
trying to describe these different types of cell death and are based on the morphological
characteristics of the dying cells. The most common will be briefly reviewed here.
Four types of cell death have been proposed: apoptosis, apoptosis-like PCD,
necrosis-like PCD, and accidental necrosis (reviewed in [151-152]). Apoptosis, triggered
by either the extrinsic or intrinsic pathway (as described above), results in the typical
morphology that has been recognized as apoptotic cell death for many years. These
typical features of apoptotic cells include: chromatin condensation into globular or
crescent shaped figures, phosphatidylserine exposure on the outer leaflet of the cell
membrane, cytoplasm shrinkage, zeiosis (defined as the dynamic plasma membrane
blebbing of a dying cell) and apoptotic body formation. Classically, apoptosis involves
activation of caspase proteases. The second form of cell death proposed by Leist et al..
[151] is apoptosis-like PCD. Here the chromatin condensation is less compact than
typical apoptosis. Other features of classical apoptosis can be present in any combination,
however, caspases are not activated. Most studies identifying “caspase-independent” cell
death refer to this type of apoptosis-like PCD. The third form of cell death is termed
necrosis-like PCD. This form of cell death occurs in the absence of chromatin
condensation or with chromatin clustering into speckles. Features of apoptosis may be
present before the cell rupture occurs. Usually this form of cell death occurs without
caspase activation, however, there are cases termed “aborted apoptosis” where caspases
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are activated early on but are later blocked as cell death occurs via caspase-independent
mechanisms. Accidental necrosis is the counterpart to PCD. Typical features of this type
of cell death are cell and nuclear swelling that lead to the rupture of the cellular
membrane.
More recently other terms for non-apoptotic cell death pathways have been
described (reviewed in [153]). Senescence is a form of permanent cell-cycle arrest that
shows distinct morphological features such as flattening of the cytoplasm and increased
granularity [153]. Senescence is accompanied by metabolic changes, genetic alterations,
and changes in protein expression patterns. Autophagy is another form of non-apoptotic
cell death that is characterized by which long-lived proteins and organelle components
are directed to and degraded within the lysosomes [153]. Morphological features of
autophagy are partial chromatin condensation, zeiosis, and massive cytoplasmic
vacuolization.
The final form of non-apoptotic cell death discussed in this review is mitotic
catastrophe [153]. This type of cell death is caused by aberrant mitosis and is associated
with the formation of multinucleate giant cells that contain uncondensed chromatin but
show nuclear fragmentation. Mitotic catastrophe is usually caspase-independent. This
type of cell death is induced by the taxane family of antitumor agents that are derived
from the European Yew tree (reviewed in [154]). Two examples of taxanes are pacilitaxel
(Taxol®) and docetaxel (Taxotere®). Both are highly effective therapeutic agents, alone or
in combination, for a variety of cancers including: breast, lung, ovarian, head and neck,
gastric, and prostate. Taxanes promote actin polymerization and prevent the
depolarization of microtubules. This leads to cell cycle arrest in the G2/M phase of the
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cell cycle and ultimately to cell death via mitotic catastrophe. Depending on the cell line,
both caspase-dependent and independent mechanisms have been described [155].
Taxotere® has been shown to be a more potent cytotoxic agent when compared to Taxol
[154]. This is probably due to the increased intracellular retention of Taxotere®.
Necrosis is defined as the unregulated process of traumatic cell destruction that
ultimately results in the disintegration of the cell. It is usually a result of physiological
conditions such as infection, inflammation, or ischemia [153]. The most common
morphological feature of necrosis is cell and nuclear swelling. The term necrosis to
describe a form of cell death has been deemed by some to be inappropriate [156]. Majno
et al. [156] acknowledge that the term necrosis is commonly misused in the literature to
describe accidental cell death. These authors say it is inappropriate because necrosis does
not indicate a form of cell death but rather it refers to changes secondary to cell death.
According to these authors, cell death occurs long before necrotic changes can be seen.
Thus, they proposed the term oncosis to describe cell death with cellular swelling,
organelle swelling, and increased membrane permeability. Swelling is caused by a
deficiency in ATP production that leads to membrane ionic pump failure [157].
Consequently, both apoptosis and oncosis lead to necrosis. Apoptosis leads to necrosis
with karyohexis (DNA strand breakage) and cell shrinkage, while oncosis leads to
necrosis with karyolysis (nuclear rupture) [156].
It has been proposed that other proteases are involved in caspase-independent
forms of cell death. Proteases such has cathepsins, calpains, and other serine proteases
have been implicated (reviewed in [151-152]). Many of these proteases have been shown
to cleave some of the classical caspase substrates such as poly (ADP) ribose polymerase
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and Bid, indicating that these proteases might also mimic the cellular effects of caspases
[158-159]. Cathepsin B, L, and D have been shown to participate in both caspasedependent and caspase-independent PCD induced by several stimuli including death
receptors [160-163].

Survival Proteins as Inhibitors of Cell Death
Deficiencies in apoptosis and other forms of cell death (discussed in the previous
section) have been associated in general with cancer, autoimmunity and infection
[157,164]. PCa has also been shown to have these deficiencies in apoptosis that renders
them resistant to cell death (reviewed in [164]). Defects in apoptosis play a role in the
initial steps of PCa development by inadequate removal of damaged cells. They also play
a role in the progression and metastasis of PCa by increasing survival in ectopic tissue
sites lacking the otherwise needed growth factors. Lastly, these defects lead to resistance
of many types of therapy used to treat PCa.
Bcl-2 is a commonly studied anti-apoptotic protein (reviewed in [164]). It protects
cells from growth factor withdrawal, irradiation, cytotoxic drugs, heat and deregulated
oncogenes. Bcl-2 expression levels increase in a variety of human cancers, including
PCa. In some tumors, such as prostate tumors, Bcl-2 expression correlates with tumor
progression while in other tumors, such as breast and lung tumors, increased Bcl-2
expression is associated with better prognosis (reviewed in [164]). Survivin is another
survival protein that upsets that balance of life and death in PCa cells. Survivin is an IAP
usually expressed only in fetal tissues. However, aberrant survivin expression is often
observed in tumors (reviewed in [164]). Expression levels of survivin are highest in the
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G2/M phase of the cell cycle and drop off during cell cycle arrest. NFkB is another a
survival protein that upon causes decreased in apoptosis following activation. NFkB is a
transcription factor that increases the expression level of anti-apoptotic proteins including
lAPs, superoxide dismutases, myc oncogenes, Bcl-2, and Rb [165]. NFkB also plays a
role in inflammation by upregulating the expression of cytokines and various growth
factors. NFkB was recently shown to be constitutively active in PCa cells and is
overexpressed in PIN and PCa [166]. Thus, NFkB may play a role in the early stages of
PCa development.

Heat Shock Proteins
Mammalian hsps have been shown to inhibit many different kinds of cell death
(reviewed in [167]). Most hsps are involved in the proper folding and/or elimination of
misfolded proteins, thus contributing to cell survival. Hsps are often overexpressed in
cancers and can contribute to malignant transformation by allowing the cells to adapt to
gradual changes in the environment and survive otherwise lethal conditions (reviewed in
[167]). Clusterin is another anti-apoptotic protein whose upregulation is associated with
many tumors including PCa [168]. Like hsps, clusterin is regulated by heat shock factor-1
and thus may also function as a molecular chaperone. Upregulation of clusterin correlates
with increased Gleason score and occurs in response to androgen withdrawal and
chemotherapy. Clusterin has been shown to confer resistance to cell death induced by
these stimuli as well as radiation. The hsps are classified into groups according to their
size as high molecular weight hsps and low molecular weight hsps (reviewed [167]). All
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high molecular weight hsps are ATP-dependent chaperones and require co-chaperones to
mediate ATP binding. The low molecular weight hsps are ATP-independent.
The high molecular weight hsp group is further divided into families: hsp90,
hsp70, and hsp60 (reviewed in [167]). The hsp70 family consists of the stress-inducible
hsp70, constitutively expressed hsc70, mitochondrial hsp75, and endoplamic reticulumassociated GRP78. Under normal conditions these chaperones assist the folding of nacent
peptides, assembly of protein complexes, and protein transportation across membranes.
Hsp70 is also a known antiapoptotic protein that binds to Apaf-1 and inhibits the
formation of the apoptosome and thus prevents the activation of caspase-9 [169-170].
Hsp72 was shown to inhibit chemical or radiation-induced apoptosis in androgendependent (LNCaP) and androgen-independent (PC3) prostate cancer cells [171]. Hsp70
can also prevent caspase-independent cell death by directly binding to and neutralizing
the AIF in Jurkat T cells [172]. However, the mechanism by which hsp70 blocked
mitochondrial membrane depolarization and the release of cytochrome c was not
elucidated. The hsp90 family of proteins consists of hsp90ot, hsp90p, and GRP94. Both
hsp90 isoforms are constitutively expressed and associate with a number of signaling
proteins, including steroid receptors like the AR [77]. Like hsp70, hsp90 prevents
apoptosome formation [173]. In addition, hsp90 binds to Akt/PKB and protects it from
dephosphorylation [174]. Hsp60 is also constitutively expressed and is found primarily
within the mitochondria. Hsp60 aids in the folding of mitochondrial proteins and
facilitates the degradation of misfolded or denatured proteins.
Hsp27 and oc-crystallins comprise the low molecular weight hsps and are
important in for preventing non-specific, aberrant protein aggregation (reviewed in
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[167]). These hsps do not require ATP for chaperone activity nor to they require
cochaperones, but seem to be dependent on the phosphorylation or oligomerization status
of the hsps. Hsp27 and ocB-crystallin are known anti-apoptotic proteins that interfere with
the activation of caspase-9 and caspase-3, respectively [175-176]. Hsp27 and aBcrystallin have been shown to decrease cellular oxidative stress levels by increasing the
levels of the antioxidant glutathione (reviewed in [167]).

Hsp27 may also exert a

protective affect by stabilizing actin microfilaments. HSP27 was also shown to directly
interact with Daxx to prevent the death receptor pathway of apoptosis [177]. Another
study showed that hsp27 is part of a complex consisting of the 26S proteosome and
phosphorylated-lKB [178]. Thus, hsp27 facilitates the degradation of IKB, resulting in the
release and activation of NFkB. Overexpression of hsp27 has been observed in PCa
specimens and its expression was shown to correlate with clinical outcome [179]. aBcrystallin binds procaspase-3 and prevents its autoproteolytic maturation [175]. aBcrystallin was also recently found to bind Bax and Bcl-Xs to prevent their translocation to
the mitochondria during apoptosis [180].

Insulin-Like Growth Factor System
Growth factors often play a key role in the balance of cell growth and cell death.
The insulin-like growth factors (IGF) are important mediators of growth, differentiation,
apoptosis, and transformation (reviewed in [181]). IGFs are crucial for normal growth
and development and can also be key mediators of malignant transformation. Both IGF-I
and IGF-II are equally effective as mitogenic agents. IGF-I is required for normal growth
after birth and is also required for the differentiation of many organ systems. IGF-I
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expression is growth hormone dependent and IGF-II expression is not. Blood levels of
IGF-I and IGF-II are high, but the insulin-like activities of these growth factors are
inhibited because they are almost completely bound to IGF binding proteins. The
circulating level of IGF-I in the blood has been associated with an increased risk of PCa.
IGF-1 transgenic mice were shown to develop PIN and PCa (reviewed in [182]). Loss of
genetic imprinting (an epigenetic phenomenon that results in the expression of one
parental allele while the other is silenced) of the IGF-II gene has been shown in PCa
tissue which may lead to an increase in mRNA levels [183].
IGF function is mediated by two IGF receptors: IGFR1 and IGFR2 (reviewed in
[181]). Both IGF-I and IGF-II can bind either receptor. IGFR1 is a member of the
tyrosine kinase receptor superfamily. Upon ligand binding numerous kinase signal
transduction pathways can be activated including PI3K and Ras/MAPK. These signaling
cascades lead to increased proliferation, resistance to apoptosis, and differentiation.
IGFR1 is overexpressed in many tumors, including PCa. IGFR2 (also known as the
mannose-6-phosphate receptor) is a potential tumor suppressor gene that is incapable of
signaling due to the lack of tyrosine kinase activity [184]. IGF-II binds IGFR2 with 100
fold higher affinity than IGF-I. This receptor down regulates growth in many cell types
by binding IGF-II, which is then internalized and degraded within lysosomes.
There are six IGFBPs that play key regulatory roles of the IGFs (reviewed in
[181]). Expression of IGFBPs appears to be tissue specific: IGFBP-1 is expressed mainly
in the liver and endometrium, IGFBP-2 in the neural tissues and the prostate, IGFBP-4 in
bones, IGFBP-5 in bone, IGFBP-3 in the liver and a variety of nonhepatic tissues, and
IGFBP-6 in many tissues. IGFBPs can either inhibit or potentiate IGF activity. IGFBP-
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1,3,4 and 6 have been shown to inhibit IGF activity, while IGFBP-2 and 5 potentiate it
[185]. Ninety nine percent of circulating IGFs are bound to IGFBPs and 75% of bound
IGFs are found in a complex with IGFBP-3 and the acid labile subunit, a liver-derived,
growth hormone-regulated glycoprotein. Increased levels of IGFBP-3 have been
associated with a decreased risk of PCa (reviewed in [186]). IGFBP-3 prolongs the halflife of IGFs in the serum, but in tissues it can inhibit their activity by blocking interaction
with IGFR1. IGFBP-3 has also been shown to inhibit IGF activity via an IGFindependent mechanism that is not clearly understood (reviewed in [186]). A putative
receptor has been found and preliminary data shows that signaling through this receptor
activates caspase-8 in response to IGFBP-3 binding. Proteases, such as PSA, can cleave
IGFBP-3 and block the inhibitory affects of IGFBP-3.

Lens Epithelium-Derived Growth Factor
Like other survival proteins, lens epithelium-derived growth factor p75
(LEDGF/p75), also known as dense fine speckles protein of 70 kilodaltons (DFS70) [19]
and transcriptional coactivator p75 [187], may also inhibit cell death and thus play a role
in malignant transformation. The localization of the LEDGF/p75 gene on chromosome
9p22.2 is of interest because this region is a common target for a variety of human
cancers [188]. Recent studies showed that the LEDGF/p75 gene is involved in a
chromosomal translocation in patients with certain types of leukemia [189-191]. The
t(9;ll)(p22;pl5) translocation was found independently in two different patients with
Acute Myeloid Leukemia [189,191] and in one patient with biphenotypic leukemia [190].
In this translocation the C-terminus of LEDGF/p75 gene (chromosome 9p22) is fused to
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the N-terminus of the NUP98 gene (chromosome llpl5). The NUP98 protein is a
component of the nuclear pore complex and most likely functions as a docking protein
involved in nucleocytoplasmic transport. While it is not clear how this fusion may lead to
leukemogenesis, one possibility is that the fusion may result in the loss of normal
function of the proteins involved. Alternatively, there might be a gain of function
abnormality. For instance, in the NUP98-LEDGF/p75 fusion, the PWWP domain of
LEDGF/p75 is replaced by the FXFG repeats of NUP98, which interact with cAMPresponsive element-binding proteins, known as strong transcription transactivators [189].
Thus, the fusion protein may be an aberrant transcription factor. Yet another possibility is
that as a result of the translocation the PWWP domain of LEDGF/p75 (further discussed
below) is disrupted and cellular growth is deregulated.
LEDGF/p75 is the target of an autoantibody response in many inflammatory
disorders such as atopic dermatitis, atopic dermatitis with cataracts, Vogt-Koyana-Harada
(VKH), asthma, and interstitial cystitis (reviewed in [192]). This protein consists of 530
amino acids with a highly conserved N-terminal region called HATH domain,
homologous to the N-terminus of members of the hepatoma-derived growth factor family
(HDGF) [187,193-194]. This region is also called the PWWP domain due to the presence
of a highly conserved proline-tryptophan-tryptophan-proline motif. LEDGF/p75 has an
alternatively spliced form, p52, which is a potent transcription coactivator implicated in
the coupling of transcription and pre-mRNA splicing processes [187,195-196]. The
biological function of LEDGF/p52 is not clearly understood and is currently under
investigation in our laboratory. LEDGF/p52 is a 333 amino acid protein that shares the
first 325 N-terminal amino acid residues with LEDGF/p75, differing only in the last eight
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residues. The LEDGF gene consists of approximately 15 exons and 14 introns [188].
LEDGF/p75 mRNA is derived from exons 1-15, which results from the removal of all the
intervening sequences. The p52 mRNA contains exons 1-9 and 24 nucleotides of the
ninth intron that encodes its extreme C-terminal eight amino acids not present in
LEDGF/p75. Presently, there is no known disease associated with autoantibodies against
p52, and the autoantibodies that react with LEDGF/p75 do not recognize p52.
Both LEDGF/p75 and LEDGF/p52 contain the PWWP domain. Other proteins
besides the HDGF family also contain this domain. They include DNA mismatch repair
proteins, DNA-methyl transferases, and transcription activators that regulate cell growth
and differentiation [197-198]. The PWWP domain was identified by protein sequence
analysis and contains multiple putative nuclear localization sequences and casein kinase
sites and is presumably involved in the pro-survival activities of the protein [193]. Stec et
al. [197] speculated that this domain may regulate protein-protein interactions. However,
there is also evidence that the PWWP domain of the mammalian DNA methyltransferase
DnmtSb has a basic surface that binds DNA in vitro [199]. Ge et al. [200] confirmed
these findings in vivo, concluding that the PWWP domain is a chromatin targeting
domain that is essential for the function of methyltransferases.
LEDGF/p75 has been shown to be a survival factor that confers resistance to
stress-induced cell death [176,192,198,201-202]. Overexpression or exogenous addition
of recombinant LEDGF/p75 to the medium of cells in culture stimulated growth and
prolonged the survival of HepG-2, lens epithelial cells (EEC), Cos-7, skin fibroblasts and
keratinocytes in serum-free medium, or in response to thermal, oxidative, or ethanol
stress [193,202-204]. In support of this data, antibodies to LEDGF/p75 added to the
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medium of LEC induced cell death by sequestering the protein in the medium and
keeping it from entering the cells to act as a pro-survival factor [193,205]. LEDGF/p75
has been shown to protect human retinal pigment epithelial cells from oxidative stress
and UV irradiation [206]. The protein also protects photoreceptor cells against light
damage in normal rats and against inherited photoreceptor degenerations in the Royal
College of Surgeons (RCS) rats [207]. By using a green fluorescence protein (GFP)tagged LEDGF/p75, Fatma et al. [208] showed that the fusion protein was secreted from
transfected LEC, and was capable of reentering the cells where it was transported back to
the nucleus. A recent study confirmed LEDGF/p75 does contain a nuclear localization
sequence identified at residues 148-156 [209]. The mechanism by which LEDGF/p75
crosses the plasma membrane is unknown. However, a sequence resembling the human
immunodeficiency virus (HIV) TAT protein was identified in the N-terminus of
LEDGF/p75 [176]. This sequence may facilitate the penetration of the membrane by
LEDGF/p75. Another possible mechanism of penetration is through its numerous
potential myristylation sites (found by sequence analysis of the protein), which could
facilitate the transport through the cytoplasmic membrane [210].
Our laboratory and others are currently investigating the mechanism by which
LEDGF/p75 promotes cell survival against stress induced cell death. The most likely
mechanism underlying this pro-survival activity is the transactivation of pro-survival
genes through direct interaction of LEDGF/p75 with heat shock elements (HSE)
(nGAAn) and stress response elements (STRE) (A/TGGGGGaA/T) in the promoter
regions of these genes. LEDGF/p75 has been shown to transactivate anti-oxidant protein
2 (AOP-2), involucrin, alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH),
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hsp27, aB-crystallin, and hsp90 [176,202,204,211-212]. More specifically, the Nterminus of LEDGF/p75 (residues 1-187) was shown to bind exclusively to the consensus
core sequence of the STRE but not to the consensus sequence of the ELSE. Conversely,
the C-terminus (residues 188-530) bound to the consensus sequence of the HSE
(nGAAn), but not to that of the STRE [213]. Sharma et al.. showed that LEDGF/p75 can
be inactivated by TGFp by inhibition of the transactivation activity of LEDGF/p75 and
attenuation of its DNA binding ability [214]. AOP-2 is an anti-oxidant protein that
protects DNA from damage caused by ROS [211]. Involucrin is another protective
protein that is a surface marker of differentiation in keratinocytes. It is a transglutaminase
substrate that aids in the assembly of the cornified envelope of the epidermis [212]. Both
ADH and ALDH are important enzymes required for the conversion of vitamin A
(retinal) to retinoic acid (RA) [202]. RA is the active form of retinal and is essential in the
growth, development, and maintenance of epithelia. RA is also a key molecule in eye and
photoreceptor development.
LEDGF/p75 has also been shown to play a role in the integration of the human
HIV genome into cellular DNA [215].

The HIV integrase protein orchestrates the

insertion of the viral genome into the cellular chromosomal DNA. This process is
preceded by the formation of a preintegration complex (PIC), which contains a copy of
the viral genome associated with both viral and cellular proteins. Cherepanov et al. [215]
proposed that LEDGF/p75 may play an important role in the activation of HIV by stress
stimuli and speculated that the protein may be a docking site for the PIC. Preferential
integration into this potential docking site may contribute to more efficient provirus
expression under the state of chronic oxidative stress associated with Acquired
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Immunodeficiency Syndrome (AIDS). In a subsequent paper, this group also showed that
in addition to being a docking site, LEDGF/p75 is responsible for the chromosomal
targeting of the integrase into the host genome [216]. Cherepanov et al. [217] identified
the integrase binding domain of LEDGF/p75 (residues 347-429) that is required for its
interaction of the HIV integrase protein.
Studies conducted in our laboratory showed that LEDGF/p75 is cleaved by
caspases-3 and -7 during apoptosis at the DEVPD

'J A

and DAQD 486 sites to generate

fragments of 72, 68, and 65 kD [198] (Figure 10). LEDGF/p75 was found to be
predominantly cleaved into a 65 kD fragment, which was shown to be produced by the
cleavage of the protein at two sites: DEVPD30|G and DAQD486jG. This cleavage was
found to be mediated by the effector caspases-3 and -7, but not caspase-6. A subsequent
cleavage of the 65 kD fragment was shown to generate a 58 kD fragment and was
produced from a cleavage at a third site, WEID85f N. Full-length LEDGF/p75 protein was
shown to prolong the survival of HepG-2 liver tumor cells cultured in serum free
medium. The expression of the 65 kD fragment prevented prolonged survival, slowed cell
proliferation, and appeared to enhance the rate of apoptosis, suggesting that cleavage of
the protein during apoptosis abolishes its pro-survival activity. Cleaved forms of the
protein colocalize with the fragmented chromatin seen in apoptotic cells, suggesting that
they retain the ability to bind DNA. This is thought to occur through a predicted A/T
hook region (residues 194-198) maintained in both cleavage fragments. This motif has
been identified in transcription coactivators such as the high mobility group proteins. A/T
hook regions allow transcription coactivators to bind the minor groove of short stretches
of AT-rich regions of DNA and thus regulate the transcription of genes in close
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Figure 10. Diagram of LEDGF/p75 and the cleavage fragments
formed during apoptotic cell death. LEDGF/p75 is cleaved early in
apoptosis by caspases at the DEVPD30 or DAQD486 sites to
generate a putative 72 kD fragment (undetected in apoptotic
lysates) and a 68 kD fragment, respectively. Further cleavage of
the 72 kD fragment at the DAQD486 site or cleavage of the 68 kD
fragment at the DEVPD30 site generates the 65 kD fragment. The
65 kD fragment is cleaved late in apoptosis at the WEID85 site to
generate a 58 kD fragment, which essentially lacks a PWWP
domain.
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proximity. Investigators in our laboratory are currently studying whether the cleavage
fragments of LEDGF/p75, which seem to retain the ability to bind DNA, retain
transcriptional activation properties.
The present study focuses on the role of LEDGF/p75 in PCa. Through an analysis
of the ANA response in PCa, we identified LEDGF/p75 as a novel TAA in PCa. This
data led us to the hypothesis that LEDGF/p75 is aberrantly expressed in prostate
tumors, which could lead to the prolonged survival of cells within the prooxidant
environment of the prostate during the early stages of tumorigenesis. Further analysis
showed that LEDGF/p75 is overexpressed in PCa tumors and cells lines. These
observations prompted us to examine the biological impact of LEDGF/p75
overexpression in prostate cells. We provide here the first evidence that overexpression
of LEDGF/p75 in PCa cells has a protective effect against caspase-independent cell death
induced by high levels of the oxidants t-butyl hydroperoxide and Taxotere®. The data
presented here has implications for understanding the role of LEDGF/p75 in increasing
prostate tumor survival in an environment of high oxidative stress.
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Abstract
Background: Cancer patients produce autoantibodies to self-proteins called tumorassociated antigens (TAA). These autoantibodies represent potentially valuable markers
for identifying therapeutic targets. This study was designed to identify novel TAA in
prostate cancer (PCa).
Methods: Serum autoantibodies to the survival protein lens epithelial-derived growth
factor (LEDGF/p75) were detected by immunofluorescence microscopy, ELISA, and
immunoblotting. Expression of LEDGF/p75 in prostate cells and tumors was evaluated
by immunoblotting or immunohistochemistry. Apoptotic cleavage of LEDGF/p75 was
detected by immunoblotting.
Results: Anti-LEDGF/p75 autoantibodies were detected by ELISA in 18.4% of PCa
patients and 5.5% of matched controls (p < 0.001). LEDGF/p75 expression was detected
in 93% of prostate tumors but not in normal prostate. Strong expression of the protein
was observed in 61% of prostate tumors. Cleavage of LEDGF/p75 was detected in
apoptotic PCa cells.
Conclusions: The high expression of LEDGF/p75 in prostate tumors could be induced by
inflammation and oxidative stress. LEDGF/p75 cleavage fragments generated during
prostate tumor cell death might trigger autoantibodies under inflammatory conditions in
certain patients.

Key Words: apoptosis; autoantibodies; LEDGF/p75; prostate cancer; tumor-associated
antigens
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Introduction
The serum autoantibody repertoire from cancer patients is currently being actively
exploited for the identification of TAA and the design of TAA panels or arrays [1-3].
Such arrays would facilitate autoantibody profiling and potentially aid in the serological
diagnosis and prognosis of tumors. Although the factors leading to autoantibody
production in cancer patients are not clear, emerging data indicate that TAA are
autologous intracellular proteins (e.g. Survivin and p53) that present altered regulation,
structure, or function in tumors [4-6]. Hence, cancer-associated autoantibodies have been
considered as reporters identifying aberrant cellular mechanisms underlying malignancy
[5]Although autoantibody responses to intracellular proteins have been extensively
investigated in a wide variety of cancers [1-6], information about these responses in
prostate cancer (PCa) is still limited. Early studies demonstrated the presence of
antinuclear autoantibodies (ANA) in PCa patients [7-8] but the autoantibodies were also
found in patients with benign prostatic hyperplasia (BPH). This, along with the fact that
ANA had not yet been widely associated with cancer at the time, led to the conclusion
that in PCa these autoantibodies might be representative of non-specific markers pointing
to other immunological processes [7-8].
In recent years, several groups have exploited the serum autoantibody repertoire
from PCa patients to identify several candidate TAA. The list of these antigens include
5a-reductase [9], p53 [10], prostasomes [11], glucose-regulated protein-78 kD (GRP78)
[12], MUC1 [13], and PARIS-1 [14]. Zhang et al. [2] demonstrated recently the presence
of serum autoantibodies to a panel of known TAA in various human cancers, including
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PCa. In that study, autoantibody reactivity to the individual TAA rarely exceeded 20% in
the cancer patient populations (as compared to less than 5% in normal human sera).
However, successive addition of TAA to a mini-array of seven antigens resulted in a
dramatic increase in the number of positive antibody reactions in cancer patients but not
in healthy controls. Interestingly, cancers of the prostate, breast, and lung showed distinct
profiles of autoantibody reactivity in which specific TAA were preferentially targeted.
These results strongly suggested that uniquely constituted antigen panels or mini-arrays
might provide an alternative approach for discriminating autoantibody reactivity between
cancer patients and control individuals and distinguishing between some types of cancer.
The identification of additional TAA is therefore essential for designing specific antigen
arrays for autoantibody profiling in cancer populations.
To advance our identification of potential TAA targeted by circulating
autoantibodies in PCa patients, we undertook a comprehensive analysis of the serum
ANA repertoire in this cancer type. We observed that while the general frequency and
titers of ANA in PCa patients were relatively similar to those in matched controls,
significant differences could be detected between the two groups in the autoantibody
response to an individual autoantigen, the lens epithelial-derived growth factor p?5
(LEDGF/p75). In addition, we detected high expression of this antigen in prostate
tumors, particularly advanced stage tumors, but not in normal prostate. Cleavage of
LEDGF/p75 was also detected in apoptotic prostate cancer cells. LEDGF/p75, also
known as transcription co-activator p75 [15-16] and dense fine speckled protein of 70 kD
(DFS70) [17], is a survival protein that protects mammalian cells from stress-induced
apoptosis by upregulating the expression of anti-apoptotic heat shock proteins [16,18].
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We demonstrated recently that this pro-survival function is abrogated during apoptosis by
caspase-induced cleavage of the protein [19]. The autoantibody response to LEDGF/p75
in certain PCa patients suggests that the immunogenicity of this protein might be
increased in prostate tumors, perhaps as a consequence of aberrant expression combined
with proteolytic cleavage in tumor cells dying under an inflammatory environment.

Materials and Methods

Patient Samples
Serum samples were obtained with informed consent from randomly selected
patients with PCa (n=207) and a control group of age-matched male patients with no
clinical evidence of PCa (n=166) seen at Loma Linda University Medical Center and
Faculty Medical Offices. The average age was 71.9 years old (range 46-100) for the PCa
group and 64.9 years old (range 46-100) for the matched control group. It has been
established in autopsy studies that silent PCa is often present in elderly males 120]. Since
this study was designed to analyze the serum antinuclear autoantibody repertoire in PCa,
two additional control groups less likely to have PCa were also selected for the study.
One group consisted of healthy blood donors (n=82) with an average age of 31.5 (range
18-59). Sera from these donors, designated normal human sera (NHS), were obtained
from the serum bank of the W.M. Keck Autoimmune Disease Center of The Scripps
Research Institute and were used to establish ELISA cut-off values in recent studies of
cancer-associated autoantibodies [2,21]. The second group consisted of a random
selection of 44 male blood donors from the San Bernardino Blood Bank, with an average
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age of 47.0 (range 20-76), and was used in ANA screening studies. This study was
approved by the Institutional Review Board of Loma Linda University.

Cell Lines
Cell lines were obtained from the American Type Culture Collection (Rockville,
MD), with the exception of PrEC (Cambrex, Walkersville, MD) and 55T and 41T
(BRFF, Jamsville, MD).

Cells were grown in 5% C02 at 37°C using the media

recommended by the suppliers.

Preparation of Recombinant His-tagged LEDGF/p75
A pET-28a plasmid (Novagen, Madison, WI), encoding full-length LEDGF/p75
with an NH2-terminal 6xHis tag was transformed into BL21-Codon Plus competent
Escherichia coli (Stratagene, La Jolla, CA). Bacterial cultures induced to overexpress
LEDGF/p75 with isopropyl-beta D-thiogalactopyranoside (IPTG) were centrifuged and
pellets were resuspended in binding buffer containing 20 mM sodium phosphate pH 7.4,
0.5 M NaCl, 0.02% NaN3, and the Complete™ protease inhibitor cocktail (Roche,
Indianapolis, IN). The suspension was sonicated, centrifuged, and the supernatant was
passed through a HiTrap Chelating column using the AKTAFPLC (Amersham Biosciences,
Piscataway, NJ). Bound LEDGF/p75 was eluted with binding buffer containing 0.5 M
imidazole. The purity and integrity of recombinant LEDGF/p75 was assessed by SDS
PAGE and Coomassie Blue staining (data not shown). Preparations containing fulllength LEDGF/p75 were used for ELISA analysis after determining protein
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concentrations using the BioRad DC Protein Assay Kit (BioRad Laboratories, Hercules,
CA).

Indirect Immunofluorescence (IIF) Microscopy
Prostate cancer cells grown on coverslips were washed with PBS, fixed and
permeabilized in methanol/acetone (3:1 v/v), and stained with a highly specific human
anti-LEDGF/p75 serum from a PCa patient diluted at 1:200. Fluorescein-5-isothiocyanate
(FITC)-conjugated goat anti-human IgG antibody (Caltag Laboratories, San Francisco,
CA) was used as secondary detecting reagent at a 1:100 dilution. Cells were
counterstained with 4’,6-diamidino-2-phenylindole (DAPI) for DNA visualization and
examined under a fluorescence microscope. Pre-fixed HEp-2 cell slides (Bion, Park
Ridge, IL) were used to detect serum ANA following the staining procedure indicated
above. Sera were initially tested at a 1:100 dilution and considered positive for ANA only
if the nuclear or cytoplasmic fluorescence in the HEp-2 cells was significantly higher
than the fluorescence of cells incubated with NHS used at a 1:100 dilution.
Discrimination between positive and negative sera was facilitated by a Spot Imaging
System (Diagnostic Instruments, Sterling Heights, MI), which allowed the simultaneous
display on a computer screen of images from NHS, positive control sera, and
experimental sera. All images were acquired under identical conditions. Ambiguous
results were considered negative.

Immunoblotting
Whole cell lysates were prepared as indicated previously [22] and the protein
concentration in the lysates was determined using the BioRad DC Protein Assay Kit to
68

ensure equal loading of proteins per lane in sodium dodecyl sulfate polyacrylamide gels.
Electrophoresis and immunoblotting were performed using standard procedures [23].
Patient sera were used at a dilution of 1:100.

ELISA
ELISA procedures were performed essentially as indicated by Zhang et al. [2].
Briefly, purified recombinant LEDGF/p75 was diluted in phosphate buffered saline
(PBS) to a final concentration of 0.5 qg/mL and 200 pL of this dilution were used to coat
Immulon-2 Flatbottom microtiter plates (Fisher Scientific, Tustin, CA) for 16 h at 4°C.
After removal of the protein solution, plates were blocked with 0.1% gelatin in PBS for 2
h at 4°C. The plates were washed four times with PBS/0.05% Tween 20 (PBST). Patient
sera diluted at 1:200 in serum diluent solution (1 mg/ml gelatin, 0.75 mg/ml bovine
gamma globulin, and 1 mg/ml bovine serum albumin in PBST) were then added to each
well. After 1.5 h at room temperature, plates were washed four times with PBST. Each
well was then incubated for 1.5 h with horseradish peroxidase (HRP)-conjugated goat
anti-human IgG (Caltag Labs, San Francisco, CA) at a 1:4000 dilution. The plates were
washed four times with PBS and developed by incubating each well with 200 pi
peroxidase substrate solution (1 mg/ml 2,2-azino-bis[3-ethylbenzthiazoline-6-sulfonic
acid] with 0.005% hydrogen peroxide in citrate buffer, pH 4.6) for 2 h. Each serum
sample was tested in triplicate and the average absorbance at 490 nm was used for data
analysis. The cutoff value designating positive reactions was calculated as the mean
absorbance value of a group of 82 NHS, different from the gender- and age-matched
control group, plus three standard deviations (SD). Patient sera and NHS were tested
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simultaneously. All positive sera, and some negative sera, were tested in triplicate in at
least two independent experiments. Each confirmation ELISA experiment included at
least 10 NHS and a positive control serum (a rabbit antibody against LEDGF/p75). The
10 NHS samples were selected to represent a range of 2 SD above and below the mean of
the 82 NHS and the average value of the 10 NHS were used in each experiment to
normalize all absorbance values to the standard mean of the 82 NHS. For preabsorbtion
experiments, diluted patient sera (1:200) were incubated with 15 pg/mL of recombinant
LEDGF/p75 for 1 h at 37°C prior to testing by ELISA.

Immunohistochemistry
Human prostate cancer Histo™-Array slides (Imgenex, San Diego, CA) were
fixed for 1 h at 55°C. The slides were deparaffinized, rehydrated and stained using the
Biogenic i6000 auto Stainer (Biogenex Corporation, San Ramon, California) following
the manufacturer’s standardized immunohistochemistry protocol. Briefly, the sections
were immersed in the Citra-Plus antigen retrieval solution (BioGenex). Antigen retrieval
was performed by microwaving the slides for 2 minutes at 100% power followed by 10
minutes at 20% power. Slides were then cooled in the antigen retrieval solution for 20
minutes. Non-specific peroxidase activity was blocked for 15 minutes with 3% hydrogen
peroxide in 10% methanol and non-specific protein binding sites were blocked with
Power Block© universal blocking reagent (Biogenex Corporation) for 10 minutes.
Sections were incubated for 1 h with a primary rabbit anti-LEDGF/p75 antibody (1:500),
rinsed in PBS 3 times, then incubated with the Multi-link© (Biogenex Corporation)
biotinylated secondary antibody for 20 minutes followed by incubation with a
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streptavidin-coated peroxidase Supersensitive Label© (Biogenex Corporation) for 20
minutes. The antibody-localized antigen was then detected by a 5-minute peroxidase
activation of a water-insoluble 3-Amino-9-Ethylcarbazole (AEC) chromagen (Romulin
AEC-Biocare Medical, Walnut Creek, CA) that forms a reddish-orange precipitate.
Sections were then counterstained lightly with hematoxylin (Sigma-Aldrich, St. Lois,
MO) and mounted with Permount (Fisher Scientific).

Induction of apoptosis
Apoptosis was induced in LNCaP, PCS, and DU145 cells by exposure to 4 pM
staurosporine (STS) (Alexis Biochemicals, San Diego, CA) for up to 24 h or by exposure
to 100 ng/mL actinomycin D (Act D) (Sigma) for 4 h followed by 100 ng/mL TRAIL (R
& D Systems, Minneapolis, MN) for up to 24 h.

Statistical Analysis
Chi Square analysis was used to determine the significance of differences in ANA
frequencies in the prostate cancer group and the control groups. Chi Square was also used
to determine whether LEDGF/p75 staining in tumor tissue correlated with tumor stage.
For the ELISA data, an unpaired t-test (two tailed) was used, while for the preabsorbtion
experiments a paired analysis (two tailed) was performed.
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Results
Analysis of the Circulating ANA Repertoire in PCa by IIF Microscopy
Using IIF microscopy in HEp-2 slides, we screened sera from 207 patients with
clinically diagnosed PCa, 166 age-matched men with no clinical evidence of PCa (based
on medical history), and 44 randomly selected male blood bank donors for the presence
of circulating ANA. The ANA frequency was 29% for PCa patients, 24% for the matched
controls, and 4.5% for the blood bank donors (Table II). ANA frequency (based on
positive reaction at 1:100 dilution) was significantly increased in both the prostate cancer
group and the matched control group when compared to the blood bank donors (p<0.002
and p<0.02, respectively). ANA titers were determined by serial dilutions starting at 1:80,
1:160, 1:320 etc. until sera became negative. Average titers for the PCa group, matched
control group, and blood bank donors were 1:450, 1:344, and 1:160, respectively. While
the general frequency and titers of ANA in the PCa and matched control groups were not
significantly different, it was noted that differences in specific antibody staining patterns
could be detected between the two groups. A staining pattern characterized by dense fine
speckles in interphasic nuclei and bright staining of mitotic chromosomes was
predominant in the PCa group (Table II, Figure 11). This staining pattern, characteristic
of autoantibodies to DFS70 (an alternative name for LEDGF/p75)[17], was present in
14% (29/207) of the PCa sera, compared to 4.2% (7/166) in sera from the matched
control group, and 2.3% in sera from blood bank donors (Table II). Other ANA staining
patterns were also observed in the three groups (Table II).
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Figure 11. Detection of autoantibodies to LEDGF/p75 by indirect
immunofluorescence (IIF) microscopy in sera from patients with
prostate cancer. The staining pattern in FIEp-2 cells of a reference human
serum containing autoantibodies to LEDGF/p75 [17] and a rabbit antiLEDGF/p75 antibody are shown. This pattern consists of dense fine
speckles in interphase nuclei and bright staining of mitotic
chromosomes. Two representative sera from patients with PCa (P096
and PI 19) display the same LEDGF/p75 pattern. All cells were
counterstained with DAPI to confirm the nuclear localization of
LEDGF/p75.
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Detection of LEDGF/p75 Autoantibodies in PCa sera by ELISA
To explore the possibility that LEDGF/p75 could be the target of an autoantibody
response in some patients with PCa, sera from PCa patients and the matched control
individuals were tested by ELISA against purified recombinant LEDGF/p75. This
analysis showed that 18.4% (38/206) of the PCa patients produced autoantibodies to
LEDGF/p75, compared to 5.5% (9/164) of the matched controls (Figure 12A). The mean
absorbance value for the whole PCa group was 0.213 + 0.02 whereas the mean value for
the matched control group was 0.047 + 0.008 (p<0.001). The cutoff for positive antibody
reactivity against LEDGF/p75 was 0.268, which was defined as an absorbance greater
than three standard deviations above the mean value for 82 NHS obtained from healthy
donors. This relatively stringent cutoff criterion has been used in previous studies on
autoantibody responses in cancer [2,4,21]. The mean absorbance value of NHS was 0.057
+ 0.070. Only two NHS had values above the cut-off (0.399 and 0.298, respectively). We
used the NHS, rather than the gender- and age-matched control group, to determine the
cutoff for positivity to facilitate a comparison of the frequency and levels of antiLEDGF/p75 antibodies in PCa patients with those of age-matched men without clinically
apparent PCa. Forty patients with BPH were also tested for the presence of the antiLEDGF/p75 antibody. No significant differences were observed between patients with
BPH and normal controls (Figure 12B).
To determine the specificity of the anti-LEDGF/p75 antibody reactivity,
representative patient sera (5 PCa and 2 matched control) were pre-incubated with
recombinant LEDGF/p75 and then tested by ELISA. Non-preabsorbed sera were tested
simultaneously with matching preabsorbed sera. The specificity of the anti-LEDGF/p75

76

Figure 12. Detection of anti-LEDGF/p75 reactivity by ELISA. A. AntiLEDGF/p75 autoantibodies were detected by ELISA in sera from
patients with prostate cancer (n=206) and a gender- and age-matched
control group (n=164). The horizontal line indicates the cutoff value for
positive antibody reactivity against LEDGF/p75 (> 0.268), which was
defined as an absorbance greater than three standard deviations above
the mean value for 82 normal human sera (NHS). All samples were
tested in triplicate in at least two independent experiments. The mean
OD of the prostate cancer group was significantly higher than that of the
matched control group (p<0.001) as determined by a two-tailed,
unpaired Student’s t test. B. Anti-LEDGF/p75 autoantibodies in sera
from patients with BPH (n = 40) and NHS (n = 40). The cutoff value for
positive antibody reactivity against LEDGF/p75 (>0.103) was defined as
an absorbance greater than three standard deviations above the mean
value for the 40 NHS. C. Analysis of the specificity of anti-LEDGF/p75
reactivity in ELISA by blocking selected patient sera with soluble
recombinant protein. Five PCa sera (P096, P020, P010, P021, P082) and
two matched control sera (COOS and COOS) were pre-incubated with
(black bars) and without (white bars) purified recombinant LEDGF/p75
and then tested by ELISA. Significance of the reduction (*) was p <
0.001 using a paired, two-tailed Student's t-test. The reactivity of sera
from PCa patients and the matched controls was assessed
simultaneously. The results shown are mean values of three
determinations in three independent experiments.
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reactivity was evidenced by the significant decrease of absorbance values after
preabsorption (Figure 12C).

Detection of LEDGF/p75 Autoantibodies in PCa sera by Immunoblotting
To confirm that LEDGF/p75 was a target of an autoantibody response in some
patients with prostate cancer, we performed immunoblotting analysis of the ELISA and
IIF positive sera. Figure 13 shows representative sera reacting in immunoblots of whole
LNCaP cell lysates with a protein of approximately 75 kD that had identical migration as
the LEDGF/p75 protein recognized by a reference antibody. Both the
immunofluorescence staining patterns shown in Figure 11 and the reactivity with a band
around the 75 kD region are typical of serum autoantibodies to LEDGF/p75 [17].
In the immunoblotting analysis, 8 of the 38 PCa sera (27.7%) positive by ELISA
reacted strongly with a 75 kD band in the lysates (examples provided in Figure 13: sera
P001, P002, and P096). Intriguingly, none of the 9 matched control sera that were
positive by ELISA reacted with this band (data not shown). We also identified 8
additional PCa sera with IIF staining patterns typical of that of anti-LEDGF/p75
antibodies, with ELISA reactivity just below the cut-off, which were positive by
immunoblotting (see Figure 13: sera P019, P051, P072, P088, P093, PI 15, P119, and
PI 80). Two sera from the matched control group displaying the dense fine speckled IIF
pattern and poorly reactive by ELISA, also reacted with a 75 kD band (see Figure 12:
sera C069 and Cl34). In summary, 46 of 206 PCa sera (22.3%) reacted with LEDGF/p75
by either ELISA or by immunoblotting against LNCAP lysates, in contrast to 11 of 164
(6.7%) matched controls. Upon examining the clinical history of the majority of the
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Figure 13. Immunoblot of representative sera from patients with prostate cancer (P)
and gender- and age-matched control individuals (C) that displayed the
immunofluorescence staining pattern shown in Figure 11. Note that these sera reacted
with a protein of approximately 75 kD with migration identical to the LEDGF/p75
protein recognized by a reference human serum [17]. The blot is representative of at
least three independent experiments.
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patients producing the anti-LEDGF/p75 antibody we found no correlation between the
presence of this antibody and PSA levels, Gleason score, tumor stage, or therapeutic
regimen (data not shown).

Expression ofLEDGF/p75 Protein in Prostate Cell Lines
Previous studies on LEDGF/p75 have shown its expression in various non-tumor
mammalian cell types such as lens epithelial cells, fibroblasts, and keratinocytes [18] and
in a few tumor cell lines (e.g., Jurkat, HeLa, and HepG2) [19]. However, to date there are
no published studies addressing whether this protein is widely expressed in tumors. Since
the data presented above indicate that LEDGF/p75 is the target of humoral immunity in a
subset of patients with PCa, we sought to determine whether the protein is expressed in
prostate tumor cells and in other tumor cell types. Using a high titer, relatively
monospecific anti-LEDGF/p75 serum from patient P096, we detected expression of
LEDGF/p75 by immunoblotting in a panel of prostate cell lines that included six tumor
(DU 145, PCS, LNCaP, 4IT, 22Rvl, RWPE-2), two transformed non-tumor (RWPE-1,
and Pwr-IE), one transformed benign prostatic hyperplasia (55T), and one primary
normal prostate (PrEC) (Figure 14A). The lowest LEDGF/p75 expression appeared to be
in the normal PrEC cell line, suggesting the possibility that the protein might be
overexpressed in tumor or transformed cells. Expression of LEDGF/p75 was also
detected in other non-prostate tumor cell lines (Figure 14B), with lower expression
observed in liver HepG2 tumor cells.
Using IIF microscopy, we observed strong nuclear staining associated with
moderate cytoplasmic staining in LNCaP (androgen-dependent) and PCS (androgen-
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Figure 14. Expression of LEDGF/p75 in prostate and other tumor cell lines detected
by immunoblotting. A. Expression of LEDGF/p75 in a panel of prostate cell lines
(tumor: DU 145, PCS, LNCaP, 4IT, 22Rvl, RWPE-2; transformed non-tumor:
RWPE-1 and Pwr-IE; transformed benign prostatic hyperplasia: 55T; and primary
normal, PrEC). Twenty pg of total cellular protein were loaded per lane. P-actin was
used as a sample loading control. B. Expression of LEDGF/p75 in the tumor cell
lines Jurkat, A293, HL60, Colo320, and HepG2, and in FDC-P1 myeloid
hematopoietic progenitor cells. LEDGF/p75 was detected in whole cell lysates
blotted onto nitrocellulose using serum from PCa patient P096. Blots are
representative of at least two independent experiments.
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independent) prostate tumor cells (Figure 15). Relatively weaker staining was observed
in PrEC normal prostate cells, consistent with the immunoblotting results (Figure 14).
The nuclear localization of LEDGF/p75 has been documented previously [17].

Expression ofLEDGF/p75 Protein in Prostate Tissue
To explore the possibility that LEDGF/p75 might be overexpressed in prostate
tumors, an expression analysis of the protein in prostate tissue was performed by
immunohistochemistry. For these experiments we used human prostate cancer Histo TM
Array slides (Imgenex, San Diego, CA). These slides contain 56 prostate tumors
specimens and 3 normal prostate specimens within the same tissue array. Clinical
information for each specimen, provided by Imgenex, is summarized in Table III. It
should be noted that the Gleason score provided by Imgenex was taken directly from the
pathology report. This score is the sum of the two most frequent histological patterns of
the entire prostate. Thus, the tissue sample on the array may not necessarily be
representative of that score. For this reason, a field Gleason score was assigned to most
tissue samples. However, a few of the tissues could not be scored since a hematoxylin
and eosin stained array was not available.
The Histo™-Array slides were stained with either a rabbit anti-LEDGF/p75
serum or the rabbit pre-immune serum as an irrelevant antibody control. Staining
intensity was scored as strong, weak, or negative by a pathologist. The 3 normal tissues
(#57, 58, 59) showed very little or no staining (Table IV and Figure 16A), as determined
by the similar staining intensity of the anti-LEDGF/p75 and pre-immune sera. One tumor
tissue (#13) showed strong positive staining with both the pre-immune serum and the
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Figure 15. Expression of LEDGF/p75 in prostate cell lines detected by IIF
microscopy. LEDGF/p75 is expressed predominantly in the nuclei of LNCaP, PCS,
and PrEC cell lines. Weak staining of the protein was observed in PrEC cells.
Corresponding DAPI images are provided. Immunostaining was performed using
serum from PCa patient P096. Images are representative of at least two independent
experiments.
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Table III. Clinical information of the prostate tissues present on the Imgenex Histo TM
Array slides.
Stage
LEDGF/p75 Staining
TNM
Gleason
Field Gleason
Diagnosis
N
T2aN0M0
7
3
adenocarcinoma
IV
S
T4NxMb
10
5
2
adenocarcinoma
S
IV
TxNxMlc
3
adenocarcinoma
5
3
IV
S
T3aN0M1b
4
adenocarcinoma
10
4
W
T2N0M0
7
3
5
adenocarcinoma
S
T2bN0M0
5
3
adenocarcinoma
6
S
4
TxNOMO
7
adenocarcinoma
7
S
T3aN0M0
3
6
adenocarcinoma
8
S
T2N0M0
4
3
adenocarcinoma
9
S
IV
4
TxNxMlb
adenocarcinoma
9
10
N
IV
?
TxNxMlb
8
11
adenocarcinoma
IV
S
T3bN1M0
5
adenocarcinoma
10
12
51
S*
5
adenocarcinoma
9
13
81
W
IV
M1
8
5
14
adenocarcinoma
70
W
?
T2bN0M0
adenocarcinoma
6
71
15
W
IV
4
M1
9
adenocarcinoma
64
16
S
IV
4
T4N0M0
adenocarcinoma
9
17
72
W
T2N0M0
3
3
adenocarcinoma
67
18
N
IV
4
T2N1M0
7
59
adenocarcinoma
19
W
I
T1NxM0
4
7
adenocarcinoma
20
72
W
T2N0M0
7
3
adenocarcinoma
21
78
W
IV
4
M1b
adenocarcinoma
9
22
73
S
T4NxM1
IV
4
10
adenocarcinoma
23
73
S
IV
M1b
7
4
24
adenocarcinoma
63
S
4
adenocarcinoma
9
25
75
IV
S
T4NxM1c
4
10
adenocarcinoma
26
57
S
TxNIMI
IV
3
adenocarcinoma
10
27
60
S
T3N0M0
4
3
adenocarcinoma
28
78
IV
S
TxNIMO
4
9
adenocarcinoma
29
61
W
4
T2N0M0
9
69
adenocarcinoma
30
IV
S
T4NxM1
9
5
adenocarcinoma
63
31
S
IV
T4NxM1c
4
8
adenocarcinoma
32
60
W
IV
TxNIMO
4
9
adenocarcinoma
33
61
S
3
8
34
71
adenocarcinoma
U
4
9
64
adenocarcinoma
35
W
IV
TxNIMO
5
9
adenocarcinoma
36
61
W
T2N0M0
5
adenocarcinoma
9
37
69
IV
S
T4NxM1
4
9
adenocarcinoma
38
61
W
IV
T3N1M0
3
9
adenocarcinoma
68
39
W
IV
T2N1M0
3
adenocarcinoma
9
44
40
S
4
T2N0M0
7
adenocarcinoma
41
77
W
T3N2M1
IV
4
adenocarcinoma
9
42
74
S
IV
T4NxM1
4
7
adenocarcinoma
43
80
S
T3N0M0
?
5
44
adenocarcinoma
80
S
IV
T3N2M1
5
10
62
adenocarcinoma
45
W
T3N0Mx
6
3
adenocarcinoma
46
68
IV
S
Mlb
5
9
adenocarcinoma
47
58
S
T2N0M0
3
8
adenocarcinoma
48
77
IV
S
T3N0M1
?
9
adenocarcinoma
65
49
W
IV
TxN0M1
5
9
adenocarcinoma
50
66
IV
S
T3NxM1b
3
9
adenocarcinoma
51
86
N
IV
T4N0M0
5
embryonal rhabdomyosarcoma
52
48
S
IV
4
T4N0M0
9
adenocarcinoma
62
53
S
IV
T4N0M0
4
8
adenocarcinoma
54
63
IV
S
M1
?
9
adenocarcinoma
55
59
IV
S
T2N0M1
?
9
adenocarcinoma
56
59
N
normal
57
48
N
normal
75
58
N
71
normal
59
S =strong, W =weak, N = negative, U =unsatifactory tissue, ? =could not be determined, * =pre-immune serum showed strong staining
Sample

1

Age
74
88
76
70
64
69
80
74
56
87
65
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Figure 16. Expression of LEDGF/p75 in prostate cancer tissue.
Imgenex Histo™-Array tissues were stained with a rabbit antiLEDGF/p75 antibody or the pre-immune serum, both used at a 1:500
dilution. Representative pictures show A. two normal tissues (#58 and
#59) and B. two prostate cancer tissues (#59 and #24). LEDGF/p75 is
expressed at very low levels in normal prostate tissue and is highly
expressed in the nuclei of prostate cancer cells. C. LEDGF/p75 is also
highly expressed in morphologically normal tissue (arrows) adjacent to
the tumor area (#22) and in D. BPH tissue.
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LEDGF/p75 antibody and thus was not included in the analysis. Tissue sample #35 was
also excluded because it was of poor quality. Of the 54 cancer specimens, 50 (93%)
expressed the protein. Thirty three (61%) tumor samples showed strong staining, 17
(31%) showed weak staining, and 4 (7%) were negative (Table IV, Figure 16B). Most
of the tumors showing high expression of LEDGF/p75 were stage III and IV tumors;
however, because the number of tumors in stages I-III provided in the tissue array was
relatively small, it was not possible to establish a statistically significant correlation
between high LEDGF/p75 expression and tumor stage. Of the 3 tumor specimens that
were negative, one was from a patient diagnosed with embryonal rhabdomyosarcoma, a
soft tissue tumor of striated muscle that can affect any organ. Interestingly, LEDGF/p75
was also found in the tumor samples to be highly expressed in morphologically normal
tissue within the tumor microenvironment (Figure 16C). LEDGF/p75 expression was also
detected in BPH tissue (Figure 16D).

Cleavage ofLEDGF/p75 in Apoptotic Prostate Tumor Cells
Dying cells (both apoptotic and necrotic) are considered as reservoirs of
potentially immunostimulatory forms of intracellular antigens f22-25]. The proteolytic
cleavage of specific proteins during tumor cell death could potentially generate, under
inflammatory conditions, fragments with increased immunogenicity that might trigger
humoral and cell-mediated immune responses [26]. We demonstrated in a recent study
that LEDGF/p75 is cleaved in apoptotic Jurkat and HeLa cells into fragments of 65 and
58 kD, and that this cleavage abrogates its pro-survival function [19J. It was of interest to
determine whether LEDGF/p75 also undergoes cleavage during prostate tumor cell
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apoptosis. Absence of cleavage in prostate tumor cells would rule out the possibility that
circulating fragments of the protein derived from dying tumor cells could drive the
production of autoantibodies to LEDGF/p75. Furthermore, absence of cleavage of
FEDGF/p75 in these dying cells could be also indicative of mutations in its caspase
recognition sites, which would potentially enhance the pro-survival function of the
protein in tumors. To determine whether FEDGF/p75 is cleaved during prostate tumor
cell apoptosis, we induced apoptosis in FNCaP, PC3, and DU145 cells with either STS or
Act D/TRAIF. These treatments resulted in cleavage of FEDGF/p75 into its signature
caspase-induced fragments p65 and p58 (Figure 17), indicating that potentially
immunostimulatory products of the protein may be released in dying prostate tumor cells.

Discussion
Although ANA are a hallmark of systemic autoimmune disease [27], there is
compelling evidence that their production also constitutes an integral component of the
anti-tumor immune response in cancer patients [5,28-33]. These autoantibodies might
serve as immunological reporters pointing to the presence of altered autologous proteins
in tumors [5]. The identification of protein autoantigens targeted by autoantibodies in
PCa and other cancers is a prerequisite for developing TAA arrays for the profiling of
humoral immune responses in cancer. This would be important for defining potential
targets of immunotherapy and novel markers for diagnosis and prognosis. In this study,
we screened sera from 207 PCa patients, 166 age-matched men with no clinical evidence
of PCa, and 44 blood bank male donors for the presence of autoantibodies to potential
TAA. Using IIF microscopy and ELISA, we detected autoantibodies to LEDGF/p75 in
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Figure 17. Cleavage of LEDGF/p75 in prostate cancer cell lines
undergoing apoptosis. A. Representative immunoblot blot showing the
cleavage of LEDGF/p75 into 65 and 58 kD fragments in Jurkat T cells
(used as positive control) and DU 145 cells induced to die by apoptosis
with 2 and 4 pM STS, respectively. B. Apoptosis was induced in
LNCaP, DU145, and PCS cells by exposure to 100 ng/mL Act D for 4 h
followed by treatment with 100 ng/mL TRAIL for up to 24 h. Act
D/TRAIL-induced apoptosis generated the 65 and 58 kD fragments in
LNCaP cells. In DU 145 and PCS cells, only the 65 kD fragment was
visible. Since the 58 kD fragment is a late cleavage product of
LEDGF/p75 [19], its absence from these blots is likely due to the slower
rate of Act D/TRAIL-induced apoptosis in DU 145 and PCS. Bands were
detected in the blots using serum from PCa patient P096.
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PCa patients at frequencies (14-18%) that were significantly higher than in matched
controls and blood bank donors. These frequencies were within the range observed for
other autoantibodies in cancer [2,4,32-33]. For instance, Zhang et al. [2] recently detected
by ELISA autoantibodies to c-myc, p53, Cyclin Bl, p62, Koc, IMP1, and Survivin in our
cohort of PCa patients at individual frequencies ranging from 2.9 to 25.2%, depending on
the antigen. These results reinforce the notion that the autoantibody response in human
cancers is highly heterogeneous and typically occurs at frequencies below 30% for
individual antigens. However, increased detection of autoantibodies and definition of
distinct tumor-associated autoantibody profiles in cancer can be achieved using uniquely
constituted TAA arrays [2,34].
We observed an incomplete correlation in the detection of anti-LEDGF/p75
antibodies between the different immunoassays used in our study (ELISA,
immunoblotting, and IIF). This divergence has been observed in previous studies on
autoantibody responses to Survivin and p53 and could be attributed to differences in the
sensitivity of the various assays as well as differences in the way the antigen is exposed
to the autoantibodies in the individual assays [4,35]. It should be also considered that
cancer-associated autoantibodies might display heterogeneity in epitope recognition
within a given antigen. Consequently, some patients would produce autoantibodies
against non-denatured epitopes that are more efficiently detected by IIF or ELISA,
whereas others may produce antibodies against denatured epitopes that are more
efficiently detected by immunoblotting. Thus, the combined use of different assays may
enhance detection of specific autoantibodies in a particular cancer type.
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Given the possibility that immunity to LEDGF/p75 in aging men might
conceivably be related to the presence of a prostate tumor, it would be of interest to
determine in prospective studies with the matched control group whether antibody
reactivity to this protein precedes tumor detection. Although we did not observe a
correlation between anti-LEDGF/p75 antibody positivity and specific clinical parameters
(e.g. PSA levels, Gleason score, tumor stage, and therapeutic regimen) it would be of
interest to revisit this issue in a larger cohort of PCa patients producing this antibody.
We hypothesized that the antibody response to LEDGF/p75 in PCa could be
indicative of aberrant expression of this protein in certain prostate tumors. Since prostate
tissue specimens from patients producing anti-LEDGF/p75 autoantibodies were not
available, we examined by immunohistochemistry the expression levels of the protein in
a commercially available prostate tissue array (Imgenex Histo™-Array). We observed
that while the 3 normal prostate tissues samples in the array did not express or minimally
expressed LEDGF/p75, 50 of 54 (93%) prostate tumor specimens expressed the protein.
The majority of the prostate tumor specimens showed high expression of the protein (33
of 54, 61%). However, it was not possible to establish a significant correlation between
strong immunostaining and tumor stage because of the relatively small number of tumor
samples in stages I-III. The high LEDGF/p75 expression in prostate tumors and low
expression in normal prostate pointed to this protein as a potential marker of prostate
malignancy.

This remains to be confirmed in a larger number of tumor samples

representing all the different clinical stages. Interestingly, LEDGF/p75 expression was
also strong in morphologically normal epithelium located within the tumor
microenvironment. The morphologically “normal” area within a prostate tumor may not
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necessarily be genetically normal. For instance, Chuaqui et al. 136] observed that at the
molecular level, normal epithelium adjacent to a prostate tumor may not be similar to
epithelium distant from the tumor. These investigators noted that adjacent normal tissue
may be a tumor precursor, or alternatively, may be reactive to the invasive tumor with an
atypical genetic profile.
The high expression of LEDGF/p75 in prostate tumors and their adjacent
“normal” tissue is likely to be induced by inflammatory and oxidative stress conditions,
which are associated with the development of prostate cancer (reviewed in 137]). Ripple
et al. [38] reported that an oxidative shift occurs during the aging process leading to an
increase in the levels of oxidative stress in the prostate. There is also evidence for an
increase in oxidative stress in the benign epithelium of prostate cancer tissue compared to
that of normal prostate tissue [39]. LEDGF/p75 exerts a protective effect against
apoptosis induced by oxidative stress and other cellular stresses, and its expression is
upregulated in response to these stresses [18]. The protective effects of LEDGF/p75 are
mediated by its ability to transcriptionally activate genes encoding heat shock proteins
(Hsp), including Hsp27, Hsp90, aB-crystallin, and antioxidant protein 2 (AOP2) [18,40].
The expression of these genes in turn induces an apoptosis inhibitory effect because Hsp
interfere with key components of the apoptotic machinery [41-43]. Interestingly, Hsp27
is overexpressed in 31% of hormone refractory PCa [44], suggesting that this
overexpression could be induced in prostate tumors by the high levels of LEDGF/p75. It
would be of interest to examine whether increased expression of LEDGF/p75 in prostate
tumors correlates with increased expression of Hsp27 and other heat shock proteins. We
hypothesize that inflammation and increased oxidative stress in the prostate tumor
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microenvironment induces LEDGF/p75 expression, leading to increased Hsp levels,
consequently enhancing tumor cell survival.
Increased expression of LEDGF/p75 in prostate tumors and caspase-mediated
cleavage of the protein in dying tumor cells may lead to the generation of immunogenic
forms of the protein which, under the inflammatory conditions of the malignant prostate,
might elicit an autoantibody response in certain PCa patients. We cannot rule out,
however, the possibility that anti-LEDGF/p75 autoantibodies might be linked to a tumorunrelated inflammatory disorder, given that these autoantibodies have also been detected
in various inflammatory conditions such as atopic dermatitis and asthma 145 j. However,
the significantly lower frequency of these autoantibodies in the matched control group
would argue against this possibility. Moreover, analysis of available clinical records of
PCa patients positive for anti-LEDGF/p75 antibody failed to reveal previous history of
any of these conditions for most patients. It should be noted that atopic dermatitis and
asthma are also mediated by oxidative stress and inflammation [46-47], raising the
interesting possibility that humoral immunity to LEDGF/p75 could be a feature of certain
disease conditions associated with these factors.
In summary, our data show that autoantibodies to the survival protein
LEDGF/p75 are present in the serum of certain patients with PCa and that this protein is
highly expressed in prostate tumor tissue and cleaved into distinct fragments in apoptotic
prostate cancer cells. These results suggest that increased expression of LEDGF/p75 in
prostate tumors, combined with its cleavage during apoptosis of prostate tumor cells, may
have implications for the production of autoantibodies to this protein. It should be
examined in future studies whether LEDGF/p75 mRNA levels are differentially
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expressed in tumor versus normal cell lines and/or tissue. It would also be of interest to
determine whether increased expression of LEDGF/p75 promotes survival of normal and
tumor prostate cells against a panel of apoptotic and stress stimuli. In addition, studies
should be performed to determine the frequency of autoantibodies to this protein in other
cancer types. LEDGF/p75 was previously identified as an autoantigen in chronic
lymphocytic leukemia (CLL), using the SEREX technique (serologic identification by
recombinant expression cloning). Interestingly, the gene encoding LEDGF/p75 has been
localized to chromosome 9p22.2, a common target for a variety of cancers [48J.
Chromosomal translocations at this site, resulting in a fusion protein between NUP98 and
LEDGF/p75 have been identified in some patients with acute myeloid leukemia [48]. If
proven to play a role in prostate cancer or other cancer types, LEDGF/p75 may serve not
only as a target of novel anti-tumor drugs but also as a candidate antigen for
immunotherapy.
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Abstract
Lens epithelium-derived growth factor p75 (LEDGF/p75) is a transcription
coactivator that protects mammalian cells from stress-induced apoptosis through the
transcriptional upregulation of stress response and anti-apoptotic proteins such as heat
shock protein 27, aB-crystallin, antioxidant protein 2, and involucrin. Previously, our
group showed that LEDGF/p75 is the target of autoantibodies in a subset of prostate
cancer patients and that the protein is overexpressed in prostate cell lines and tumors.
LEDGF/p75 has also been shown previously to be upregulated in response to oxidative
stress. There is increasing evidence that oxidative stress plays an important role in the
early development of prostate cancer. To investigate the biological impact of LEDGF/p75
overexpression in prostate tumors, RWPE-2 prostate cancer cells stably overexpressing
LEDGF/p75 were developed. Overexpression of LEDGF/p75 in RWPE-2 cells conferred
resistance to t-butyl hydroperoxide (TBHP) or Taxotere®-induced cell death but not to
cell death induced by classical apoptotic stimuli such as staurosporine and TRAIL. Both
TBHP and Taxotere® were shown to induce a caspase-independent cell death with
necrotic features. RWPE-2 cells overexpressing LEDGF/p75 showed decreased levels of
reactive oxygen species and the upregulation of the endoplasmic reticulum protein 57kD
(ERp57), a thiol-dependent reductase. Taken together, these results suggest that
overexpression of LEDGF/p75, which may be triggered by the oxidative stress
environment in the prostate, might provide a growth advantage to prostate cells through
the upregulation of ERp57, thus contributing to the development and progression of
prostate cancer.
Key words: LEDGF/p75, cell death, prostate cancer, oxidative stress, ERp57
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Introduction
Lens epithelium-derived growth factor p75 (LEDGF/p75), also known as dense
fine speckles protein of 70 kilodaltons (DFS70) [1] and transcriptional coactivator p75
[2], has been shown to be upregulated in response to heat and oxidative stress [3].
LEDGF/p75 is also a survival factor that confers resistance of mammalian cells to stressinduced cell death [4-8]. The protein also protects photoreceptor cells against light
damage in normal rats and against inherited photoreceptor degenerations in the Royal
College of Surgeons (RCS) rats [9]. Overexpression or exogenous addition of
recombinant LEDGF/p75 to culture medium stimulated growth and prolonged the
survival of HEpG-2, lens epithelial cells (EEC), Cos-7, skin fibroblasts and keratinocytes
in serum-free medium, or in response to thermal, oxidative, or ethanol stress [8,10-12].
Recently, LEDGF/p75 has been shown in our laboratory to be cleaved during apoptosis
and that this cleavage abolishes its pro-survival activity [4].
LEDGF/p75 appears to confer survival against cellular stress through the
transactivation of pro-survival genes via direct interaction with heat shock elements
(nGAAn) and stress response elements (A/TGGGGGaA/T) in the promoter regions of
these genes. LEDGF/p75 has been shown to transactivate pro-survival genes such as
antioxidant protein 2 (AOP2), involucrin, alcohol dehyrdogenase (ADH) and aldehyde
dehydrogenase (ALDH), hsp27, aB-crystallin, and hsp90 [5,8,12-14]. Overexpression of
hsp27 has been observed in prostate cancer (PCa) specimens and its expression was
shown to correlate with clinical outcome [15]. Increased levels of hsp27 have also been
recently shown to play a cytoprotective role in the development of androgen
independence [16].
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LEDGF/p75 is the target of an autoimmune response in many inflammatory
disorders such as atopic dermatitis, atopic dermatitis with cataracts, Vogt-KoyanagiHarada (VKH), asthma, and interstitial cystitis (reviewed in [6]). We also demonstrated
previously that a subset of prostate cancer (PCa) patients make autoantibodies to
LEDGF/p75 (Chapter 2) and that this protein is overexpressed in prostate cancer cell
lines and tissue.
PCa is the leading cause of illness and death among men in the United States and
Western Europe. In 2003, the American Red Cross estimated that 221,000 new cases of
PCa were diagnosed and about 29,000 men died of the disease (www.cancer.org). Small
prostate carcinomas have also been found in men at autopsy, up to 29% in men 30-40
years old and up to 64% in men 60-70 years old [17]. Chronic inflammation is a risk
factor for certain cancers such as liver, colon, stomach, bladder, cervical, ovarian, and
lung cancer [18]. It is also been speculated that chronic inflammation may also be a risk
factor for PCa development. Inflammatory infiltrate has been associated with PCa in
almost 60% of cases studied [19]. Life-style factors and dietary factors have been shown
to increase the risk of PCa (reviewed in [20-21]). Life style factors such as number of
sexual partners, age at first sexual experience, and history of sexually transmitted disease
have been associated with an increased risk of PCa [22]. Diets rich in animal fats and
meat have also been associated with an increased risk. In contrast, diets rich in fruits and
vegetables are associated with a decreased risk of PCa. Antioxidants, such as lycopene,
vitamin E, and selenium, have been shown to decrease the risk of PCa [23]. Lycopene is
a potent antioxidant and free-radical scavenger that has been shown to have numerous
modes of action that block PCa progression (reviewed in [24]). Vitamin E is another
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antioxidant located in the cell membrane and is known to block lipid peroxidation [23].
Selenium is a required cofactor for glutathione peroxidase antioxidant activity (reviewed
in [23]). A recent study showed that spontaneous PCa incidence in transgenic mice could
be reduced four fold when the mice were fed a combination of antioxidants (vitamin E,
selenium, and lycopene) at physiologically relevant levels [25].
The identification of genes associated with the susceptibility to PCa and those
with common somatic alterations suggests that inflammation and oxidative stress of the
prostate contributes to the development of PCa (reviewed in [20]). The goal of this study
was to investigate the biological significance of the upregulation of LEDGF/p75 in PCa
cells. This study shows that LEDGF/p75 enhances resistance of RWPE-2 PCa cells to
caspase-independent cell death, with features of necrosis, induced by the oxidants TBHP
or Taxotere®, but not to classical apoptotic stimuli.

RWPE-2 cells overexpressing

LEDGF/p75 showed decreased levels of reactive oxygen species (ROS) and upregulation
of the endoplasmic reticulum protein p57 (ERp57), a thiol-dependent reductase. Thiolcontaining proteins play major roles in maintaining the redox state of the cell and are of
great importance in the cytoprotection from oxidative stress (reviewed in [26]). Taken
together, these results suggest that overexpression of LEDGF/p75, which may be
triggered by the oxidative stress environment in the prostate, might provide a growth
advantage to prostate cells through the upregulation of ERp57, thus contributing to the
development and progression of prostate cancer.
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Materials and Methods
Cell Lines
RWPE-2 cells were obtained from the American Type Culture Collection (Manassas,
VA) Cells were grown in 5% CO2 at 37 °C in Keratinocyte Serum Free Medium
supplemented with 5 ng/mL epidermal growth factor and 0.05 mg/mL bovine pituitary
extract (Invitrogen, Carlsbad, CA). Cells were cultured as recommended by the supplier.

Induction of Cell Death
RWPE-2 cells were treated with: 150 pM t-butyl hydroperoxide (Fisher Scientific,
Tustin, CA), 3 pM N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl Taxol (docetaxel or
Taxotere®) (Aventis Pharmaceuticals Products, Inc.

Collegeville, PA), 4

pM

staurosporine (STS) or 100 ng/mL TRAIL plus 100 ng/mL actinomycin D. Images of cell
morphology were obtained using Hoffmann Modulation on an Olympus 1X70 Inverted
Microscope (Olympus America, INC., Melville, NY) and the Spot Imaging System
(Diagnostic Instruments, Sterling Heights, MI).

Generation ofStable Transfectants
The LEDGF/p75 gene was previously cloned into the mammalian expression
vector pcDNA3.1+ (Invitrogen) [4]. Both the pcDNA3.1+ vector alone (negative control)
and pcDNA3.1+//e^gf vector were transfected into RWPE-2 cells using the
Lipofectamine transfection reagent (Invitrogen) as suggested by the supplier. Briefly,
RWPE-2 cells were seeded at a density of 250,000 cells per 60 mm dish. 3 pg of DNA
was added to 300 pL medium. In a separate tube, 20 pL of the transfection reagent was
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added to 300 jaL medium. The diluted DNA was then added to the diluted transfection
reagent and this mixture was incubated at room temperature for 40 minutes to allow lipidDNA complexes to form. Cells were washed with PBS and 2.4 mL fresh medium was
added to the dishes. The complexes were added dropwise to the cells. Eight hours post
transfection, complexes were removed and cells were further incubated for 48 h. Cells
were then split into three 100 mm dishes and selection for positive colonies was started
by adding 100 pg/mL G418 (Fisher Scientific). Medium was changed 2-3 times per week
until visible colonies were observed on the plates. Colonies were expanded and assayed
for increased expression of LEDGF/p75 by electrophoresis and immunoblotting analysis.

Cell Viability Assay (Crystal Violet Staining)
RWPE-2 cells were seeded in triplicates at a density of 15,000 cells per well in
96-well plates (200 pL/well) and incubated overnight to allow the cells to adhere to the
plates. At the conclusion of each treatment, the cells were washed with 200 pL/well cold
PBS and then fixed in 3.7% paraformaldehyde (Sigma-Aldrich, St. Lois, MO) (100
pL/well) for 30 minutes. Cells were washed three times by immersing the plates in
distilled water. The crystal violet solution (2.3% w/v crystal violet, 0.1% w/v ammonium
oxalate, 20% v/v ethyl alcohol; Sigma) was diluted 1:4 in distilled water. 100 pL of the
diluted crystal violet solution was then added to each well and incubated for 15 minutes
at room temperature. The excess stain was removed by immersing the plates in distilled
water multiple times until the water remained clear. The plates were left for 5-10 minutes
to dry. Ten percent acetic acid (Fisher Scientific) in distilled water was added to the cells
(lOOpL /well) and incubated on a rotator for 10 minutes to allow the crystal violet
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retained by the cell nuclei to dissolve. The OD570 was read on the uQuant (BioTek®
Instruments, Inc., Winooski, VT) microplate reader. Crystal violet binds DNA within
viable cells. The amount of stain present in the well after the incubation with acetic acid
is directly proportional to the number of live cells. Viability is reported as percent of
untreated cells.

DAPI Staining by Immunofluorescence Microscopy
Cells were seeded in 8-well Lab-Tek® Permanox® chamber slides (Fisher
Scientific) at a density of 30,000 cells/well. Cells were allowed to adhere to the slides
then treated with the various death-inducing stimuli indicated above. Cells were washed
with PBS, fixed, and permeabilized with methanol/acetone (3:1 v/v) for 10 min at -20 °C.
Fixing solution was then removed and the slides were dried at room temperature 5-10
minutes. Cover slips were mounted using VectaShield containing DAPI (Vector
Laboratories, Burlingame, CA) and the edges were sealed with clear nail polish. DAPI
staining was analyzed using an Olympus BX50 Fluorescent Microscope (Olympus).
Images were obtained using the Spot Imaging System (Diagnostic Instruments).

Lactate Dehydrogenase (LDH) Release Assay and Caspase Activity Assay
LDH release and caspase activity assays were performed simultaneously. The
one-step caspase activity assay was adapted from Carrasco et al. [27]. Briefly, RWPE-2
cells were seeded in triplicates at a density of 15,000 cells per well in Optilux black/clear
bottom 96-well plates (Fisher Scientific) (200 pL/well) and incubated 6-8 h to allow the
cells to adhere to the plates. After induction of cell death, 100 pL of medium from each
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well was transferred to clear, non-tissue culture treated 96-well plates (Fisher Scientific)
and used for the LDH assay. The Cytotoxicity Detection kit (LDH) (Roche, Indianapolis,
IN) was used to measure LDH content in the medium. Reaction mixture was prepared as
instructed by combining the catalyst with the dye solution. The reaction mixture was
added (100 pL /well) and the plate was incubated in the dark for 30 minutes. The OD490
was read on the uQuant (BioTek® Instruments) microplate reader. The fold of LDH
released was calculated by dividing the mean OD of treated cells by that of untreated
cells.
The caspase activity assay was then performed in the Optilux black/clear bottom
96-well plates as follows. Stocks of 3X caspase activity assay buffer (150mM HEPES pH
7.4, 450mM NaCl, 150mM KC1, 30mM MgCl2, 1.2mM EGTA, 1.5% NP-40, 30%
sucrose) were made and stored at -80 °C. Just prior to use, 30 mM dithiothreitol (DTT)
(Sigma), 3mM phenylmethylsulfonyl fluoride (PMSF) (Sigma), 150 pM Ac-DEVDAMC (Alexis Biochemicals, San Diego, CA) were added to the 3X caspase assay buffer.
Fifty microliters of this solution was added to each well and the plates were incubated at
37 °C for 1 h. Fluorescence intensity (excitation 360 nM/emission 460 nM) was read
using the FLx800 fluorescence microplate reader. Fold activation was calculated as the
optical density ratio of treated to untreated cells.

Whole-Cell Lysate Preparation and Protein Quantification
Both untreated and cells treated with various stimuli were washed with PBS
containing the COMPLETE Protease Inhibitor Cocktail (Roche). Both the medium and
wash solution were collected in the same tube and centrifuged at 14,000 rpm for 10
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minutes to collect detached cells. Lysis buffer (lOOmM Tris HC1, pH 6.9, 4% SDS, 10%
glycerol, and protease inhibitor cocktail) was then added to attached cells and cells were
scraped off the dish and transferred to a 1.5 mL eppendorf tube. The mixture of attached
cells was then added to the detached cell pellet to obtain the whole cell lysate. Lysates
were then boiled at 100°C for 5 minutes and cooled on ice. Lysates were sonicated to
shear DNA and were then stored at -80 °C. Total protein concentration was determined
using the DC Protein Assay kit (BioRad, Hercules, CA) to ensure equal loading of
protein.

Electrophoresis
Proteins were separated by SDS-PAGE using the NuPAGE™ system (Invitrogen)
unless otherwise indicated. Ten micrograms of total cell lysate was used to prepare
samples in NuPAGE™ sample buffer and reducing agent. The samples were heated at 72
°C for 10 minutes and separated on NuPAGE™ 4-12% Bis-Tris gels in the XCell
SureLock mini-cell at 200 V for 65 min according to supplier’s instructions. Gels were
transferred to Pure-Nitrocellulose (BioRad) in the NuPAGE™ XCell blot module at 25 V
for 2 h according to manufacturer’s instructions.
In some experiments proteins were separated using the Mini Protean II (BioRad)
system according to manufacturer’s instructions. Briefly, 10 pg of total cell lysate were
used to prepare samples in cell lysis buffer (100 mM Tris-HCl pH 6.9, 4% SDS, 10%
glycerol) containing complete protease inhibitor cocktail (Roche), 2% bromophenol blue,
and 4% p-mercaptoethanol. Samples were boiled at 100°C for 5 minutes and separated
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on 12% Tris-HCl ready gels (BioRad) at 200 V for 45 min. Proteins were transferred to
Pure-Nitrocellulose using the BioRad Mini TransBlot Cell at 350 mA for 75 minutes.

Immunoblotting
Immunoblotting was performed using standard procedures. Briefly, the
membranes were blocked in 5% milk in Tris buffered saline-Tween (TBST: 20 mM TrisHCl, 137 mM NaCl, 0.05% Tween) overnight at 4 °C. Membranes were washed in TBST
after incubation with primary antibodies for 30 minutes. Detection of bound primary
antibodies was achieved using a HRP-conjugated goat anti-human (1:5000) or goat anti
mouse (1:2000) IgG secondary antibody (Zymed, San Francisco, CA) in combination
with enhanced chemiluminescence (Western Lightning Kit, Perken Elmer, Boston, MA).
Antibodies used in this study included goat polyclonal anti-Lamin B (Santa Cruz
Biotechnologies,

Santa

Cruz,

CA),

rabbit

polyclonal

anti-ERp57

(Stressgen

Biotechnologies, Inc., San Diego, CA), and mouse monoclonal anti-hsp90 (Stressgen).
Well-characterized, high titer human autoantibodies to topoisomerase I and LEDGF/p75
were kind gifts from Dr. Eng M. Tan (The Scripps Research Institute, La Jolla, CA).
These human antibodies have been used previously in numerous studies focused on
autoantigen cleavage during cell death [28-30].

ROS Detection
The

oxidation-sensitive

fluorescent

probe

2,,7,-dichlorodihydrofluorescin

diacetate (DCFH-DA) (Molecular Probes, Carlsbad, CA) was used to detect ROS within
cells. DCFH-DA is a nonfluorescent dye that readily permeates the cell membrane. Once
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inside the cell DCFH-DA undergoes hydrolysis by cellular esterases into 2’,7’dichlorofluorescin (DCFH), also a non-fluorescent form. DCFH is further oxidized by
cellular ROS to produce the fluorescent molecule 2’,7’-dichlorofluorescein (DCF). For
ROS detection upon TBHP and Taxotere® treatment, RWPE-2 cells were seeded at a
density of 15,000 cells per well in 96 well plates. Cells were incubated at 370C for about
24 h then incubated with 5 pM DCFH-DA for 1 h. The cells were washed three times to
remove any excess DCFH-DA then treated with 5 pM Taxotere® or 150 pM TBHP for 90
minutes. Fluorescence intensity (excitation 360 nM/emission 460 nM) was measured
using the FLx800 fluorescence microplate reader (BioTek® Instruments, Inc., Winooski,
VT). Immediately following the fluorescence detection, the medium was removed from
the wells and cells were washed with PBS and stained with crystal violet as described
above. Fluorescence intensity was normalized to cell number determined by the crystal
violet viability assay.
For detection of ROS by flow cytometry, cells were seeded at a density of 1 X 106
cells per 100 mm dish and incubated at 37°C for about 24 h. Cells were then incubated
with 5 pM DCFH-DA in keratinocyte serum-free medium without bovine pituitary
extract or epidermal growth factor (basal KSF) for 20 minutes. After two washes cells
were trypsinized and pelleted by centrifugation at 4000rpm for 5 minutes at 4 °C. The
supernatant was removed and the pellet was washed in 1 mL Dulbecco’s PBS (DPBS,
Fisher Scientific). Cells were again centrifuged as above and the cell pellet was
resuspended in 1 mL DPBS. Fluroescence intensity of 10,000 cells was then measured by
the BD FACS-Calibur™ flow cytometer (BD Biosciences, San Jose, CA).
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Kinetworks™ Stress/Heat Shock Protein Screen
The Kinetworks TM Stress/Heat Shock Protein Screen is a service provided by
Kinexus Bioinformatics Corporation (Vancouver, British Columbia). As part of this
service, the expression level of 25 stress and heat shock proteins is quantified and
compared between samples (see table VI for the list of proteins included in the
screening). Cell lysates to be screened were prepared as instructed by Kinexus [31]. The
protein concentration of each lysate was determined using the DC Protein Assay
(BioRad) and 500 pg of each sample was prepared for shipment according to Kinexus
instructions. The final concentration of each lysate was 1 mg/mL. Four samples of the
RWPE-2 stable transfectants were tested by this screening: Untreated vector 2 cells,
vector 2 treated with 150 pM TBHP for 6 h, untreated LEDGF 12, and LEDGF 12
treated with 150 pM TBHP for 6 h.

Statistical Analysis
One-way ANOVA with Bonferroni’s Mulitple Comparison Post hoc test was
performed to determine significant differences in viability between the parental RWPE-2
and RWPE-2 stable cell lines when treated with various stimuli. ANOVA was also used
to evaluate caspase activation, LDH release, and ROS induction in these same cell lines.
GraphPad Prism software was used for all statistical analysis.
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Results
Overexpression of LEDGF/p75 in RWPE-2 cells confers resistance against cell death
induced by TBHP and Taxotere
In order to investigate the biological significance of the overexpression of
LEDGF/p75 in prostate cancer cells, we developed RWPE-2 prostate cancer cell lines
that stably overexpressed the protein. RWPE-2 cells were chosen for this analysis
because they were previously found to have relatively low endogenous expression of the
protein (Chapter 2; Figure 14). Two colonies expressing the highest level of LEDGF/p75
were chosen for the survival analysis (Figure 20A). RWPE-2 cells stably transfected with
the pcDNA3.1+ vector alone were used as mock transfected, negative control cell lines.
An initial dose response analysis was performed using various concentrations of
TBHP (Figure 18) and Taxotere® (Figurel9) for either 6 h of treatment followed by an 18
h recovery period, or for 24 h of treatment without a recovery period. Overexpression of
LEDGF/p75 enhanced RWPE-2 resistance to cell death induced at all concentrations of
TBHP in the 6 h treatment with 18 h recovery. However, 150 pM TBHP showed the best
protection level in both cell lines overexpressing LEDGF/p75 (LEDGF 8 and LEDGF 12;
Figure 18A). For the 24 h treatment, the protective affect of LEDGF/p75 was only
observed at 150 uM (Figure 18B). Thus, we determined the optimal survival assay
conditions for TBHP to be treatment with 150 pM for 6 h followed by an 18 h recovery
period. For Taxotere®, the 6 h treatment and 18 h recovery period only showed slight
protection by LEDGF/p75 when 5 pM Taxotere® was used. After 24 h of treatment
without a recovery period, the best protection level was observed with 3 pM Taxotere .
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Figure 18. TBHP dose response in RWPE-2 cells. Parental and stable cells were
treated with the indicated concentrations of TBHP for A) 6 h followed by an 18 h
recovery period in complete growth medium or B) 24 h with no recovery period. The
crystal violet assay was then performed to assess cell viability. Each graph represents
one experiment performed in triplicate.

117

A
120 -n

100
&
5
ra

80

>
c
o

60

■ 7uM
5uM
□ 3uM
□ 1uM

I 40
20
0
RWPE-2

Vec 2

Vec 3

LEDGF8

LEDGE 12

B

Figure 19. Taxotere® dose response in RWPE-2 cells. Parental and stable cells were
treated with the indicated concentrations of Taxotere® for A) 6 h followed by an 18 h
recovery period in complete growth medium or B) 24 h with no recovery period. The
crystal violet assay was then performed to assess cell viability. Each graph represents
one experiment performed in triplicate.
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Figure 20. Overexpression of LEDGF/p75 in RWPE-2 cells confers
resistance to cell death induced by TBHP and Taxotere®but not STS or
TRAIL/ActD. A) Stable overexpression of LEDGF/p75 in RWPE-2
clones # 8 and 12 detected by immunoblot. |3 actin was used as a loading
control. Crystal Violet Viability Assay of parental RWPE-2, cells
transfected with empty pcDNA vector, or LEDGF/p75 transfected cells
treated with B) 150 pM TBHP for 6 h with an 18 h recovery period C) 3
pM Taxotere® for 24 h without a recovery period D) 4 pM STS for 6 h
with an 18 h recovery period and E) 100 ng/mL TRAIL + ActD for 6 h
with an 18 h recovery period. Each graph represents the average of at
least 3 independent experiments performed in triplicates. (*p<0.001)

119

A
<b

^
o

p

^
o

o'
O
N/

<c

A?
/Q

<<7

LEDGF/p75

P actin

B

C
100

100

**

90

**

80

90

**

80

f 70

f

60 -j
>

50

o

40

0)

Q-

70

^ 60
> 50

II I

30
20
10
0

RWPE-2

Vec 2

Vec 3

c
o
o
0-

40
30
20
10

LEDGF 8

LEDGE
12

0

DTT

RWPE-2

D

E
100
90
80

70
« 60
5
C

50

©

S

©
Q-

40
30
20
10
0 h—

11 LI I

RWPE-2

Vec 2

Vec 3

LEDGF 8

LEDGF 12

RWPE-2

120

Vec 2

Vec 3

LEDGF 8

LEDGF 12

Thus the optimal survival assay conditions for treatment with Taxotere* were 3 pM for
24 h.
To further explore the survival activity of LEDGF/p75 in PCa cells, survival
assays using the above-determined conditions were performed. Cells were treated with
150 pM TBHP for 6 h followed by an 18 h recovery period in medium without TBHP.
Cell viability was quantified using the crystal violet assay. Percent viability was
determined as the percent of the optical density of treated cells compared to that of
untreated cells. As seen in Figure 20B, upon TBHP treatment cell viability was decreased
to 30% in parental RWPE-2 cells and cells transfected with vector alone. Cell viability
was only slightly decreased in cells overexpressing LEDGF/p75, upon TBHP treatment.
The viability of the two clones LEDGF/p75 #8 and #12 was 70 and 80%, respectively.
Thus, LEDGF/p75 conferred significant levels of protection from cell death induced by
TBHP (p<0.001). Significant protection from TBHP-induced cell death was also
observed in cells treated with DTT (Figure 20B), a known reducing agent that blocks
lipid peroxidation [32]. RWPE-2 parental cells and cells transfected with vector alone
showed dramatic morphological changes, such as cell rounding and swelling after TBHP
treatment (Figure 21). These changes were not observed in cells overexpressing
LEDGF/p75.
We also wanted to determine if LEDGF/p75 could protect RWPE-2 cells from
cell death induced by other stimuli. RWPE-2 parental cells and the stable transfectants
were treated with other death inducing stimuli and cell viability was monitored as above.
LEDGF/p75 showed protection from cell death induced by the therapeutic agent
Taxotere® (Figure 20C) (p<0.001). Protection levels were similar to those observed with
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Figure 21. Morphological changes of RWPE-2 cells after treatment with TBHP, as
visualized by Hoffman modulation microscopy. Parental RWPE-2, cells transfected
with empty vector, and cells stably overexpressing LEDGF/p75 were treated for 6 h
with 150 pM TBHP. RWPE-2 and vector alone cells show dramatic morphological
changes such as cell rounding and swelling, whereas cells overexpressing
LEDGF/p75 exhibit the cellular morphology of untreated cells.
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TBHP treatment. However, LEDGF/p75 was unable to protect RWPE-2 cells from the
classical apoptotic stimuli staurosporine (Figure 20D) or TRAIL/ActD (Figure 20E) at
concentrations used for these stimuli.

Characterization of TBHP and Taxotere®-induced cell death
Notably, LEDGF/p75 protected RWPE-2 cells from cell death induced by TBHP
or Taxotere®, but not from classical apoptotic cell death induced by either STS or
TRAIL/ActD. In order to characterize the type of cell death induced by TBHP and
Taxotere®, we first examined cell morphology upon treatment using Hoffmann
modulation microscopy. As seen in Figure 22 (left panel), untreated cells are flat and
spindle-shaped. Upon TBHP and Taxotere® treatment for 12 h, cell rounding and
swelling was observed. In contrast, cells treated with TRAIL/ActD or STS show classical
apoptotic characteristics such as cell shrinkage and membrane blebbing.
To further characterize the cell death induced by TBHP and Taxotere , we
examined the nuclear morphology of these cells using DAPI staining and fluorescent
microscopy (Figure 22 right panel). Cells treated with TBHP showed nuclear swelling
with no pyknosis, or chromatin condensation. Taxotere® showed nuclear swelling of
some nuclei, but also showed evidence of nuclear fragmentation in some cells, which was
more consistent with mitotic catastrophe (reviewed in [33]). Both TRAIL/ActD and STS
treated cells showed chromatin condensation, margination, and fragmentation typical of
apoptosis.
The above results indicate that TBHP and Taxotere® at the concentrations used do
not induce cell death with typical morphological features of apoptosis. To determine
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Figure 22. Cellular and nuclear morphology of RWPE-2 cells treated
with various death-inducing stimuli. Cells were treated as in Figure 20
for 12 h. Left panel: cell morphology visualized by Hoffman modulation
microscopy. Right panel: nuclear morphology as visualized by DAPI
staining under fluorescence microscopy. TBHP treated cells show
cellular and nuclear swelling. Taxotere® treated cells also show cellular
swelling and swelling of some nuclei. Some nuclei also show
fragmentation that is more characteristic of mitotic catastrophe. STS and
TRAIL show typical apoptotic morphology including cell shrinkage and
membrane blebbing with typical chromatin fragmentation and
margination. Left and right panel images do not correspond to each
other.
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whether caspases are involved in TBHP or Taxotere®-induced cell death, fluorometric
caspase activity assays were performed. The Ac-DEVD-7-amino-4-methlycoumarin (AcDEVD-AMC) substrate was added to cells treated with the various stimuli. Endogenous
caspases-3 and 7 recognize the DEVD motif of the substrate and cleave it after the
aspartate residue in the PI position. This cleavage releases the AMC fluorochrome and
the resulting fluorescence can be quantified using a fluorescent microplate reader. An
increase in fluorescence is indicative of increased cleavage of the substrate and thus
increased caspase activation within the cell. As expected, TRAIL/ActD treatment led to a
significant increase in caspase activity at 6, 9, and 12 h compared to untreated cells
(Figure 23). STS treatment also led to a significant increase in caspase activity at 6, 9,
and 12 h compared to untreated cells. Treatment with either TBHP or Taxotere® did not
induce significant increases in caspase activity at any time points.
To further investigate caspase activity during cell death induced by the different
treatments, immunoblotting analysis was performed to examine the cleavage of known
caspase substrates. For example, Lamin B is a nuclear envelope protein that is cleaved by
caspases into a 45 kD fragment during apoptotic cell death [30]. Topoisomerase one
(Topol) is a DNA repair protein that is also cleaved by caspases into a 70 kD fragment
during apoptosis [29] and is cleaved by other proteases into a 45 kD fragment during
primary and secondary necrosis [28,30]. Lamin B was cleaved into the 45 kD fragment
when RWPE-2 cells were treated with TRAIL/ActD or STS (Figure 24A). The cleaved
form of lamin B appeared after 6 h of TRAIL/ActD treatment and after 12 h of STS
treatment. These results were consistent with those from the caspase activity assays,
where treatment with TRAIL/ActD led to a higher level of caspase activation when
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Figure 23. Detection of caspase-3 and -7 (DEVDase) activity by fluorometric assay .
RWPE-2 cells were treated with 150 jaM TBHP, 100 ng/mL TRAIL +100 ng/mL
ActD, 4 jaM STS, or 3 jaM Taxotere ®for the indicated time points, then incubated
with the Ac-DEVD-AMC substrate for 1 h. Fluorescence intensity (excitation 360
nM/emission 460 nM) was read using the FLX800 fluorescence microplate reader.
Fold activation was calculated as the ratio of treated cells versus untreated cells. The
graph represents the average of 3 independent experiments performed in triplicates.
(**p<0.001, *p<0.05).
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Figure 24. Caspase activity determined by immunoblotting analysis of
the known caspase substrates Lamin B and Topo I. RWPE-2 cells were
treated as in Figure 23 and whole cell lysates were collected at 0, 6, 12,
24, and 48 h. A goat polyclonal Lamin B antibody and a wellcharacterized, high titer human autoantibody to Topo I were used. Lamin
B is cleaved into a 70kD kD fragment during apoptosis only.
Topoisomerase I is cleaved into a 70 kD fragment during apoptosis and
into a 45 kD fragment during caspase-independent cell death. Blots are
representative of at least 2 independent experiments.
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45 kD

compared to treatment with STS. Neither TBHP nor TaxotereH treatments resulted in the
cleavage of Lamin B (Figure 24A). However, TBHP did induce cleavage of Topo I into
its signature 45 kD necrotic fragment (Figure 24B). Neither Taxotere® nor STS induced
cleavage of Topo I into this necrotic fragment. TRAIL/ActD induced cleavage of Topo I
into the 45 kD necrotic band at late time points only. At these time points caspase
activation levels had dropped dramatically indicating that the cells were undergoing
secondary necrosis [28]. Together with the caspase activity assays, these data suggest that
TBHP and Taxotere®, at the concentrations used in this study, induce a caspaseindependent form of cell death in RWPE-2 cells.
As shown in Figures 21 and 22, TBHP and Taxotere®-induced cell death were
associated with cellular and nuclear swelling. This is a feature of cell death identified as
oncosis (defined as death by swelling), although most would identify it as necrosis [34].
In this form of cell death cytoplasmic membrane permeabilization and subsequent rupture
occur. To demonstrate the loss of cytoplasmic membrane integrity in TBHP and
Taxotere® treated cells, lactate dehyrdogenase (LDH) assays were performed. LDH is
normally found within the cytoplasm of cells. LDH is released from the cells when the
cell membrane is permeabilized or disrupted during necrotic cell death. Thus, the amount
of LDH in the supernatant of treated cells is an indicator of cell membrane disruption
caused by the treatment. A signficant increase in LDH release was observed in cells
treated with TBHP and Taxotere® (Figure 25). LDH release increased almost 2 fold after
24 h of TBHP treatment (p<0.001). Taxotere® showed a more steady increase of about
1.5 fold in LDH release from 6 to 24 h (p<0.05 at 6 h and 9 h and p<0.01 at 12 h and 24
h). These results are consistent with a caspase-independent cell death with necrotic
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Figure 25. Detection of cell membrane disruption by the Lactate dehydrogenase
release assay. RWPE-2 cells were treated as before for the time points indicated. The
supernatants were collected and assayed for the presence of LDH as described in
Methods. The graph represents the average of 3 independent experiments performed
in triplicates. (**p<0.001, *p<0.01)
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features. STS treatment for up to 24 h did not result in an increase in LDH release, which
typically occurs only in late stages of apoptotic cell death. TRAIL/ActD treatment
resulted in no significant increase in LDH release at early time points, but did show
significant increase at 12 h (p<0.05). This is consistent with the development of
secondary necrosis at late time points, which is supported by both the caspase activity
assay where caspase activity decreased after 12 h and the fact that Topol was cleaved into
its necrotic fragment of 45 kD (Figures 23 and 24).

ROS Detection in TBHP and Taxotere® Treated Cells
As shown above, LEDGF/p75 protects RWPE-2 cells from caspase-independent
cell death induced by TBHP and Taxotere®. TBHP is an organic peroxide and a known
oxidant. Many studies have shown an increase in ROS production upon treatment with
TBHP [35-38]. In order to investigate whether Taxotere® also acts as an oxidant, RWPE2 cells were incubated with DCFH-DA. This is a nonfluorescent dye that permeates the
cell membrane and through a two-step process becomes oxidized to its fluorescent form
in the presence of ROS within the cell (Figure 26). An increase in fluorescence indicates
an increase of ROS levels within the cell. Cells treated with TBHP showed a significant
increase in ROS levels after 90 minutes of treatment (Figure 27) (p<0.001). Cells treated
with Taxotere® also showed a significant increase in ROS levels (p<0.05). Thus, both
TBHP and Taxotere® are potent oxidants that disrupt the pro-oxidant/antioxidant balance
within the cell.
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Figure 26. Detection of reactive oxygen species (ROS) using 2,,7,-dichlorofluorescin
diacetate (DCFH-DA). Detection of ROS within cells is a two-step process. DCFHDA is a nonfluorescent dye that readily permeates the cell membrane. Once inside
the cell DCFDA undergoes hydrolysis by cellular esterases into 2,,7’dichlorofluorescin (DCFH), a non-fluorescent form. DCFH is further oxidized by
cellular ROS to produce the fluorescent molecule 2,,7,-dichlorofluorescein (DCF).
Figure kindly provided by J. Paul Robinson, Ph.D. (Purdue University
jpr@flowcyt.cyto.purdue.edu, Web: www.cyto.purdue.edu)
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Figure 27. Detection of ROS in RWPE-2 cells treated with TBHP and Taxotere®.
Cells were incubated with DCFH-DA for 1 h and washed three times in PBS. Cell
were then treated with either 1 juM or 5 jaM Taxotere® or 100 \xM TBHP for 90
minutes. Fluorescence intensity (excitation 360 nM/emission 460 nM) was read using
the FLX800 fluorescence microplate reader. An increase in fluorescence is indicative
of increased ROS within the cell. Fluorescence intensities were normalized to cell
number using the crystal violet viability assay. Graph represents the average of 3
independent experiments performed in triplicates. (**p<0.001, *p<0.05).
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Figure 20B showed that DTT also protected RWPE-2 cells from TBHP-induced
cell death. Therefore, it is possible that LEDGF/p75 protects cells from TBHP-induced
cell death by decreasing the intracellular levels of oxidative stress. In order to explore this
possibility, we investigated the endogenous levels of ROS in the parental RWPE-2 cells
and cells overexpressing LEDGF/p75. Cells were again incubated with DCFH-DA and
analyzed by flow cytometry. Cells overexpressing LEDGF/p75 showed a decrease in the
fluorescence intensity when compared to RWPE-2 cells (Figure 28). This indicates that in
the cells overexpressing LEDGF/p75 the levels of ROS are lower than those of RWPE-2
where the expression of LEDGF/p75 is relatively low.

Kinetworks™Stress/Heat Shock Protein Screen
In order to further explore a possible mechanism by which overexpression of
LEDGF/p75 enhances RWPE-2 resistance to TBHP and Taxotere®-induced caspaseindependent cell death, Kinetworks TM protein profiling was performed by Kinexus
Bioinformatics Corporation (Vancouver, Canada). Kinexus uses a multi-immunoblotting
apparatus to probe the lysates for the quantitative expression of 25 known heat shock and
stress related proteins using validated commercial antibodies in the Kinetworks TM KHSP1.0 screen. Lysates of untreated or cells treated with 150 pM TBHP were prepared
following procedures recommended by Kinexus. Four samples were tested by this
method: cells stably transfected with empty vector (untreated and treated with 150 pM
TBH for 6 h) and cells stably overexpressing LEDGF/p75 (clone #12) (untreated and
treated). Proteins profiled in the screen included those listed in Table V. The untreated
empty vector lysate was used to determine the basal expression level and protein
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Figure 28. Detection of endogenous levels of ROS in RWPE-2 cells and cells
overexpressing LEDGF/p75. Cells were incubated with DCFH-DA, washed three
times in PBS, trypsinized, and pelleted. The pellet was washed with PBS and
resuspended in 1 mL PBS. Fluorescence intensity was determined using FACS
analysis. RWPE-2 cells treated with 3 mM DTT for 6 h showed a reduction in ROS
levels as evidenced by a decrease in fluorescence intensity. LEDGF/p75
overexpression also resulted in a reduction of ROS levels, although the reduction was
less than that induced by DTT. The graph is representative of 2 independent trials. Ctl
= cells incubated in medium (without DCFH-DA)
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Table V. List of proteins included in the Kinetworks™ Stress/Heat Shock Protein Screen.
No.

1.
2.
3.
4.
5.
6.
7.
8.

9.
10.
11.
12.
13.
14.
15.
16.
17.
18.

19.
20.
21.
22.
23.
24.
25.

Abbreviation
APG1
APG2
COX-2

elF2 a
ERp57
ERp72
GROEL
GRP75
GRP78
GRP94
hHR23B
HIP
HO-1
HO-2
HSC70
HSF4
HSP25
HSP40
HSP47
HSP60
HSP70
HSP90o.
HSP105
HSPBP1
STI1/HOP-p60

Full Name of Protein
APG1
APG2
Cyclo-oxygenase 2
Eukaryotic translation initiation factor 2 alpha
Estrogen receptor 57 KDa
ER Estrogen receptor 72 Kda
GroEL
Glucose regulated protein 75
Glucose regulated protein 78
Glucose regulated protein 94
Human RAD23 homolog B
Hsp70/Hsc70 interacting protein
Heme oxygenase 1
Heme oxygenase 2
Heat shock 70 protein 8
Heat shock transcription factor 4
Heat shock 25 KDa protein
DnaJ (HSP40) homolog. subfamily B member 1
Heat shock protein 47
Heat shock 60 KDa protein (chaperonin)
Heat shock 70 KDa protein
Heat shock 90 KDa protein, alpha
Heat shock 105 KDa protein
Hsp 70 binding protein 1
Stress inducible protein 1
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expression in cells transfected with empty vector treated with TBHP, and cells stably
overexpressing LEDGF/p75, untreated or treated with TBHP, were compared to this
control. Data is presented as fold increase or decrease in expression as compared to
untreated empty vector cells. Only 2 fold changes were considered as possible real
changes and further explored in our laboratory. Of the 25 proteins analyzed, 4 showed
more than 2 fold upregulation (Table VI). The largest induction observed was that of the
ER protein of 57 kD (ERp57), also known as glucose related protein of 58 kD (GRP58),
[39-40] which showed a 3.69 fold induction in empty vector cells treated with TBHP
(Figure 29 and Table VI). This protein also showed a 33.5 fold induction in untreated
cells stably overexpressing LEDGF/p75 and a 13.62 fold increase in LEDGF/p75
overexpressing cells treated with TBHP. A 4.54 fold induction in hsp90 was also
observed in cells overexpressing LEDGF/p75, but not in other samples. The heat shock
transcription factor 4 (HSF4) was upregulated 2.85 fold in LEDGF/p75 cells treated with
TBHP. A 3.17 fold induction of the stress inducible protein 1/heat shock organizing
protein (Hop) was also observed in untreated LEDGF/p75 cells.
In order to confirm the results of the Kinetworks TM KHSP-1.0 screen analysis, we
chose the two proteins with the highest induction level and tested them by conventional
immunoblot analysis. Expression level of ERp57 was compared in parental RWPE-2
cells, empty vector cells, and cells overexpressing LEDGF/p75. Upregulation of ERp57
was observed in cells overexpressing LEDGF/p75 by conventional immunoblotting
(Figure 30). Expression levels of hsp90 in these same lysates did not appear to change
significantly.
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Table VI. Summary of the Kinetworks™ Screening Results.

Protein
APG1
Cox-2
Hsp40
ERp57
ERp72
elF2a
Grp75
Grp78
Grp 94
Hsp105
Hsp60
GroEL
Hsp70
Hsc70
APG2
Hsp90
Hsp25
Hsp47
HSF4
H01
H02
HspBPI
Hip
hHR23B
Hop

Vector (TBHP;
no
ne
ne
t 3.69
nc
I' 1.58
nc
ne
4/ 2.13
nc
nc
nc
1.58
nc
nc
't 7.14
4- 2.13
4- 1.54
nc
ne

p75 (untreated)
nc
ne
ne
133.55
nc
t 1.41
nc
ne
nc
nc
4/1.79
nc
nc
nc
nc
t 4.54
t 1.59
nc
nc
ne

t 1.62
ne

nc
ne
nc
t 1.58
t 3.17

4^ 2

4- 3.33
nc

p75 (TBHP)

^1.5
ne
ne
113.62
nc
t 1.18
^1.64
ne
sb 3.0
4/ 2.08
nc
4/ 1.52
nc
nc
nc

4-5.56
nc
4/ 3
t2.85
ne
nc
ne
4/3.13
4^2.44
nc

Numbers represent fold changes in expression levels when compared to Vector untreated cells.
'I' = upregulation, 4/= downregulation, nc = no change in expression, ne = no expression detected
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Figure 29. Kinetworks™ multi-immunoblotting analysis (KHSP1.0). Vector alone
transfected cells and cells stably overexpressing LEDGF/p75 (untreated and treated
with 150 pM TBHP for 6 h) were individually analyzed. The four proteins showing
the largest induction are indicated.
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Figure 30. Conventional immunoblot analysis of ERp57 and Hsp90 expression in
RWPE-2 cells overexpressing LEDGF/p75. Untreated RWPE-2 parental cells, cells
stably transfected with vector alone, and cells overexpressing LEDGF were tested for
upregulation of ERp57 and Hsp90 to confirm the Kinetworks™ mulit-immunoblotting
analysis . Upregulation of ERp57 is observed in cells overexpressing LEDGF/p75.
There appears to be no difference in hsp90 expression among the cell lines tested, pactin is used as a loading control.
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Discussion
LEDGF/p75 has been shown previously to be upregulated in response to various
stress stimuli [5]. Overexpression or exogenous addition of recombinant LEDGF/p75 to
the medium of cells in culture stimulated growth and prolonged the survival of HEpG-2,
lens epithelial cells (EEC), Cos-7, skin fibroblasts and keratinocytes in serum-free
medium, or in response to thermal, oxidative, or ethanol stress [8,10-12].
Data from the previous chapter suggests that LEDGF/p75 is overexpressed in
prostate cancer cell lines and tissues. However, the survival activity of the protein has not
been evaluated in prostate cancer cells. To explore the relevance of LEDGF/p75
overexpression in prostate tumor cells, we developed RWPE-2 cells that stably
overexpress the protein. Increased expression of LEDGF/p75 was shown to protect these
cells from cell death induced by the oxidant TBHP. DTT also protected parental RWPE-2
cells from TBHP-induced cell death. DTT is a known reducing agent that blocks both
lipid peroxidation [32] and TBHP-induced cell death [37]. This suggests that lipid
peroxidation plays a role in TBHP-induced cell death in RWPE-2 cells. This is supported
by the fact that LDH is released from cells treated with TBHP, indicative of cell
membrane disruption, which occurs upon lipid peroxidation. This is consistent with other
studies that have shown that in other cell lines (immortalized LECs and opossum kidney
cells) TBHP induces cell death via membrane disruption through lipid peroxidation [3637]. Another study also showed that in human neuroblastoma cells TBHP induced a
caspase-independent cell death that the authors identified as necrosis [38]. Palomba et al.
[35] showed that TBHP induced a necrotic form of cell death in PC 12 cells.
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In order to further explore a possible mechanism by which LEDGF/p75 protects
RWPE-2 cells from TBHP-induced cell death, cell lysates were tested for the expression
of 25 different heat shock and stress related proteins using the Kinetworks™ KHSP-1.0
screen. This analysis showed that in untreated cells overexpressing LEDGF/p75 the
expression level of ERp57 was increased 33 fold when compared to cells transfected with
empty vector. This was confirmed by conventional immunoblot analysis conducted in our
laboratory. ERp57 has been localized to the endoplasmic reticulum (ER) and shown to
bind specifically to secretory glycoproteins containing N-linked oligosaccarhides [41-43].
ERp57 has been shown to be a thiol-dependent reductase [39-40,44-46] but its precise
functions remain to be established. Since ERp57 resides in the ER and is known to play a
role in calcium homeostasis, it is plausible that the upregulation of ERp57 by
LEDGF/p75 protects RWPE-2 cells from TBHP-induced cell death by both calcium
modulation as well as its reductase activity. Thiol-containing proteins are major
contributors to the redox state of the cells [26]. Further analysis is needed to explore the
role ERp57 plays in LEDGF/p75-mediated protection. An alternative hypothesis that also
needs further exploration is that the induction of ERp57 is due to accumulation of
misfolded ectopically expressed LEDGF/p75. This could be tested by determining
whether overexpression of other unrelated proteins leads to ERp57 induction.
The Kinetworks™ KHSP-1.0 screen also showed upregulation of another protein
albeit at a much lower levels that ERp57. Hsp90 was shown to be upregulated 4.5 fold in
untreated LEDGF/p75 overexpressing cells compared to untreated vector cells. This
would be consistent with the previous report that LEDGF/p75 transactivates heat shock
protein genes, including hsp90 [5]. However, this upregulation was not confirmed by
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conventional immunoblot analysis in our laboratory. The fold induction of hsp90 was
much smaller than that of ERp57. It is possible that our immunoblotting protocol may not
be as sensitive as that used in the Kinetworks TM screen. Different lysis buffers were used
for the two lysate preparations and more protease inhibitors were added to the lysis buffer
used in the Kinetworks TM screen. The lysis buffer used for the conventional immunoblot
analysis used in our laboratory contains a complete protease inhibitor tablet from Roche.
However, since this tablet does not inhibit all classes of proteases, additional inhibitors
were required by Kinexus for the large scale screening analysis. It is plausible that in the
lysates made for the conventional immunoblot analysis, proteolysis might have occurred,
masking small differences in protein expression between the samples.
LEDGF/p75 also increased resistance of RWPE-2 cells to Taxotere®-induced cell
death. Taxotere® is a member of the taxane family of antitumor agents that are derived
from the European Yew tree (reviewed in [47]). Taxanes promote actin polymerization
and prevent the depolarization of microtubules. This leads to cell cycle arrest in the G2/M
phase of the cell cycle and ultimately to cell death via mitotic catastrophe, which can
occur through either caspase independent or caspase dependent mechanisms depending
on the cell line [33,48]. Taxotere'

is currently a therapeutic agent, alone and in

combination, for a variety of cancers including: breast, lung, ovarian, head and neck,
gastric, and advanced stages of prostate cancer (reviewed in [47]). RWPE-2 cells treated
with Taxotere'

showed significant LDH release, suggesting that the cytoplasmic

membrane was disrupted. This is also consistent with the report by Schimming et al. [49]
that showed that the anti-tumor effect of Taxotere® is related to cell lysis and not to its
ability to induce apoptosis. Interestingly, Taxotere® did not induce Topo I cleavage into
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the characteristic 45 kD necrotic band even though all other assays point to a caspaseindependent cell death with necrotic features such as cell swelling and LDH release. A
recent study showed that cathepsin B mediates caspase-independent cell death induced by
Taxol® [50]. Unpublished data from our laboratory indicates that cathepsins L and H, but
not cathepsin B, induce cleavage of Topo I. It is possible that Taxotere®-induced cell
death may not involve cathepsin L, H activation and thus Topo I is not cleaved into its
necrotic fragment. It appears that in RWPE-2 cells high concentrations of Taxotere
induce a caspase-independent form of mitotic catastrophe that results in disruption of the
cell membrane. How LEDGF/p75 protects from this form of cell death is unknown at this
time. Taxotere® does induce the production of ROS, thus the protective effect of
LEDGF/p75 may be induced through its ability to upregulate redox enzymes such as
AOP-2, ERp57, or other antioxidant proteins that have not been identified yet.
LEDGF/p75 was unable to protect RWPE-2 cells from cell death induced by
classical apoptotic stimuli at the concentrations used in our experiments. This is
consistent with a study by Cohen et al. [51] that showed the glutathione peroxidase
homologue encoded by HIV-1 protects MDCK cells from TBHP-induced cell death, but
not STS-induced cell death. TRAIL/ActD activates the extrinsic apoptotic pathway that
occurs through death receptor signaling. STS is known to induce the intrinsic apoptotic
pathway leading to mitochondrial membrane permeability and cytochrome c release that
leads to the subsequent formation of the apoptosome and activation of caspases. One
possibility to explain why LEDGF/p75 does not protect RWPE-2 cells from STS or
TRAIL/ActD-induced apoptosis is that LEDGF/p75 transactivates other proteins
involved in protection against stress stimuli that were not included in the Kinetworks TM
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KHSP-1.0 screen. These putative proteins may not be involved in protection against STS
or TRAIL/ActD-induced cell death. A second possibility is that the concentrations of
TRAIL/ActD and STS used in this study were too high, leading to a rapid cell death that
prevented LEDGF/p75 from transcriptionally upregulating hsps such as the anti-apoptotic
protein hsp27.
In summary, our data shows that in RWPE-2 prostate cancer cells, LEDGF/p75
protects from caspase-independent cell death induced by the oxidants TBHP and
Taxotere®. These cells show an increased expression of ERp57 which may be responsible
for the protective activity of LEDGF/p75. Interestingly, LEDGF/p75 did not protect
prostate cancer cells from apoptosis induced by either STS or TRAIL/ActD. There is
accumulating evidence that inflammation and oxidative stress play an important role in
the early development of PCa. LEDGF/p75 levels are known to increase during cellular
stress conditions, including oxidative stress [3]. An increase in LEDGF/p75 expression
could be induced by the oxidative stress conditions existing within the prostate
environment and might result in enhanced tumor cell survival. Inhibition of cell death by
LEDGF/p75 would lead to an accumulation of DNA damage caused by ROS. Enhanced
cell survival and accumulation of DNA damage together could foster the progression of
PCa. It would be of interest to investigate the expression levels of LEDGF/p75 in other
tumors associated with inflammation and oxidative stress (such as colon, stomach
bladder, cervical, ovarian, and lung cancers [18]). Thus, LEDGF/p75 could be a potential
therapeutic target for PCa and other cancers associated with inflammation and increased
oxidative stress.
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CHAPTER 4
DISCUSSION

Autoantibodies and Tumor Associated Antigens
Although ANA are a hallmark of systemic autoimmune disease [1], there is
compelling evidence that their production also constitutes an integral component of the
anti-tumor immune response in cancer patients [24-25,27,35,218-220]. The production of
autoantibodies in patients with cancer is now an area of increasing interest in the field of
cancer research. Autoantibodies produced in cancer patients may play a role in the anti
tumor immune response associated with malignant transformation and thus provide
unique opportunities to identify and investigate the nature of autoantigens associated with
tumorigenesis. These autoantibodies might serve as immunological reporters pointing to
the presence of altered autologous proteins in tumors [27]. The immune system often
recognizes abnormalities of cellular proteins involved in carcinogenesis before clinical
symptoms appear [27]. Thus, autoantibodies have potential diagnostic and prognostic
capabilities during the early stages of tumorigenesis. ANA have also been used to screen
cDNA expression libraries in order to identify novel genes encoding autoantigens
associated with key cellular functions. This has lead to an increase in our knowledge of
cellular processes such as DNA replication, transcription, RNA processing, cell cycleregulation, mitosis, apoptosis, and signal transduction [3].
One question that remains unanswered is how self intracellular proteins, to which
the immune system is normally tolerant, become immunogenic and elicit the production
of ANA. One alteration that can elicit an autoimmune response is overexpression of the
protein. For example, the autoimmune response to p53 has been shown to correlate with
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the presence of point mutations that lead to missense protein products [49]. It might be
expected that the autoantibodies to p53 would recognize new epitopes in the region were
the point mutations occurred. However, this was found not to be the case as these
autoantibodies reacted equally well with wild type p53 and the mutated forms of the
protein [23,45]. These studies also showed that the autoepitopes targeted by the immune
response were at either of the terminal ends of the protein, far from the central region
where the point mutations most frequently occur. Thus, it may not be an abnormal
structure that elicits an autoimmune response to p53, but rather the abnormal
accumulation of the protein. Under normal conditions p53 is expressed transiently in the
nucleus and quickly degraded. Mutated forms of the protein exhibit increased
stabilization that leads abnormal accumulation of p53 in the cytoplasm.
Another explanation of how normal cellular proteins become immunogenic is
through aberrant expression, or expression of the protein during abnormal stages of
development. This appears to be the case with p62, a member of a family of mRNA
binding proteins that binds to insulin-like growth factor II (IGF-II) mRNA and regulates
the translation of IGF-II [35]. While p62 is normally expressed in fetal tissues, its
expression is lost in adult tissues [35]. It has been shown to be aberrantly expressed in
liver tumor tissue [29]. Autoantibodies to p62 have been found in patients with
hepatocellular carcinoma [36] and prostate cancer [221]. The aberrant expression of p62
in adult tumors might elicit the autoimmune response seen in these patients.
An emerging hypothesis for the loss of tolerance to self proteins is that these
proteins are modified during cell death and under pro-inflammatory conditions trigger an
immune response [4-5]. Such modifications include proteolysis [4,6-7], oxidation [8-9],
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transglutaminase crosslinking [10], citrunillation [11], and ubiquitin conjugation and
deconjugation [5]. There is evidence that proteolysis of self proteins into distinct
fragments occurs during the different forms of cell death: apoptosis [12-17], primary
necrosis [6], secondary necrosis, and caspase-independent cell death [15]. The cleavage
of these self proteins could lead to the presentation of cryptic or novel epitopes that may
have increased immunogenicity, ultimately resulting in the triggering of an autoantibody
response under pro-inflammatory conditions [4,6-7].
The autoantibody response in human cancers is highly heterogeneous and
typically occurs at frequencies below 30% for individual antigens. However, increased
detection of autoantibodies and definition of distinct tumor-associated autoantibody
profiles in cancer can be achieved using uniquely constituted TAA arrays [71,220,222].
The identification of protein autoantigens targeted by autoantibodies in PCa and other
cancers is a prerequisite for developing TAA arrays for the profiling of humoral immune
responses in cancer. This would be important for defining potential targets of
immunotherapy and novel markers for diagnosis and prognosis.
Zhang et al. [71] recently demonstrated the presence of serum autoantibodies to a
panel of known TAA in various human cancers, including a PCa population from Loma
Linda University Medical Center. In that study, autoantibody reactivity to the individual
TAA rarely exceeded 20% in the cancer patient populations (as compared to less than 5%
in normal human sera). However, successive addition of TAA to a mini-array of seven
antigens resulted in a dramatic increase in the number of positive antibody reactions in
cancer patients but not in healthy controls. Interestingly, cancers of the prostate, breast,
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and lung showed distinct profiles of autoantibody reactivity in which specific TAA were
preferentially targeted.
The concept of testing cancer sera against TAA in a mini-array was also recently
explored by Sreekumar et al. [72]. The array used in this study consisted of 12 antigens.
A significant increase in immunoreactivity to oc-methylacyl-CoA racemase (AMACR)
was observed, while no significant differences were observed with the other 11 antigens.
No correlations between the presence of the AMACR antibody and clinical or
pathological parameters (PSA, Gleason score, tumor stage, or biochemical recurrence)
were found. However, when the humoral response to AMACR alone was used to detect
PCa among a given population, a specificity of 71.8% and sensitivity of 61.6% was
observed. More importantly, when a population was narrowed to patients having PSA
levels from 4-10 ng/mL, the humoral immune response to AMACR had its sensitivity
increased to 78.9% and the specificity increased to 80.6% in discriminating between PCa
and control patients. These results provide strong evidence that alternative approaches
that could be used in conjunction with the PSA test can be developed for the diagnosis of
PCa. This study also suggested that the identification of unique prostate cancer-specific
TAA is essential for designing specific antigen arrays for autoantibody profiling in cancer
populations.

Identification and characterization ofLEDGF/p75 as an autoantigen in prostate cancer
To advance our knowledge of potential TAA targeted by circulating
autoantibodies in PCa patients, we undertook a comprehensive analysis of the serum
ANA repertoire in this cancer type. We observed that while the general frequency and

155

titers of ANA in PCa patients were relatively similar to those in matched controls,
significant differences could be detected between the two groups in the autoantibody
response to an individual autoantigen, the lens epithelial-derived growth factor p75
(LEDGF/p75). In this study (described in detail in Chapter 2), we screened sera from 207
PCa patients, 166 age-matched men with no clinical evidence of PCa, and 44 blood bank
male donors for the presence of autoantibodies to potential TAA. Using IIP microscopy
and ELISA, we detected autoantibodies to LEDGF/p75 in PCa patients at frequencies
(14-18%) that were significantly higher than in matched controls and blood bank donors.
These frequencies were within the range observed for other autoantibodies in cancer
[35,53,71,220]. Given the possibility that immunity to LEDGF/p75 in aging men might
conceivably be related to the presence of a prostate tumor, it would be of interest to
determine in prospective studies with the matched control group whether antibody
reactivity to this protein precedes tumor detection. It would also be of interest to include
LEDGF/p75 and AMACR in the previously tested mini-array [71] to determine the
efficacy of the mini-array as a diagnostic tool.
Our data showed that a subset of prostate cancer patients make antibodies to
LEDGF/p75. This suggested that there might be something abnormal with the protein in
prostate tumor cells. Thus, we hypothesized that the antibody response to LEDGF/p75 in
PCa could be indicative of aberrant expression or structural alteration of this protein in
certain prostate tumors. Immunoblot analysis of a panel of prostate cell lines showed low
expression levels of LEDGF/p75 in PrEC, a primary normal cell line, whereas expression
was high in PCa cell lines. We also investigated the expression levels of the protein in
prostate tissue. For these experiments we used human prostate cancer Histo™-Array
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slides. Of the 54 cancer specimens, 50 (93%) expressed the protein. Most of the tumors
showing high expression of LEDGF/p75 were stage III and IV tumors; however, because
the number of tumors in stages I-III provided in the tissue array was relatively small, it
was not possible to establish a statistically significant correlation between high
LEDGF/p75 expression and tumor stage. In future studies an analysis of LEDGF/p75
expression in normal prostate, PIA, PIN, localized PCa and metastatic PCa of all tumor
stages would reveal correlations between tumor stage and LEDGF/p75 expression level.
This information would be important to determine whether LEDGF/p75 could serve as a
prognostic marker of PCa.
Interestingly, LEDGF/p75 was also found in the prostate tumor samples to be
highly expressed in morphologically normal tissue within the tumor microenvironment.
This suggests that the presence of the tumor is influencing the normal adjacent tissue.
The morphologically “normal” area within a prostate tumor may not necessarily be
genetically normal. For instance, Chuaqui et al. [223] observed that at the molecular
level, normal epithelium adjacent to a prostate tumor may not be similar to epithelium
distant from the tumor. These investigators noted that adjacent normal tissue may be a
tumor precursor, or alternatively, may react to the invasive tumor with an atypical genetic
profile.

The high expression of LEDGF/p75 in prostate tumors and their adjacent

“normal” tissue is likely to be induced by inflammatory and oxidative stress conditions,
which are associated with the development of prostate cancer (reviewed in [81]). Ripple
et al. [124] reported that an oxidative shift occurs during the aging process leading to an
increase in the levels of oxidative stress in the prostate. There is also evidence for an
increase in oxidative stress in the benign epithelium of prostate cancer tissue compared to
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that of normal prostate tissue [224]. This is consistent with our observations that
LEDGF/p75 was highly expressed in BPH tissue as well as PCa tissue.
Previous studies conducted in our laboratory showed that LEDGF/p75 is cleaved
by caspases-3 and -7 during apoptosis to generate fragments of 72, 68, 65, and 58 kD
[198]. The predominant cleavage fragments are those of 65 and 58kD produced by
cleavage at the DEVPD30 and DAQD486 sites. In the present study we also showed that
LEDGF/p75 is cleaved into the 65 and 58 kD fragments in LNCaP, PCS, or DU 145 PCa
cells undergoing apoptosis. It is possible that cleavage of LEDGF/p75 in dying tumor
cells may lead to the generation of immunogenic forms of the protein which, under the
inflammatory conditions of the malignant prostate, might elicit an autoantibody response
in certain PCa patients.
The induction of an immune response to LEDGF/p75 observed in PCa patients
appeared to be associated with the presence of the PCa since the frequency of the
autoantibodies was significantly lower in the control groups. We cannot rule out,
however, the possibility that anti-LEDGF/p75 autoantibodies might be linked to a tumorunrelated inflammatory disorder, given that these autoantibodies have also been detected
in various inflammatory conditions such as atopic dermatitis and asthma [192]. However,
the significantly lower frequency of these autoantibodies in the matched control group
would argue against this possibility. Moreover, analysis of available clinical records of
PCa patients positive for anti-LEDGF/p75 antibody failed to reveal previous history of
any of these conditions for most patients. It should be noted that atopic dermatitis and
asthma are also mediated by oxidative stress and inflammation [137,225], raising the
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interesting possibility that humoral immunity to LEDGF/p75 could be a feature of certain
disease conditions associated with these factors.
In addition, studies should be performed to determine the frequency of
autoantibodies to this protein in other cancer types, especially those associated with
inflammation and oxidative stress. LEDGF/p75 was previously identified as an
autoantigen in chronic lymphocytic leukemia (CEL), using the SEREX technique
(serologic identification by recombinant expression cloning). Interestingly, the gene
encoding LEDGF/p75 has been localized to chromosome 9p22.2, a common target for a
variety of cancers [189]. Chromosomal translocations at this site, resulting in a fusion
protein between NUP98 and LEDGF/p75 have been identified in some patients with
acute myeloid leukemia [189]. If proven to play a role in prostate cancer or other cancer
types, LEDGF/p75 may serve not only as a target of novel anti-tumor drugs but also as a
candidate antigen for immunotherapy.

Prostate cancer and oxidative stress
Chronic inflammation is a risk factor for other cancers such as liver, colon,
stomach, bladder, cervical, ovarian, and lung cancer [121]. It is also been speculated that
chronic inflammation may also be a risk factor for PCa development. Inflammatory
infiltration has been associated with PCa in almost 60% of cases studied [122]. Even
though a direct causal role for chronic inflammation in the development of PCa has not
been established, there is indirect evidence that the two are linked. Evidence that
antioxidant enzyme levels, specifically glutathione peroxidase and catalase, are increased
in PCa tissue suggests that the prostate is indeed in a state of oxidative stress [123]. The
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oxidative stress within the prostate may be induced by the aging process itself [124],
dietary factors, increased metabolism, mitochondrial dysfunction, hypoxia or from
inflammatory cells that are responding to the presence of a pathogen [125]. It was shown
that hydrogen peroxide levels are increased in both mouse and human prostate tumors
and that in the mouse this increased level of hydrogen peroxide correlates with increased
tumorigenecity [126]. The fact that dietary antioxidants have been shown to reduce the
risk of PCa [83] is also evidence that oxidative stress plays a role in PCa tumorigenesis.
Further evidence comes from a recent study that demonstrated sequence that variants of
the Toll-like receptor 4 (TLR4) gene are associated with PCa risk [128]. TLR4 is
involved in the innate immune response to gram-negative bacteria. The sequence variant
was observed in the 3 ’ untranslated region of the gene and conferred a 26% increased risk
of PCa and a 39% risk of being diagnosed before the age of 65. This finding supports a
role for a bacterial-associated response pathway in the development of PCa. The innate
immunity defense proteins RNASEL and MSR1 have also been associated with
carcinogenesis, supporting the concept that the host’s inflammatory response to the
pathogen, not the presence of the pathogen itself, facilitates carcinogenesis.
The mechanisms by which inflammation and oxidative stress contribute to the
initiation and progression of PCa are not fully understood. Potential mechanisms include
the production of: 1) inflammatory cytokines, such as tumor necrosis factor (TNF-a), IL6, and transforming growth factor |3 (TGF-(3); 2) angiogenic factors, such as vascular
endothelial growth factor, which affect various host cell functions including cell survival,
growth, differentiation, and metastasis; and 3) ROS [132]. It has been proposed that the
mechanism of PCa development is through the generation of ROS and reactive nitrogen
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species (RNS) produced by inflammatory phagocytes designed to eradicate pathogens
[86,133]. These ROS not only cause damage to pathogens but also are thought to cause
damage to the host as well. This damage may not be adequately repaired before
regeneration occurs, thus leading to the onset of cancer.
Cancer cells are more prone to oxidative damage than normal cells due to the high
proliferation rate in these cells [138]. DNA damage caused by ROS includes DNA strand
breaks, the formation of apurinic/apyrimidinic sites, DNA-protein crosslink formation,
and modified base production. Oxidative DNA base lesions include 8-hydroxyguanine
(8-oxoG), 8-hydroxyadenine (8-oxoA), and 5-hydroxycytosine (50HC). The hydroxyl
radical, singlet oxygen, and peroxynitrite have been shown to form these lesions [139].
Trzeciak et al. [138] showed that levels of these damaged bases were shown to increase
in PC3 and DU 145 PCa cells when they were exposed to radiation and recovered under
normal culture conditions to allow for a period of repair [138]. In their analysis of the
repair mechanism in these cells, these authors revealed that there is a decrease in the base
excision repair enzyme, OGGI, which is the glycosylase that repairs 8-oxoG lesions.
This suggests that there may be defective repair mechanisms in PCa cells that results in
sustained DNA damage. Another study confirmed the increase in 8-oxoG levels in the
urine of PCa patients [139], but did not find an association between pretreatment PSA
values, clinical T stage, metastasis, or Gleason score and the increase in 8-oxoG levels.
Fleshner et al. [83] have shown that oxidative stress in benign epithelium of PCa patients
is higher than that of normal patients. Thus oxidative stress leads to an increase in DNA
damage that often accumulates in prostate cells due to a lack of appropriate cell death and
results in tumorigenesis.
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The role ofsurvival proteins in protection from cell death
Defects in apoptosis are common in cancer cells. Progression of tumorigenesis
occurs due to the loss of sensitivity to normal cell death processes that normally eliminate
damaged cells. Understanding the role of the survival proteins that are involved in the
acquisition of a cell death resistant phenotype are vitally important for the development
of therapeutic strategies for the treatment of cancer.

The most commonly studied

survival protein is Bcl-2. Bcl-2 is able to protect cells against a wide variety of apoptotic
stimuli including growth factor withdrawal, irradiation, cytotoxic drugs, heat, monocytes,
deregulated oncogenes, and in some cases, the activation of cell death receptors
(reviewed in [164]). Bcl-2 can also inhibit necrotic cell death induced by chemical
anoxia, myocardial ischemia, P-amyloid, staurosporine with rotenone, or a combination
of cytokines (reviewed in [226]). It should be noted, however, that Bcl-2 does not protect
from all necrotic stimuli. Bcl-2 is unable to block necrosis induced by peroxinitrite or the
mitochondrial uncoupler 3-acetylpyridine (reviewed in [226]). The protective activity of
Bcl-2 occurs primarily through its ability to regulate mitochondrial membrane
permeability. Bcl-2 expression levels increase in a variety of human cancers, including
PCa. In some tumors, such as prostate tumors, Bcl-2 expression correlates with tumor
progression while in others, such as breast and lung tumors, increased Bcl-2 expression is
associated with better prognosis (reviewed in [164]).
The hsps are a group of proteins that have various survival activities and protect
cells from death. Hsp70 and hsp27 are the most widely studied hsps and can inhibit
apoptosis induced by heat shock, oxidative, stress, ischemia/reperfusion, TNF, UV, and
anticancer drugs (reviewed in [226]). Overexpression of hsps as also been shown to
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protect cells from necrotic forms of cell death induced by heat shock, oxidative stress,
and ischemia/reperfusion (reviewed in [226]). The mechanism of hsp70 or hsp27
protection appears to be associated with the blockage of mitochondrial disruption
(reviewed in [226]). It is unlikely that this is a direct modulation since neither of these
hsp are localized to the mitochondria. It has been suggested that hsp mostly likely
suppress signal transduction pathways that lead to mitochondrial damage and cell death.
A recent study showed that hsp70 may also exert pro-survival activity by blocking
lysosomal membrane permeabilization [227].
ER stress-related chaperones are a group of proteins related to heat shock proteins
that have also been shown to protect a variety of cell lines from both apoptotic and
necrotic cell death.

Prior ER stress induced the expression of GRP78, GRP94, and

calreticulin. The upregulation of these stress proteins led to the resistance of the porcine
kidney cell line LLC-PK1 to TBHP-induced cell death [228]. Treatment of these cells
with GRP78 antisense RNA decreased expression of GRP78 and sensitized cells to
TBHP-induced cell death. Another study by Bedard et al. [229] showed that upregulation
of the ER stress proteins (GRP78, GRP94, calreticulin, and protein disulfide isomerase)
by tunicamycin treatment protected LLC-PK1 cells from oxidative stress-induced cell
death following treatment with TBHP or menadione. This cell line was also protected
from covalent modifications of proteins induced by iodoacetamide or N-acetyl-pbenzoquinoneimine. This study also showed that even though HepG2 cells also showed
increased ER chaperone expression, these cells were only resistant to iodoacetamideinduced cell death. H4IIE (a rat hepatocyte cell line) showed resistance to N-acetyl-pbenzoquinoneimine-induced cell death. The protective effect of these proteins was
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attributed to the maintenance of calcium homeostasis within the endoplasmic reticulum.
These authors concluded that either the molecular pathways of cell death for the different
stimuli are cell-type specific or the function of the ER stress proteins depends on cell
type.
Upregulation of GRP78 enhances resistance to other cell death stimuli as well.
Upregulation of GRP78 by treatment with dimethyl prostaglandin E2 has also been
shown to protect LLC-PK1 kidney cells from oncosis induced by hydrogen peroxide or
iodoacetamide treatment [230]. This study also showed that knock down of GRP78
expression by antisense treatment inhibited the protective effect of the protein. Reddy et
al. [231] showed that GRP78 protects from etoposide, doxorubicin, and camptothecininduced apoptosis by blocking caspse-7 activity in Chinese hamster ovary cells. GRP78
also conferred resistance to oxidative injury in PC 12 neuronal cells [232].
Other ER stress proteins also contain pro-survival activity and protect mammalian
cells from a variety of stimuli. Upregulation of GRP94, achieved by treatment with the
calcium ionophore A23187, reduced necrotic cell death induced by ischemia in rat
cardiomyocytes [233]. Bando et al. [234] demonstrated GRP94 protection of the
neuroblastoma cell line SH-SY5Y from ischemia/reperfusion injury. These authors
showed that the protective activity of GRP94 was mediated through the interference of
caspase-3 activation and calpain activity as well as maintenance of intracellular calcium
levels.
The inhibitor of apoptosis proteins (lAPs) are another group of survival proteins
that upset the balance of life and death in PCa cells. lAPs inhibit apoptosis by directly
blocking caspase activation (reviewed in [164]). Survivin is an IAP usually expressed
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only in fetal tissues. However, aberrant survivin expression is often observed in a variety
of tumors (reviewed in [164]). Expression levels of survivin are highest in the G2/M
phase of the cell cycle and levels drop off during cell cycle arrest. In the early stages of
mitosis, survivin interacts with the mitotic spindle. Blockage of this interaction results in
the loss of the antiapoptotic effect of survivin. Thus, overexpression of survivin may
result in cell cycle progression of transformed cells through mitosis.
NFkB is another a survival protein that upon its activation results in decreased in
apoptosis levels. NFkB is a transcription factor that is upregulated by inflammation and
increases the expression level of anti-apoptotic proteins including lAPs, superoxide
dismutases, myc oncogenes, Bcl-2, and Rb [165]. Recent evidence also shows that NFkB
can also upregulate the serine protease inhibitor 2A (Spi2A) that can protect cells from
caspase independent cell death induced by TNF in the presence of Zvad [235]. Spi2A
was shown to block lysosomal proteases, especially cathepsin B. NFKB also plays a role
in inflammation by upregulating the expression of cytokines and various growth factors.
NFkB was recently shown to be constitutively active in PCa cells and overexpressed in
PIN and PCa [166]. Thus NFkB may play a role in the early stages of PCa development.

Survival activity ofLEDGF/p75 in prostate cancer cells
The known protective effects of LEDGF/p75 are mediated by its ability to
transcriptionally activate genes hsp27, aB-crystallin, and hsp90 [176,204] The
expression of these genes in turn induces an apoptosis inhibitory effect due to the ability
of Hsps to interfere with key components of the apoptotic machinery [167,175].
Interestingly, Hsp27 is overexpressed in 31% of hormone refractory PCa [179],
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suggesting that this overexpression could be induced in prostate tumors by the high levels
of LEDGF/p75. Unfortunately, since the Kinetworks™ screen did not contain hsp27, we
do not know if LEDGF/p75 upregulates hsp27 in our system. It would be of interest to
examine whether increased expression of LEDGF/p75 in prostate tumors correlate with
increased expression of Hsp27 and other heat shock proteins.
Previous studies have shown that overexpression or exogenous addition of
recombinant LEDGF/p75 to the medium of cells in culture stimulates growth and
prolongs the survival of HEpG-2, lens epithelial cells (EEC), Cos-7, skin fibroblasts and
keratinocytes in serum-free medium, or in response to thermal, oxidative, or ethanol
stress [193,202-204]. Therefore, we hypothesized that through its survival activity,
overexpression of LEDGF/p75 in prostate cells leads to increased resistance of these cells
to cell death and, potentially, to development of prostate tumors. No studies have
examined the survival activity of LEDGF/p75 in PCa cells.
In order to explore the survival activity of LEDGF/p75 in prostate cells we
developed RWPE-2 cells that stably overexpress the protein. As presented in Chapter 3,
increased expression of LEDGF/p75 was shown to protect these cells from cell death
induced by TBHP, a known oxidant that causes a variety of effects within the cell. These
effects include peroxidation of cellular lipids, oxidation of glutathione, loss of protein
thiols, release of ER calcium, a general increase in cytosolic free calcium, and a
permeability transition in the mitochondrial inner membrane [236-240]. DTT also
protected parental RWPE-2 cells from TBHP-induced cell death. DTT is a known
reducing agent that blocks both lipid peroxidation [241] and TBHP-induced cell death
[242]. This suggests that lipid peroxidation plays a role in TBHP-induced cell death in
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RWPE-2 cells. This is supported by the fact that LDH is released from cells treated with
TBHP, indicative of cell membrane disruption, which occurs upon lipid peroxidation.
This is consistent with other studies that have shown that in other cell lines (immortalized
LECs and opossum kidney cells) TBHP induces cell death via membrane disruption
through lipid peroxidation [242-243]. Another study also showed that in human
neuroblastoma cells TBHP induced a caspase-independent cell death that the authors
identified as necrosis [244]. Palomba et al. [245] showed that TBHP induced a necrotic
form of cell death in PC 12 cells.
In order to further explore a possible mechanism by which LEDGF/p75 protects
RWPE-2 cells from TBHP-induced cell death, cell lysates were tested for the expression
of 25 different heat shock and stress related proteins using the Kinetworks TM KHSP-1.0
screen. This analysis showed that in untreated cells overexpressing LEDGF/p75 the
expression level of ERp57 was increased 33 fold when compared to cells transfected with
empty vector. ERp57 has been localized to the endoplasmic reticulum (ER) and shown to
bind specifically to secretory glycoproteins containing N-linked oligosaccarhides [246248]. ERp57 has been shown to be a thiol-dependent reductase [249-253] though its
precise functions remain to be established.
The mitochondria play an important role in both apoptotic and necrotic cell death.
It has been shown that TBHP in the presence of calcium induces oxidation of NADPH
and membrane protein thiol groups, which leads to cross-linked protein aggregates and
the disruption of the mitochondrial membrane leading to cell death [254-256]. Since
ERp57 resides in the ER and is known to play a role in calcium homeostasis, it is
plausible that the upregulation of ERp57 by LEDGF/p75 protects RWPE-2 cells from
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TBHP-induced cell death by both calcium modulation as well as its reductase activity.
Thus, ERp57 may block calcium release from the ER and block disruption of the
mitochondrial membrane and cell death induced by TBHP. Thiol-containing proteins are
major contributors to the redox state of the cells [257].
ERp57 is a member of the protein disulfide isomerase (PDI) oxidoreductase
family and has two thioredoxin-like domains [258]. Thioredoxin is a cytosolic reductase
that plays important roles in the redox regulation of signal transduction and in
cytoprotection against oxidative stress [259]. Inhibition of thioredoxin reductase was also
recently shown to inhibit the pro-survival transcription factors NFkB and AP-1 that led to
the sensitization of tumor cells to hydrogen peroxide treatment and ionizing radiation
[260]. ERp57 shows significant homology with PDI, which is a well-characterized ERresident enzyme that interacts with various substrates to catalyze their oxidation,
reduction, and isomerization (reviewed in [261]). ERp57 has also been shown to form a
complex with calreticulin and calnexin [246,262], two other ER chaperones that bind
selectively and transiently to glycoproteins that carry aspargine-linked carbohydrate side
chains [263-264]. The complex between ERp57, calreticulin, and calnexin aids in the
assembly of the major histocompatibility compex I and other newly synthesized proteins
[265]. ERp57 may be a component of the glycoprotein-specific folding machinery in the
ER and may also play a role in regulating the redox state of proteins in the ER in a
calcium-dependent manner [266]. Further analysis is needed to determine whether ERp57
is overexpressed in prostate cell lines and tumors, if overexpression of ERp57 can protect
RWPE-2 cells from TBFIP-induced cell death, and to further explore the role ERp57
plays in LEDGF/p75-mediated protection. An alternative hypothesis that also needs
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further exploration is that the induction of ERp57 is due to accumulation of misfolded
ectopically expressed LEDGF/p75. This could be tested by determining whether
overexpression of other unrelated proteins leads to ERp57 induction.
The Kinetworks™ KHSP-1.0 screen also showed upregulation of other proteins,
albeit at much lower levels than ERp57. It should be emphasized that this screen was
conducted only once and that the results need to be confirmed by conventional
immunoblotting analysis. Hsp90 was shown to be upregulated 4.5 fold in untreated
LEDGF/p75 overexpressing cells compared to untreated vector cells. This would be
consistent with the previous report that LEDGF/p75 transactivates heat shock protein
genes, including hsp90 [176]. However, this upregulation was not confirmed by
conventional immunoblot analysis in our laboratory. The fold induction of hsp90 was
much smaller than that of ERp57. It is possible that our immunoblotting protocol may not
be as sensitive as that used in the Kinetworks TM screen. Different lysis buffers were used
for the two lysate preparations and more protease inhibitors were added to the lysis buffer
used in the Kinetworks™ screen. The lysis buffer used for the conventional immunoblot
analysis used in our laboratory contains a complete protease inhibitor tablet from Roche.
However, since this tablet does not inhibit all classes of proteases, additional inhibitors
were required by Kinexus for the large scale screening analysis. It is plausible that in the
lysates made for the conventional immunoblot analysis, proteolysis might have occurred,
masking small differences in protein expression between the samples.
The stress induced protein/heat shock organizing protein (Hop) was also
upregulated (about 3 fold) in cells overexpressing LEDGF/p75. Hop is a co-chaperone
that has been shown to bind and stabilize complexes in which hsp90 is bound to its target
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proteins and thus facilitates proper protein folding of key regulatory factors such as
kinases and steroid hormone receptors by mediating ATP binding [267]. Further study on
Hop needs to be conducted to determine if LEDGF/p75 directly transactivates the
promoter region of the gene encoding this co-chaperone.
The screen also showed the upregulation of heat shock factor 4 (HSF4) in
LEDGF/p75 overexpressing cells that were treated with TBHP. HSF4 is a unique
member of the heat shock factor family [268-270]. Other heat shock factors, such as
HSF1 and HSF3 mediate the transcription of hsps and other chaperones in response to
cellular stress. This transcriptional activity is mediated by the binding of HSFs to heat
shock response elements located in the promoter regions of these genes. HSF4 has been
shown to bind the heat shock elements, however, it does not have transcriptional activity
and serves as a repressor of hsp expression [268-270]. This is consistent with the
Kinetworks™ data that shows downregulation of Hsp90 in LEDGF/p75 cells treated with
TBHP. Here HSF4 levels increase 2 fold and Hsp90 levels decrease. Even though
LEDGF/p75 seems to play a role in the upregulation of HSF4, upregulation of HSF4 is
not entirely dependent on LEDGF/p75 as evidenced by the observation that untreated
cells overexpressing LEDGF/p75 do not show upregulation of HSF4. Also, upregulation
of HSF4 is not induced by TBHP treatment alone since vector alone cells treated with
TBHP show no change in expression level when compared to untreated cells.
LEDGF/p75 was unable to protect RWPE-2 cells from cell death induced by
classical apoptotic stimuli at the concentrations used in our experiments. TRAIL/ActD
activates the extrinsic apoptotic pathway that occurs through death receptor signaling.
STS is known to induce the intrinsic apoptotic pathway leading to mitochondrial
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membrane permeability and cytochrome c release that leads to the subsequent formation
of the apoptosome and activation of caspases. However, the initiating event that causes
the mitochondrial membrane disruption remains obscure. Cell death in PC 12 cells
induced by STS has been shown to be mediated through the formation of ROS [271].
Another study showed that incubation with the pan-caspase inhibitor Z-VAD-fmk
inhibits STS-induced ROS production, implicating the activation of caspases in the
generation of ROS [272]. However, whether STS induced apoptosis is mediated by the
production of ROS remains controversial because others attribute the slight increase in
ROS, when compared to TBHP treatment, in HL60 cells treated with STS as a
consequence of the inhibition of the electron transport chain that occurs due to
mitochondrial disruption [273]. Thus, ROS accumulation may be a consequence of
mitochondrial membrane permeability, not a direct cause of the death insult.
Another possibility to explain why LEDGF/p75 does not protect RWPE-2 cells
from STS or TRAIL/ActD-induced apoptosis is that it, through the upregulation of
ERp57, may protect cells from ER disruption, loss of calcium homeostasis in the ER, and
high levels of oxidative damage including lipid peroxidation. These events may not be
associated with either STS or TRAIL/ActD-induced cell death. A third possibility is that
LEDGF/p75 transact!vates other proteins involved in protection against stress stimuli that
were not included in the Kinetworks TM KHSP-1.0 screen. These putative proteins may
not be involved in protection against STS or TRAIL/ActD-induced cell death. Fatma et
al. [211] showed that in EEC that overexpress LEDGF/p75 the antioxidant protein-2
(AOP-2) is also upregulated and protects these cells from oxidative stress. The survival
activity of LEDGF/p75 against different stimuli may not always depend on the
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upregulation of hsps. A fourth possibility is that the concentrations of TRAIL/ActD and
STS were too high, leading to a rapid cell death that prevented LEDGF/p75 from
transcriptionally upregulating hsps such as the anti-apoptotic protein hsp27.

Summary
Figure 31 provides a summary of the potential roles LEDGF/p75 may play in the
early development of PCa. ROS generated from inflammatory cells or from exogenous
sources increase the oxidative stress environment within the prostate. This increase in
oxidative stress then results in the upregulation of LEDGF/p75. The upregulation of the
protein combined with its cleavage during apoptosis could elicit the production of the
anti-LEDGF/p75 autoantibodies detected in a subset of patients with PCa. Increased
expression of LEDGF/p75 may protect PCa cells from further oxidant injury by two
potential mechanisms. The first could be through the upregulation of hsps hsp27, otBcrystallin, and hsp90 [176], resulting in increased resistance to apoptosis. LEDGF/p75
may also protect cells from caspase-independent cell death triggered by oxidants through
the upregulation of other stress-related or antioxidant proteins including ERp57.
Resistance to both forms of cell death would allow prostate cells to survive in the high
oxidative stress environment associated with the prostate. This survival would lead to the
accumulation of ROS-mediated damage (including damage to DNA, proteins, and lipids)
within the cell. Other somatic mutations including the silencing of the caretaker gene
gstpl may potentially contribute to the increase of DNA mutations within the cell leading
to tumor formation and progression.
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Figure 31. Possible roles of LEDGF/p75 in prostate carcinogenesis.
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Future studies should focus on the analysis of the potential link between
LEDGF/p75 and ERp57 in prostate cancer progression. For example, the expression of
ERp57 in prostate cancer tissue could be examined using the Imgenex Histo-Array to
determine if the expression of ERp57 correlates with that of LEDGF/p75. Also, it would
be of interest to explore the possibility that ERp57 is a direct transcriptional target of
LEDGF/p75. It would also be of interest to overexpress ERp57 in RWPE-2 cells and
determine if the expression of ERp57 is enough to protect these cells from TBHPinduced cell death. A cDNA microarray analysis of RWPE-2 cells overexpressing
LEDGF/p75 could also be performed to identify other potential targets of LEDGF/p75
that have not yet been identified. These proteins along with ERp57 but could be
responsible for the protective activity of LEDGF/p75.
Other future studies should be aimed at determining whether LEDGF/p75 is a
good molecular target for the treatment of PCa. Smart et al. [260] suggested the following
criteria for an ideal molecular target: 1) overexpressed in tumor cells; 2) enhance tumor
proliferation; 3) exhibit pro-survival signaling attributes; 4) incite a pro-survival effect,
and 5) enhance resistance to therapeutic modalities. Inhibition of this ideal molecular
target should reverse each of these effects and result in regression of the tumor. These
authors not only established the criteria for an ideal molecular target but also used them
to identify thioredoxin reductase as a potential target for anticancer agents that induce
oxidative stress. Through the data presented in Chapters 2 and 3, LEDGF/p75 might also
be a potential target for antitumor therapy that induces oxidative stress. LEDGF/p75
fulfils criteria number 1, 3, 4, and 5. Proliferation of tumor cells was not addressed by
this study. However, LEDGF/p75 demonstrates at least 4 out of the 5 criteria for an ideal
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molecular target. Targeting LEDGF/p75 survival activity through the knock down of
expression levels using RNA interference or by interfering with its survival activity via
small peptide inhibitors could potentially be valuable therapies for the treatment of PCa.
This idea is validated by the fact the knock down of hsp27 sensitized PCa cells to
Paclitaxel-induced apoptosis in PCS cells [274]. This study also showed that systemic
administration of antisense hsp27 in athymic mice decreased PCS tumor progression and
significantly enhanced paclitaxel chemosensitivity. The hsp27 gene is only one of the
targets of LEDGF/p75 transactivation. By knocking down LEDGF/p75 expression or
inhibiting its activity, the sensitization effect observed in the above study could be
expanded due to the blockage of all LEDGF/p75 targets including hsp27 and ERp57.
Therefore, the antitumor effect could be greatly enhanced by inhibition of an upstream
molecule such as LEDGF/p75.
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